Randomised Controlled Trial Initialisation and Management in the Intensive Care Unit by Major, Vincent John
 1 
Vincent Major  ME Research Thesis November 2015 
Department of Mechanical Engineering 
 
University of Canterbury 
Te Whare Wānganga o Waitaha   Telephone: 64-3-366 7001 
Private Bag 4800     Facsimile: 64-3-364 2078 
Christchurch 8020, New Zealand   Website: www.mech.canterbury.ac.nz 
 
 
!
!
!
!
ME!Research!Thesis!
 
!
Randomised!Controlled!Trial!Initialisation!and!
Management!in!the!Intensive!Care!Unit!
!
!
Student:!! ! ! Vincent!John!Major!
!
Senior!Supervisor:! Dist.!Prof.!J!Geoffrey!Chase! !
!
CoESupervisor:! ! Dr.!Yeong!Shiong!Chiew!
!
Enrollment!Date:!!! 01!March!2015!
!
Submission!Date:! 11!November!2015!
 
  2 
Vincent Major  ME Research Thesis November 2015 
Table of Contents 
TABLE&OF&CONTENTS& 2!
1.0! INTRODUCTION& 6!
1.1! MOTIVATION& 6!
1.2! FUNDAMENTAL&BACKGROUND& 7!
1.2.1! CONTEXT! 8!
1.2.2! FUNDAMENTALS! 9!
1.3! RESEARCH&OBJECTIVES& 11!
2.0! REVIEW&OF&MECHANICAL&VENTILATION& 12!
INTRODUCTION& 12!
2.1! MV&PARAMETERS,&MEASUREMENTS&AND&MODES& 13!
2.1.1! BREATH!PARAMETERS!–!EVERY!BREATH!HAS!THESE! 13!
Tidal!volume! 13!
Driving!Pressure! 14!
2.1.2! MV!INPUT!SETTINGS! 14!
2.1.3! MV!MODES! 15!
2.1.4! MV!OUTCOME!MEASUREMENTS! 16!
2.1.5! SUMMARY:! 17!
2.2! THE&PROBLEMS&WITH&MV&MANAGEMENT& 17!
2.2.1! EFFECT!OF!EXCESSIVE!PRESSURE!–!BAROTRAUMA! 18!
2.2.2! EFFECT!OF!EXCESSIVE!VOLUME!–!VOLUTRAUMA! 18!
2.2.3! EFFECT!OF!TOO!LITTLE!VOLUME!AND/OR!PRESSURE!–!ATELECTRAUMA! 18!
2.2.4! BIOTRAUMA!AND!OTHER!ADVERSE!EFFECTS!RELATED!TO!SUBQOPTIMAL!MV!SETTINGS! 19!
2.2.5! ARDS!DIAGNOSIS!AS!A!RATIO!OF!BLOOD!OXYGENATION!TO!INSPIRED!OXYGEN!AND!OTHER!FACTORS! 19!
2.2.6! THE!PROBLEM!WITH!PATIENTS!–!HETEROGENEITY!IN!AFFECTED!LUNG!AND!RESPONSE! 21!
InterQpatient!variability!in!heterogeneity!of!disease!and!response! 22!
IntraQpatient!variability!1:!in!evolution!of!disease!over!time!(need!for!realQtime!vs!intermittent)! 22!
IntraQpatient!variability!2:!heterogeneity!of!the!lung!in!ARDS!or!response!to!MV!in!respiratory!failure
! 22!
2.2.7! SUMMARY:! 22!
2.3! MV&STRATEGIES&AND&TRIALS:&TO&OVERCOME&THESE&ISSUES& 23!
  3 
Vincent Major  ME Research Thesis November 2015 
2.3.1! LUNG!RECRUITMENT!STRATEGIES:!RECRUITMENT!MANOEUVRES! 23!
2.3.2! COMPLIANCE!STRATEGIES! 24!
2.3.3! LUNG!PROTECTIVE!STRATEGIES! 25!
ARDSNet:! 25!
OLA:! 26!
2.3.4! VARIABLE!VENTILATION!STRATEGIES! 27!
2.3.5! HIGH!FREQUENCY!OSCILLATION!(HFO)!AND!AIRWAY!PRESSURE!RELEASE!VENTILATION!(APRV)!STRATEGIES28!
2.3.6! TRANSPULMONARY!PRESSURE!AND!OESOPHAGEAL!PRESSURE!PEEP!TITRATION! 29!
2.3.7! SUMMARY! 29!
2.4! THE&REAL&NEEDS&HIGHLIGHTED& 30!
2.4.1! MANAGING!INTRAQPATIENT!VARIABILITY!!REALQTIME,!BREATHQTOQBREATH! 30!
2.4.2! MANAGING!INTERQ!AND!INTRAQ!PATIENT!VARIABILITY!USING!A!MEASURABLE!METRIC!FOR!PATIENTQSPECIFIC!
TITRATION!!MINIMISING!RESPIRATORY!ELASTANCE! 30!
2.4.3! RECRUIT!THE!LUNG!AND!ASSESS!PATIENTQSPECIFIC!RESPONSE!TO!PRESSURE!!USE!OF!REGULAR!RM! 30!
2.5! THE&NEED&OF&MODELCBASED&MECHANICAL&VENTILATION& 31!
2.5.1! MODELS!AND!BACKGROUND! 31!
2.5.2! MINIMUM!VS!INFLECTION!ELASTANCE! 32!
2.5.3! PEEP!SELECTION!VIA!REGULAR!RM! 32!
2.6! CHAPTER&SUMMARY:& 33!
3.0! MODELCBASED&MECHANICAL&VENTILATION:&APPLICATION&IN&A&CLINICAL&SETTING&IN&REALC
TIME&34!
3.1! MODELCBASED&VENTILATION&THEORY& 34!
3.1.1!PILOT!TRIALS! 34!
3.1.2! SINGLEQCOMPARTMENT!MODEL!AND!PHYSIOLOGY! 35!
The!SingleQCompartment!Model! 35!
3.2! THE&EARLY&PLAN&AND&PRIMARY&GOAL&FOR&HARDWARE& 39!
3.3! COMPUTER&REQUIREMENTS&TO&OPERATE&CURE&SOFT& 39!
3.4! HARDWARE&SPECIFICATIONS& 40!
3.5! COMPUTING&AND&DISPLAY&HARDWARE&CHOICES& 42!
3.6! SELECTING&A&TABLET&PC&AND&MINI&PC&FOR&TESTING& 44!
3.6.1!TABLET!PC! 44!
3.6.2!NUC!MINI!PC.! 44!
3.6.3! HEAT!TESTING!OF!MICROSOFT!SURFACE!PRO!VERSUS!NUC.! 45!
  4 
Vincent Major  ME Research Thesis November 2015 
3.7! MONITOR&SELECTION& 47!
3.7.1! TOUCH!MODE! 47!
3.7.2! SPECIFIC!CONCERNS!IN!AN!ICU!ENVIRONMENT! 48!
3.7.3! MONITOR!OPTIONS!CONSIDERED! 48!
3.7.4! SELECTING!THE!MONITOR! 50!
3.8! MOUNTING&THE&COMPUTING&HARDWARE& 50!
3.8.1! MOUNTING!CONCEPT!AND!KEY!FACTORS! 50!
3.8.2! COMMERCIALLY!AVAILABLE!MOUNTS! 51!
3.8.3! SIMPLE!CUSTOM!MOUNTING!SYSTEMS! 51!
3.8.4! PROTOTYPE!MOUNTING!DESIGN! 55!
3.8.5! LOADING!PATHS! 56!
3.8.6! PROTOTYPE!MANUFACTURE! 57!
3.8.7! PROTOTYPE!TESTING! 57!
3.9! FINAL&MOUNT&DESIGN& 58!
3.9.1! DETAILED!CALCULATIONS.! 58!
3.9.2!PROCUREMENT!COSTS! 59!
3.9.3!FINAL!ENGINEERING!DRAWINGS! 59!
3.10! CHAPTER&SUMMARY:& 60!
4.0! RETROSPECTIVE&ANALYSIS&OF&ICU&PATIENT&DATA& 61!
4.1! DETERMINING&THE&REQUIRED&NUMBER&OF&HARDWARE&UNITS& 61!
4.1.1! INTRODUCTION! 61!
4.1.2! METHODS! 62!
4.1.3! RESULTS!AND!DISCUSSION! 63!
4.1.4.1! Limitations!and!recommendations! 67!
4.1.5! SUMMARY:!UTILITY!ANALYSIS! 67!
4.2! ICU&DIAGNOSTIC&CODES&AND&ESTIMATED&RISK&OF&DEATH&METRICS& 68!
4.2.1! INTRODUCTION! 68!
4.2.2! METHODS! 68!
4.2.3! RESULTS! 69!
4.2.3.1! Diagnostic!code!groups! 70!
4.2.3.2! Diagnostic!code!subgroups! 73!
4.2.3.3! Limitations! 75!
4.2.4! SUMMARY:!ROD!ANALYSIS! 76!
4.3! RETROSPECTIVE&ANALYSIS&OF&ICU&READMISSIONS& 76!
  5 
Vincent Major  ME Research Thesis November 2015 
4.3.1! INTRODUCTION! 76!
4.3.2! METHODS! 76!
4.3.3! RESULTS!AND!DISCUSSION! 77!
4.3.3.1! Complete!ICU!cohort!of!5176! 77!
4.3.3.2! Refined!CURE!RCT!Eligible!cohort!of!645! 82!
4.3.3.3! Limitations! 84!
4.3.4! SUMMARY:!READMISSION!ANALYSIS! 84!
4.4! CHAPTER&SUMMARY:& 85!
5.0! TRIAL&COMMENCEMENT& 86!
5.1! PRE&TRIAL&COMMENCEMENT& 86!
CURE!RCT!Manual! 86!
5.2! CURE&RCT&WORKCFLOW& 86!
5.3! DATA&COLLECTION&AND&REPOSITORY& 89!
5.4! CURE&SOFTWARE&AMENDMENTS& 89!
5.5! CHAPTER&SUMMARY:& 93!
6.0! CHALLENGES&AND&FUTURE&WORK& 94!
6.1! CHALLENGES&FACED& 94!
6.1.1! HARDWARE!INTO!THE!ICU! 94!
6.1.2! INTENSIVIST!CONSENSUS! 94!
6.2! FUTURE&WORK& 94!
6.2.1!PRELIMINARY!ANALYSES! 95!
6.2.2! VIRTUAL!PATIENTS! 95!
6.2.3! IMPROVED!SIGNAL!PROCESSING! 95!
6.3! CHAPTER&SUMMARY:& 96!
7.0! CONCLUSIONS& 97!
8.0! REFERENCES& 99!
 
 
  
  6 
Vincent Major  ME Research Thesis November 2015 
1.0 Introduction 
 
Collaboration between the University of Canterbury’s Centre for Bioengineering and the 
Christchurch Hospital Intensive Care Unit (ICU) has been occurring for over 15 years. 
Recently, one focus of research has been improving the delivery of mechanical ventilation 
(MV) therapy, an essential life-support restricted to the ICU. The severely ill ICU patients 
commonly have a secondary diagnosis of acute respiratory failure, acute lung injury (ALI) or 
acute respiratory distress syndrome (ARDS). These three terms are not diagnosable by a 
specific pathogenesis responsible for each disease but instead, are syndromes classified by 
specialists to include respiratory failure or distress caused by any primary diagnosis.  
Since each patient has an incomparable disease state, a cohort of respiratory failure patients is 
extremely heterogeneous. Research has shown that the entire lung is not affected evenly by 
disease and each patient’s lungs are also heterogeneous. The significant inter- and intra-
patient variability makes both diagnosis and treatment of ALI or ARDS difficult to 
standardize. Each patient should be treated as an individual with care chosen for their specific 
lung condition at that time.  
 
1.1 Motivation 
The current standard of MV therapy in the ICU relies heavily on either clinician experience 
and intuition or a generalised approach such as recommended in large randomised controlled 
trial such as ARDSNet, EXPRESS, ALVEOLI or LOVS trials (The ARDS Network, 2000; 
Brower et al., 2004; Meade et al., 2008; Mercat et al., 2008; Briel et al., 2010). These 
generalised approaches target improved outcomes for the cohort while disregarding the 
plethora of information easily available about the individual patient’s condition. Thus, a 
method to guide patient-specific MV therapy is needed to improve individual patient 
outcomes. 
Internationally, there is a trend towards individualised care but MV therapy is effectively the 
same now as it was in the 1990s (Slutsky, 1993). The ventilator machines are more precise in 
data acquisition and can provide more information to the clinicians at the bedside. However, 
the principal strategies of MV therapy remain unchanged throughout the years. Specifically, 
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there exists relatively few non-invasive monitoring tools that are financially and clinically 
feasible (thus excluding current electrical impedance tomography [EIT] (Fagerberg et al., 
2009) and computed tomography [CT] (Slutsky and Hudson, 2006; Brenner and Hall, 2007; 
Chase et al., 2014; Sundaresan and Chase, 2011)) to monitor a patient’s breath-to-breath lung 
condition in real-time that could be used to guide MV therapy. Thus, there is a need for a 
method that can monitor patient-specific condition in real-time without compromising 
patients’ care and without added clinical protocol burden. 
Positive end-expiratory pressure (PEEP) is one of the primary mechanical ventilation 
settings, that is widely used to improve MV patients breathing (Slutsky and Hudson, 2006; 
Rouby et al., 2002; Sundaresan and Chase, 2011). Studies in experimental animal trials 
proposed that setting PEEP to where the lung had minimal elastance (or maximum 
compliance) would be clinically beneficial (Suter et al., 1975; Carvalho et al., 2007; 
Lambermont et al., 2008; Chiew et al., 2011; Pintado et al., 2013). At this point, the lung has 
expanded where the greatest volume is achieved without overstretching the lung tissue that 
can cause further lung injury. This minimal-elastance PEEP concept can be achieved using a 
model-based approach to estimate the respiratory elastance in real-time without additional 
invasive measuring tools. 
Aside from animal trials, clinical trials including pilot trials conducted by researchers from 
University of Canterbury (UC) and the Christchurch Hospital ICU have shown great promise 
in minimal-elastance PEEP selection (Chiew et al., 2011; Chiew et al., 2015c). To proceed 
with proving the efficacy of model-based ventilation to improve patient care, a randomised 
controlled trial (RCT) is required to compare model-based ventilation to the current standard 
of care in a clinical setting. RCT is regarded as the gold-standard proof of the effectiveness of 
a treatment in the medical community (Akobeng, 2005). This planned RCT with 
collaboration with Christchurch Hospital is called the Clinical Utilisation of Respiratory 
Elastance randomised controlled trial (CURE RCT). 
 
1.2 Fundamental Background 
The following fundamental background aims to briefly introduce key information related to 
both model-based ventilation before the Chapter 2.0 – Literature Review.  
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1.2.1 Context 
MV is a core support for patients in the ICU affecting up to 50% of ICU patients (≈800 
patients per year in Christchurch and 8000 per year in New Zealand) with a considerable 
associated cost (Esteban et al., 2000; Dasta et al., 2005; ANZICS, 2010) approximated near 
$1800 per patient per day. The primary objective of MV is to support the breathing of 
patients with respiratory failure (such as acute lung injury [ALI] or acute respiratory distress 
syndrome [ARDS]). The incidence of ARDS has been reported at 31 per 100,000 per year 
and may account for 36,000 deaths per year in a country the size of the US (Schoenfeld et al., 
2002). The mortality rate from ALI or ARDS is approximately 40 to 50% (The ARDS 
Network, 2000) and long-term survivors experience serious morbidity (Meade et al., 2008). 
MV supports respiratory failure by increasing airway pressure to maximise recruitment (the 
proportion of open lung units) to encourage gas-exchange and enable recovery without 
damaging healthy lung units (Mertens et al., 2009). However, while there is agreement that 
lower tidal volumes are preferred (The ARDS Network, 2000; Girard and Bernard, 2007; The 
ART Investigators, 2012), there are no guidelines (and many conflicting trial results (Amato 
et al., 1998; Brower et al., 2004; Meade et al., 2008; Mercat et al., 2008; Oba et al., 2009; 
Briel et al., 2010), many of which have failed to reach statistical significance) for optimising 
the level of added pressure or PEEP. Typically, lower PEEP is considered better (Hickling et 
al., 1990; Gattinoni et al., 2010), but can lead to increased cases of oxygen desaturation and 
hypoxemia (examples of MV failures) (Brower et al., 2004; Guerin, 2011). The result is a 
difficult problem of balancing the benefits of added pressure with the associated risks. As 
current tools and methods cannot provide insight into patient-specific response to PEEP 
(Sundaresan and Chase, 2011), the best approach to set MV remains uncertain.  
As a result, patient care can be variable and costly (Dasta et al., 2005), affecting patient-
centered quality of care and clinical outcomes (Chase et al., 2011). In particular, ventilated 
patients stay 70% longer in ICU and cost 140% more (Dasta et al., 2005) than non-MV 
patients, indicating the potential for improving care. The main problem is that the lung of a 
patient with ALI or ARDS is very heterogeneous with significant inter- and intra-patient 
variability. Thus, what works for one patient may lead to ventilator induced lung injury 
(VILI) in another (Chiew et al., 2011; Thammanomai et al., 2013). The current standard of 
care is to perform an invasive recruitment manoeuvre to determine how best to titrate care 
(Malbouisson et al., 2001; Borges et al., 2006; Fan et al., 2008; de Matos et al., 2012). Thus, 
optimising MV management requires a means of assessing patient-specific lung condition 
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and patient-specific response to MV therapy using a model-based approach, to account for 
these variabilities and optimise treatment without excessive clinical effort or recruitment 
manoeuvres (RMs). 
Recently, several new model-based metrics for assessing patient-specific lung elastance 
(Chiew et al., 2011; Chiew et al., 2012; Chiew et al., 2015c), recruitment (Sundaresan et al., 
2009; Sundaresan and Chase, 2011), and lung volume response to MV (Sundaresan et al., 
2011b) have been developed. Importantly, they all offer insight into patient-specific condition 
that is not available via typical static surrogate estimates (Lucangelo et al., 2007; Brochard et 
al., 2012), and, equally, they can be estimated breath-to-breath, and monitored as a surrogate 
of patient condition, as well as potentially being used to guide therapy (Chiew et al., 2011; 
Sundaresan et al., 2011a). These models all offer the potential to guide MV therapy choices, 
have all been individually clinically validated, but have not yet been used to prospectively 
guide therapy directly (Chiew et al., 2011; Sundaresan et al., 2011a). The upcoming CURE 
RCT seeks to prove their potential in direct clinical use. 
1.2.2 Fundamentals 
The pathogenesis of ALI or ARDS involves pulmonary edema, diffuse cellular destruction, 
lesions at the alveolar-capillary interface, alterations in permeability, alveolar collapse and 
disordered repair (Amato et al., 1998; Meade et al., 2008). However, the aetiology of 
ALI/ARDS is dependent on the patient’s primary diagnosis and is thus patient-specific. 
Although MV provides an essential life support, it can also degrade lung condition through 
regional overdistension, atelectrauma and oxygen toxicity (Slutsky, 1999). Results of the 
ARDSNet study (The ARDS Network, 2000) is the standard for current comparative trials. 
Experimental work has reported that atelectrauma is common in patients diagnosed with 
ARDS and may be more significant in ARDS mortality than originally thought (Meade et al., 
2008). Atelectrauma can be mitigated by attempting to open collapsed lung tissue with RMs 
and ventilating with high PEEP levels to prevent (re)collapse (Meade et al., 2008). Meade et 
al. (Meade et al., 2008) have proposed that MV strategies that combine low tidal volumes 
with RMs and high PEEP to prevent atelectrauma would be ideal for lung protection.  
PEEP is known to reduce hypoxemia and intrapulmonary shunting in ARDS patients and the 
clinical practice of titrating PEEP ameliorates these effects (Mercat et al., 2008). PEEP-
induced alveolar recruitment helps to avoid airway collapse and reopening, protects lung 
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surfactant and improves ventilation homogeneity within the lung (Mercat et al., 2008). 
Although alveolar recruitment and oxygenation are often related, oxygenation is complex and 
affected by many factors and therefore should not be used as a surrogate for recruitment 
(Mercat et al., 2008).  
The heterogeneity of ALI/ARDS and the complex distribution of pressures within the lung 
means that even at low PEEP some healthy lung units may be over stretched  and at high 
PEEP some unhealthy lung units may remain collapsed (Chiew et al., 2011). Repeated 
opening and closing of small airways may be prevented by higher PEEP settings (The ARDS 
Network, 2000; Amato et al., 1998). Both insufficient and excessive PEEP during MV has 
adverse effects on patient condition and recovery (Rouby et al., 2002; Treggiari et al., 2002; 
Brower et al., 2004). 
Normal subjects at rest inhale 7 to 8 mL/kg (The ARDS Network, 2000), the use of lower 
tidal volumes may reduce lung stretch and thus VILI. MV therapy using low tidal volumes is 
generally accepted to improve patient care and reduce mortality. In particular, work reported 
by The ARDS Network (2000) comparing a traditional approach, using 12 mL/kg, to a low 
tidal volume approach using 6 mL/kg reported a reduction in mortality from 39.8% to 31.0% 
(p = 0.007, n=861).  
The use of low tidal volumes and plateau pressure no more than 30 cmH2O was reported to 
increase survival among ARDS patients (The Acute Respiratory Distress Syndrome Network, 
2000). Limiting hyperinflation has become a primary objective of MV setting selection, since 
PEEP may increase hyperinflation, a compromise must be found between the improved 
recruitment and overdistension (Mercat et al., 2008).  
The patient’s unconscious attempts to breath despite being ventilated can disrupt estimation 
of respiratory elastance. Muscular efforts can increase or decrease the volume and pressure 
within the lung which is not included in most models. (The only ventilation mode to monitor 
muscular efforts is neurally adjusted ventilatory assist [NAVA] which is inherently invasive). 
The use, or overuse, of muscle relaxants to reduce the patient’s attempts to breathe may be 
clinically undesirable (Chiew et al., 2015c). However, recent work by Pintado et al. (Pintado 
et al., 2013) suggests that maximum compliance (minimum elastance) can be difficult to 
observe in some patients and muscle relaxants are necessary.  
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As PEEP increases from zero, respiratory elastance drops – as lung volume is easily 
recruitable at low pressures, volume is recruited faster than the lung pressure increases 
(Carvalho et al., 2007; Suarez-Sipmann et al., 2007; Meade et al., 2008; Chiew et al., 2011; 
Chiew et al., 2015c). At some PEEP, little or no additional lung volume is recruited with 
added PEEP and the elastance begins to rise, the lung is beginning to stretch (Chiew et al., 
2015c; Chiew et al., 2011). However, the elastance curve does not always depict a clear 
minimum elastance, in such cases the precautious selection of inflection-elastance can 
represent a ‘safer’ approach (Chiew et al., 2011).  
 
1.3 Research Objectives 
This research focuses on design and development of a randomised controlled trial to 
investigate the efficacy and effectiveness of a model-based mechanical ventilation treatment 
compared to a standard treatment. Specifically, prior to commencement of the RCT, 
preparations must be made to unsure that the clinical protocol is safe, ethical and suitable to 
address the research hypothesis; that the paperwork and data collected will be managed 
efficiently and stored appropriately; that the intrusion to both the clinicians and the patients of 
additional work or equipment in the bed-space will be minimal but justified; and the 
technicians, nurses, registrars, and intensivists are all on-board regarding the need for the 
trial, are trained regarding the clinical protocol and use of the software, and are willing to 
assist the trial.  
A summary of the thesis chapters are as shown below: 
•! Chapter 2 contains a literature review in the form of a draft review article that 
presents the clinical background and motivation for a model-based respiratory 
mechanics RCT.  
•! Chapter 3 presents the process of hardware development in preparation for the RCT.  
•! Chapter 4 introduces three retrospective analysis using past ICU data used to help 
plan for study commencement. 
•! Chapter 5 presents the process of preparing the documentation, clinical protocol and 
study plan before the RCT can begin.  
•! Chapter 6 describes the challenges faced during this research and the avenues for 
future work.  
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2.0 Review of Mechanical Ventilation 
Introduction 
Mechanical ventilation (MV) supports respiratory failure patients by increasing airway 
pressure to maximise recruitment and providing flow to reduce the work of breathing, thus 
promoting improved gas-exchange and enabling recovery. In particular, the goal is to do so 
without further damaging healthy lung units (Mertens et al., 2009), while alleviating the 
patient’s respiratory effort. However, while there is agreement that lower tidal volumes are 
preferred (The ARDS Network, 2000; Girard and Bernard, 2007), there are few specific 
guidelines and many conflicting trial results (Amato et al., 1998; Brower et al., 2004; Villar 
et al., 2006; Meade et al., 2008; Mercat et al., 2008; Oba et al., 2009; Briel et al., 2010) that 
can be used to optimise the level of positive end-expiratory pressure (PEEP) (Oba et al., 
2009). Hence, current approaches tend to prefer low tidal volumes in conjunction with either 
recruitment manoeuvres (RMs) or moderate PEEP to keep the lung open (Thammanomai et 
al., 2013).  
Although MV provides essential life support, it can also degrade lung condition through 
regional overdistension, atelectrauma, oxygen toxicity, and triggering alveolar and systematic 
inflammatory responses (Slutsky, 1999; Rose, 2010). Traditionally, lower PEEP was 
considered superior (Hickling et al., 1990; Gattinoni et al., 2010). However, lower PEEP can 
lead to increased cases of oxygen desaturation and hypoxemia (Brower et al., 2004; Guerin, 
2011) and worsened lung injury indicated by a greater number of rescue therapies and death 
after rescue therapy (Briel et al., 2010).  
In contrast, higher PEEP is known to reduce hypoxemia (Meade et al., 2008; Rouby et al., 
2002) by improving gas exchange (Oba et al., 2009) and oxygenation (Brower et al., 2004; 
Borges et al., 2006; de Matos et al., 2012). Other benefits include increasing recruitment 
(Malbouisson et al., 2001; Borges et al., 2006; de Matos et al., 2012), stabilising injured or 
collapsed alveoli (Thammanomai et al., 2013; Rouby et al., 2002) to reduce further injury or 
VILI (Brower et al., 2004; Briel et al., 2010), reducing inflammatory mediators in plasma and 
bronchoalveolar lavage fluid (Ranieri et al., 1999), and  improving ventilation homogeneity 
within the ARDS lung (Mercat et al., 2008). It has been hypothesized that MV strategies that 
combine low tidal volumes with RMs and higher PEEP to prevent atelectrauma would be 
ideal for lung protection (Meade et al., 2008; Rose, 2010).  
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However, the optimal level of PEEP is patient-specific and not easily titrated. The current 
standard of care is to perform an invasive recruitment manoeuvre (RM) to determine how 
best to titrate care (Borges et al., 2006; Fan et al., 2008; de Matos et al., 2012), but the 
specifics of the best RM for this task remains debatable (Fan et al., 2008; Guerin, 2011; 
Chiew et al., 2015c). As current tools and methods cannot provide enough insight into 
patient-specific response to PEEP (Sundaresan and Chase, 2011), particularly breath-to-
breath or hour-to-hour, the best approach to PEEP selection remains uncertain (Sundaresan 
and Chase, 2011; Chiew et al., 2015c; Rose, 2010; Thammanomai et al., 2013; Briel et al., 
2010; Spieth et al., 2011b; Talmor et al., 2008; Rouby et al., 2002). 
As a result of all these factors, the current standard of MV therapy in the ICU relies heavily 
on either clinician experience and intuition or a generalised one size fits all approach, such as 
the ARDSNet PEEP-FiO2 tables or the protocols used in the ALVEOLI, LOVS, or 
EXPRESS clinical trials (The ARDS Network, 2000; Brower et al., 2004; Meade et al., 2008; 
Mercat et al., 2008). However, due to the heterogeneity of patients and the evolution of their 
lung condition and disease state, a general approach is unlikely to be suitable for all ARDS 
patients (Sundaresan and Chase, 2011; Hubmayr, 2011a; Gattinoni, 2011a; Gattinoni, 2011b; 
Hubmayr, 2011b; Ferguson, 2012; Pintado et al., 2013). Therefore, a method to guide patient-
specific MV therapy is needed to improve individual patient outcomes. 
In this chapter, a comprehensive review of the application of mechanical ventilation in 
patients with respiratory failure is presented. In particular, an introduction on mechanical 
ventilation settings and the corresponding adverse effect due to suboptimal MV settings are 
discussed. This section is followed by the review of several large clinical trials concerning 
different MV strategies, presented to highlight the need for patient-specific methods to 
standardise patient-specific MV settings.  
 
2.1 MV Parameters, Measurements and Modes 
2.1.1 Breath Parameters – Every Breath Has These 
Tidal&volume&
Physically, tidal volume is the volume of air entering and exiting the patient’s lungs for each 
breath and is usually set by the clinician and reported by the ventilator. 
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Driving&Pressure&
Driving pressure or inspiratory pressure is the increase in lung pressure over PEEP during 
inspiration, and can be clinically limited, if desired.  
2.1.2 MV Input Settings 
Positive(End,Expiratory(Pressure((PEEP)(
As mentioned, PEEP is the baseline pressure at the end of expiration. Additional pressure and 
volume are delivered above this baseline. PEEP is used to ensure the lung remains inflated to 
allow gas-exchange. However, excessive PEEP can cause circulatory depression and increase 
pulmonary edema (Albert et al., 1985; Pinsky, 1997; Toung et al., 1978). Furthermore, 
excessive PEEP without accounting for driving pressure, may increase airway pressures and 
volumes causing overdistension (Brower et al., 2004). 
Peak(Inspiratory(Pressure((PIP)(
PIP is the sum of PEEP and driving pressure, and is thus the highest pressure in the lung 
during inspiration. Often, PIP is set at a limit to avoid ventilation at excessive pressures that 
may cause further injury (Petersen and Baier, 1983; Parker et al., 1993; Slutsky, 1999). PIP 
may be limited in pressure control modes where pressure is the independent variable. 
Tidal(Volume((Vt)(
Higher tidal volumes can assist with ventilation of carbon dioxide from the lung in patients 
with hypercapnia or delivery of oxygen to patients that have hypoxemia. However, excessive 
volumes can overinflate and stretch the lung tissue causing further injury (Chao and 
Scheinhorn, 1996; Dreyfuss and Saumon, 1998). The tidal volume is either set or monitored 
depending on the ventilation mode. Tidal volume may be limited in volume control modes, 
where it is the independent variable. 
Respiratory(Rate((RR)(and(Inspiration(to(Expiration((I:E)(ratio(
The RR is the number of breaths that occur per minute and is commonly set around 16-20 so 
that each breath is approximately 3-4 seconds in length. Spontaneously breathing patients on 
support modes set this pace themselves, and hybrid modes ensure a maximum period limit. 
In controlled modes, within the length of each breath fixed by the RR, clinicians can adjust 
the I:E ratio - the ratio of inspiration time to expiration time. Typical I:E values are between 
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1:1.6 and 1:2 allowing significantly more time for passive expiration to ensure adequate 
ventilation of carbon dioxide out of the lung (Aboab et al., 2012). 
Fraction(of(Inspired(Oxygen((FiO2)(
FiO2 is the oxygen content of the gas delivered to the patient. Air contains approximately 
21% oxygen, but higher oxygen content can be delivered by adding pure oxygen. Higher 
FiO2 allows patients to better exchange oxygen from their lungs into their blood by increasing 
the oxygen concentration and thus the rate of diffusion. However, excessive FiO2 can cause 
oxygen toxicity and further lung injury (Rachmale et al., 2012). FiO2 above 21% is often used 
for patients who, for clinical reasons, cannot be delivered higher pressures or tidal volumes.  
2.1.3 MV Modes 
Numerous different ventilation modes exist and it is common for each ventilator 
manufacturer to have their own unique versions of similar ventilation techniques. 
Fundamentally, there are several different types (Mireles-Cabodevila et al., 2009; Hasan, 
2010): 
1.! Control versus support modes: 
1.1.!Control modes strictly adhere to the chosen ventilation strategy, commonly used for 
patients that are heavily sedated, paralyzed or cannot breathe regularly for 
themselves.  
1.2.!Support modes are less invasive and assist the patient when spontaneously breathing. 
1.3.!Hybrid modes, such as synchronized intermittent mandatory ventilation (SIMV), 
allow patients to control the timing of their breathing while offering support, but also 
ensure that breaths are given to the patient when no spontaneous effort is made. 
2.! Pressure versus volume methods: 
2.1.!Pressure control methods require inputs of PEEP and driving pressure to construct 
the pressure waveform delivered to the patient. The resulting tidal volume is the 
dependent outcome. 
2.2.!Volume control methods require inputs of tidal volume (Vt) and flow profile to 
construct the volume waveform delivered to the patient. Driving pressure and 
resulting PIP are thus the dependent outcomes. 
2.3.!Both pressure or volume control methods can be delivered in either a control mode or 
support mode. 
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2.1.4 MV Outcome Measurements 
Partial(Pressure(of(Oxygen((PaO2)(or(Peripheral(Capillary(Oxygen(Saturation((SpO2)(
Oxygenation of the blood can be measured arterially as PaO2, or using pulse oximetry 
reporting SpO2. Blood oxygenation is the most common monitoring metric to ensure 
ventilation is adequate and delivering sufficient oxygen to the patient. Standard practice aims 
for minimum PaO2 > 80 mmHg (Mellemgaard, 1966; Sorbini et al., 1968) and minimum 
SpO2 on the order of 88-95% depending on the current FiO2 (Brower et al., 2004; Meade et 
al., 2008; Mercat et al., 2008).  
Minute(Ventilation(
Minute ventilation is the volume of air delivered during one minute and is effectively the 
product of the RR and Vt. Target minute ventilation goals are commonly 8-10 L/min (Soo 
Hoo, 2005; Robert J. Mason et al., 2010). 
Transpulmonary(Pressure(
PEEP and airway pressure are easily measured parameters, but may not be as clinically 
applicable as the transpulmonary pressure, the pressure difference between the alveoli and the 
pleural cavity. Due to the significant heterogeneity of ARDS patients, a set PEEP in different 
patients may not translate into consistent transpulmonary pressures (Talmor et al., 2006). 
Since the mechanics of lung collapse, recruitment and overdistension depend on the pressure 
within the lung, relative to outside the lung in the abdomen and within the pleural cavity, 
transpulmonary pressures are clearly more relevant than PEEP (Slutsky, 1999). For this 
reason, MV should provide adequate transpulmonary pressure to maintain acceptable 
oxygenation, while minimising both atelectasis and overdistension (Slutsky, 1999; Talmor et 
al., 2008). However, estimating transpulmonary pressure requires the highly invasive use of a 
balloon catheter to measure the pleural pressure (Talmor et al., 2008) and is thus not 
clinically applicable at this time. 
Invasive(/(Noninvasive(Imaging(
Computed Tomography (CT) is a gold standard for monitoring lung condition and 
recruitment. The CT images allow the clinicians to assess patient condition, response to 
different PEEP levels, alveoli recruitment / distension, and gas distributions. However, CT 
for ICU patients is costly and further exposes the patient to risk of radiation exposure 
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(Brenner and Hall, 2007; Chase et al., 2014; Sundaresan and Chase, 2011). Thus, the 
application of CT to guide therapy remains limited (Slutsky and Hudson, 2006). 
An emerging form of lung imaging is Electrical Impedance Tomography (EIT). EIT is non-
invasive and has shown good correlation with CT findings, such that it has been proposed to 
guide ventilation therapy (Adler et al., 1998; Zhao et al., 2010). However, EIT technology is 
relatively new and costly (Fagerberg et al., 2009), and there is no definite or standardized 
guideline for application at this time. More studies are required for this technology to 
implement it in regular patient care. 
2.1.5 Summary:  
MV is managed by setting several basic parameters, while checking that other measured 
parameters are within currently acceptable bounds, while intermittently making small 
changes to care based on patient response. This section has introduced some of parameters 
and described their role in current MV practice. 
It is common to manually titrate the ventilation parameters to ensure all targets are met, while 
trying to reduce the risk of further injury. Oxygenation is often monitored, while reducing 
FiO2 or PEEP to generally safer levels. However, as noted, there is no consensus on what is 
“best” or how to reach it. 
 
2.2 The Problems with MV Management 
MV is a crucial support therapy for patients with respiratory failure. However, this essential 
treatment has consequences that can cause further injury or delay recovery. Ventilator 
induced lung injury (VILI) is caused by non-optimal ventilation and manifests as a 
mechanical injury to alveoli that exacerbates the systemic inflammation common in ARDS 
patients (Zilberberg and Epstein, 1998; Dreyfuss and Saumon, 1998; Ranieri et al., 1999; 
Adams et al., 2003; Ricard et al., 2003; Gajic et al., 2004; Moloney and Griffiths, 2004; 
Carney et al., 2005; Parsons et al., 2005; Villar, 2005; Pavone et al., 2007). It can directly 
increase the risk of death (Gajic et al., 2004; Carney et al., 2005), as well as the length and 
cost of ventilation.  
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Modern MV is comprised of positive-pressure ventilation that drives air and oxygen into the 
lung during inspiration and passively lets expiration occur naturally. A healthy lung creates a 
negative-pressure inside the lung by expanding the chest wall and flexing the diaphragm, and 
pressure equalisation brings air into the lung. Air is exhaled passively, reducing the volume 
of the lung. Thus, the non-physiological, added stresses and strains caused by MV may 
initiate added trauma in any of four categories: barotrauma, volutrauma, atelectrauma, and 
biotrauma or other.  
2.2.1 Effect of Excessive Pressure – Barotrauma 
Barotrauma is the injury caused by excessive pressures in the lung. The pressure gradient 
between the alveoli and the abdomen can cause air to migrate into the interstitial tissue 
causing many of the manifestations of barotrauma (Slutsky, 1999). Early work by Peterson 
and Baier (Petersen and Baier, 1983) reported that all patients with PEEP > 40 and/or PIP > 
100 cmH2O developed barotrauma. However, more recently, Weg et al. (Weg et al., 1998) 
cast doubt on these results when they compared patients with matching disease states (ARDS 
induced by sepsis) and reported no significant difference in pneumothorax rates for high 
pressures or volumes. The pressure at incidence is likely patient-specific; to avoid barotrauma 
in a diverse cohort, pressures significantly lower than PEEP = 40 and PIP = 100 cmH2O 
should be employed. Overall, barotrauma is a result of driving pressure or PEEP that is too 
high, resulting in excessive PIP and lung pressures. 
2.2.2 Effect of Excessive Volume – Volutrauma 
Excessive volume ventilation, or volutrauma, is observed to stretch the lung tissue beyond its 
elastic limit. It can lead to pulmonary edema, increased fluid filtration, diffuse damage to 
alveoli, epithelial and microvascular permeability (Slutsky, 1999). It is a result of too large 
tidal volume, Vt either by specification or as a result of delivered driving pressure in pressure 
controlled modes. 
2.2.3 Effect of too little volume and/or pressure – Atelectrauma 
Atelectrauma is the cyclic opening and closing of alveoli during each breath. Ventilating a 
patient with respiratory failure provides higher pressures that recruit alveoli during 
inspiration, but, as the pressure drops, the diseased alveoli collapse. It is a symptom of a 
PEEP that may be too low to keep such recruited alveoli open. Experimental work has 
reported that atelectrauma is common in patients diagnosed with ARDS and may be more 
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significant in ARDS mortality than originally thought (Meade et al., 2008), further indicating 
a need for optimal patient-specific PEEP. 
2.2.4 Biotrauma and other adverse effects related to sub-optimal MV 
settings 
The most difficult lung injury to quantify in a clinical setting is biotrauma: the body’s 
response to the invasion of MV, which can lead to increases in alveolar-capillary 
permeability, surfactant inactivation and the release of inflammatory mediators (Marini and 
Gattinoni; Gattinoni et al.; Ferguson et al., 2013). One cause of multiple organ failure and 
mortality described by Slutsky and Tremblay (Slutsky and Tremblay, 1998) and later 
confirmed in an animal study by Murphy et al. (Murphy et al., 2000) is that non-protective 
ventilation strategies (Vt ~ 12 mL/kg and PEEP = 0 cmH2O) are associated with bacterial 
translocation and the transmission of pulmonary infections and inflammatory mediators into 
the circulatory system with subsequent systemic inflammation compared to protective 
ventilation strategies with moderate PEEP (10 – 12.5 cmH2O) and lower tidal volume 
ventilation (~5 mL/kg). 
Other adverse effects of MV include ventilator associated pneumonia (Cook et al.), 
pulmonary edema or fluid build-up in the lung (Brower et al., 2004), circulatory depression 
or a reduction in cardiac output due to increased chest cavity pressures (Brower et al., 2004), 
oxygen toxicity due to excessive oxygen (Ferguson et al., 2013; Slutsky, 1999), and 
hypercapnia or excessive CO2 caused by too little ventilation of CO2 out of the blood. All of 
these effects increase the risk of poor outcome. Equally, the latter two are also a result of sub-
optimal ventilation parameters and management.  
2.2.5 ARDS Diagnosis as a ratio of blood oxygenation to inspired oxygen 
and other factors 
Various pulmonary and extrapulmonary insults may lead to a patient developing respiratory 
failure. The most frequent are pneumonia and extrapulmonary sepsis (Sigurdsson et al., 2013; 
Rubenfeld and Herridge, 2007; Fan et al., 2008). A severe form of respiratory failure is 
ARDS. In 1994, the American-European Consensus Conference (AECC) defined diagnostic 
criteria for ALI and ARDS (Bernard et al., 1994): 
  20 
Vincent Major  ME Research Thesis November 2015 
Table 2.1. AECC Definition of ARDS. 
Timing: Acute and sudden onset of severe respiratory distress; 
Chest imaging: Bilateral infiltrates on frontal chest radiograph; 
Hemodynamics: The absence of left atrial hypertension (a pulmonary capillary wedge pressure 
<18 mmHg or no clinical signs of left ventricular failure); and 
Oxygenation: Severe hypoxemia (assessed by the PaO2/FiO2 ratio), where: 
 a.! ALI exists when the PaO2 /FiO2 ratio is ≤ 300 and >200 mmHg regardless 
of the PEEP and FiO2, and 
 b.! ARDS exists when the PaO2/FiO2 ratio is ≤ 200 mmHg again regardless of 
PEEP and FiO2. 
 
The AECC definition has been adapted in an attempt to better capture the syndrome. This 
new definition is referred to as the Berlin definition (The ARDS Definition Task Force, 
2012): 
Table 2.2. Berlin Definition of ARDS. 
Timing: Onset of ARDS within 1 week of a known clinical insult or new or worsening 
respiratory symptoms. 
 
Chest imaging: Either chest radiograph or CT scan reporting bilateral opacities not fully 
explained by effusions, lobar/lung collapse, or nodules.  
 
Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload. 
Requires objective assessment (e.g. echocardiography) to exclude hydrostatic 
edema if no risk factor present. 
Oxygenation: PaO2/FiO2 < 300 mm Hg with PEEP ≥ 5 cmH2O for mild ARDS, < 200 or < 
100 mm Hg for moderate or severe ARDS. 
 
The requirement of chest imaging before diagnosis and treatment of ARDS is a major 
disadvantage of the ARDS definition and standard practice. To provide prompt recruitment 
and maintenance, a RM should be performed as soon as possible for any MV patient to open 
up the lung and assist with gas exchange (Borges et al., 2006; de Matos et al., 2012). 
Diagnosis could then follow patient stabilization.  
ARDS is typically diagnosed at one moment in time near the start of ventilation (Estenssoro 
et al., 2003). However, the current PEEP at that time can greatly effect both the measured 
PaO2 and the required FiO2 for adequate oxygenation. Estenssoro et al. (Estenssoro et al., 
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2003) reported that PEEP greater than zero during initial ventilation can improve PaO2 so 
drastically that ARDS may be misdiagnosed if assessment is delayed too long, due to delay in 
blood gas extraction or waiting for chest imaging results. If each patient had been evaluated 6 
hours later, 52% would no longer fulfil the AECC definition for ARDS (P/F < 200) and 
instead be diagnosed with less severe ARDS or ALI (Estenssoro et al., 2003), possibly 
changing their overall treatment and care. In this study, no RMs were performed, and 
Estenssoro et al. attributed the improvement in P/F ratio from < 200 to > 200 over 24 hours 
for 18 of the 48 similarly ventilated patients to a relatively higher mean PEEP of 12.8 cmH2O 
after 24 hours. 
Villar et al. (2007) conducted a similar trial to Estenssoro et al., where patients were tracked. 
Approximately 40% of ARDS patients exhibited an increase in P/F ratio to above the AECC 
threshold when evaluated after 24 hours at PEEP ≥ 10 cmH2O and FiO2 ≥ 50%. Villar and 
Kacmarek (2012) warns that all respiratory failure patients start off with poor oxygenation 
and neither the AECC or Berlin definitions allows for re-evaluation of hypoxemia at 
consistent ventilator settings, in particular PEEP and FiO2. They continued to recommend the 
use of a PEEP and FiO2 trial conducted 24 hours after ARDS diagnosis stating this would be 
an easy and simple strategy to identify subpopulations and provide care based on the patient’s 
risk (Villar and Kacmarek, 2012).  
Defining ARDS/ALI within respiratory failure is an important step towards distinguishing 
between severe and moderate respiratory failure and providing appropriate care. However, 
diagnosis of ARDS is slow and followed by rapid patient evolution. Care must be taken not 
to misdiagnose patients at the wrong time. What is needed is a consistent standard of care to 
provide early ventilation support for any and all patients requiring respiratory support so that 
patients can be diagnosed when convenient. These results also clearly show the need for 
patient-specific MV that can evolve as dynamically as the patient in the first 24-48 hours. 
2.2.6 The problem with patients – heterogeneity in affected lung and 
response  
The lung of a patient with ALI or ARDS is very heterogeneous, with mixed healthy and 
diseased alveoli, thus displaying significant inter- and intra- patient variability. Thus, what 
works for one patient may lead to VILI in another (Chiew et al., 2011; Thammanomai et al., 
2013). Equally, what helps a diseased alveoli may injure a nearby healthy alveoli.  
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Inter4patient&variability&in&heterogeneity&of&disease&and&response&
Within a cohort of ARDS or respiratory failure patients, the primary diagnosis is often not 
recorded as ARDS (Ware and Matthay, 2000; Matthay et al., 2012) and the etiology of 
respiratory failure varies with each patient (Artigas et al., 1998; The ARDS Definition Task 
Force, 2012). Although the most frequent causes are pneumonia and extrapulmonary sepsis, 
very diverse cohorts have been included in ARDS or respiratory failure studies (Artigas et al., 
1998; The ARDS Definition Task Force, 2012). With the diverse causes of respiratory failure 
comes a wide distribution of lung condition and thus individual patient-specific requirements 
in optimal ventilation settings. 
Intra4patient& variability& 1:& in& evolution& of& disease& over& time& (need& for& real4time& vs&
intermittent)&
Each patient will respond to treatment and ventilation support differently. The progression of 
disease over time will affect their lung condition and the parameters for their optimal 
ventilation. Hence, care must be able to measure appropriate metrics of patient-specific lung 
condition to evolve over time. 
Intra4patient& variability& 2:& heterogeneity& of& the& lung& in& ARDS& or& response& to& MV& in&
respiratory&failure&
Within the ARDS or respiratory failure lung, it is common for some areas to be collapsed 
(atelectasis) and poorly perfused, while others are normal. MV cannot provide ventilation 
separately to the heterogenous lung areas. Considering both lungs, each with significant 
variability, selection of ‘optimal’ ventilation settings for overall lung recruitment can provide 
excessive pressures/volumes to some regions, while providing too little to others. Lung injury 
can thus be exacerbated by attempting to provide improved care by further injuring non-
aerated, collapsed alveoli. 
2.2.7 Summary: 
MV management is a therapy that must carefully balance different settings. Insufficient or 
excessive support will result in potential harm to the patients, prolonging their dependency of 
MV. This issue is exacerbated by inter-patient variability in response across cohorts, as well 
as by intra-patient variability in the evolution of condition. There is thus a strong need for 
optimal titration mechanisms that are patient-specific, specific to disease state, and can 
evolve dynamically, in real-time to patient condition.  
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2.3 MV Strategies and Trials: To overcome these issues 
2.3.1 Lung recruitment strategies: Recruitment Manoeuvres 
Recruitment defined by Fan et al. (Fan et al., 2008) is the “dynamic process of reopening 
unstable airless alveoli through an intentional transient increase in transpulmonary pressure”. 
RMs have shown to promote alveolar recruitment, increase end-expiratory volume, improve 
gas exchange, and attenuate VILI by preventing atelectrauma. (Fan et al., 2008). The tidal 
cycle during a RM shifts to where cyclic derecruitment is less likely to occur during the 
respiratory cycle given that PEEP > closing pressure of the majority of alveoli. However, 
Rose (Rose, 2010) described how effective RMs are difficult to conduct due to the 
heterogeneity of patients, and their response to pressure. Specifically, some may overdistend 
and others may fail to recruit (Suarez-Sipmann et al., 2007), as elastance, the patient-specific 
response to pressure and volume varies.  
Thus, different types of RMs have been studied with inspiratory pressures anywhere between 
30 and 60 cmH2O (Borges et al., 2006). Sustained inflations or breath holding sessions for up 
to 40 seconds, intermittent sighs with high pressure or volume, and incremental increases in 
PEEP and/or PI are common types of RM. However, trials testing RMs have failed to 
produce consistent results and the best method is yet to be confirmed (The ARDS Network, 
2003; Fan et al., 2008). Evidence does suggest that high pressure RMs may overinflate parts 
of the heterogeneous ARDS or respiratory failure lung (Carvalho et al., 2007), and 
temporarily cause circulatory depression (Odenstedt et al., 2005).  
More specifically, factors such as the method (e.g. breath holding vs. staircase PEEP), timing 
(e.g. early vs. late) and underlying etiology of ALI/ARDS (e.g. pulmonary vs. 
extrapulmonary) are reported to be important factors in the efficacy of RMs (Fan et al., 
2008). Early in the disease, atelectasis is reversible and the lung may be easily recruitable 
without negative side effects (Grasso et al., 2002). Equally, some researchers have reported 
that not all patients benefit from an RM (Guerin, 2011) or have recruitable lung volume 
(Estenssoro et al., 2003). Thus, there remains a lack of confirmation of the long term 
management, adverse effects, and generality of these findings in non-selected populations.  
By transiently increasing pressure in the lung, collapsed or non-aerated alveoli have time to 
open and recruit. Alveolar recruitment increases the aerated lung volume aiding gas exchange 
and perfusion. The clinical benefits of RMs, particularly early in care, are numerous. 
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However, the efficacy of RMs degrade over time as the lung settles into a collapsed state and 
is thus again, more difficult to recruit (Rocco et al., 2010; Gattinoni et al., 2006). The links 
between respiratory failure severity, recruitability and other outcome measurements require 
further investigation in large randomized trials.  
2.3.2 Compliance strategies 
Static compliance (1/elastance) has been reported to change significantly with both tidal 
volume and PEEP (Suter et al., 1975; Suter et al., 1978) (Venegas et al., 1998; Harris et al., 
2000). The local maxima of compliance at a patient-specific PEEP was noted to be dependent 
on the ventilated tidal volume and explained in terms of position on the static PV curve (Suter 
et al., 1975; Suter et al., 1978) (Venegas et al., 1998; Harris et al., 2000). In general, higher 
tidal volumes reduce the PEEP of maximum compliance (Suter et al., 1975; Suter et al., 
1978) (Venegas et al., 1998; Harris et al., 2000). 
The gold-standard approach to obtain a static PV curve is the super syringe method that fills 
the lung before emptying it in a controlled stepwise manner allowing equilibrium in between 
each step. The points are connected to form the sigmoidal static PV curve. The produced loop 
can be used to optimise PEEP and tidal volume. Specifically, PEEP can be set in between the 
lower inflection point (LIP) and upper inflection point (UIP) of the static PV curve. The super 
syringe method is clinically cumbersome and highly invasive, as it requires detachment from 
the ventilator (Lu and Rouby, 2000; Harris, 2005) for up to fifteen minutes (Sundaresan and 
Chase, 2011). Static PV curves can be obtained directly from some modern ventilators, but 
require the patients to be sedated and thus are still invasive and a significant interruption to 
care (Sundaresan and Chase, 2011). 
Stahl et al. (Stahl et al., 2006) described the potential in monitoring dynamic respiratory 
mechanics over incremental PEEP, such as a staircase RM, to estimate both mechanics and 
recruitment simultaneously. They reported that dynamic respiratory mechanics could be used 
as a diagnostic tool and would be more appropriate than using static mechanics (Stahl et al., 
2006). Comparing static and dynamic compliance Stahl reported that dynamic compliance 
was less than static compliance, but the difference was dependent on alveolar pressure. 
Overall, static compliance neglects airway resistance and misrepresents the dynamics of the 
lung by assuming a static or quasi-static condition. Monitoring dynamic compliance reports 
smaller compliance (higher elastance) values, indicating the significance of dynamic effects. 
  25 
Vincent Major  ME Research Thesis November 2015 
Tracking dynamic compliance is possible breath-to-breath over incremental PEEP. Thus, 
using dynamic compliance or elastance as a surrogate of lung condition can be used to 
quantify recruitment and guide care.  
2.3.3 Lung protective strategies  
As a result of the difficulties and risks of MV, the goals of MV have changed over the last 
two decades to focus on minimising VILI while maintaining acceptable ventilation. 
(Ferguson et al., 2013). Avoiding atelectasis and overdistension of alveoli can attenuate 
alveolar and systematic inflammatory responses (Rouby et al., 2002) and should translate into 
a measureable improvement in ARDS/ALI patient outcomes (Slutsky, 1999). Hence, 
protection or risk mitigation has become a primary treatment endpoint. 
A protective ventilation strategy is one aiming to minimise VILI and find a balance between 
oxygenation and CO2 elimination targets. Rose (Rose, 2010) described the “mortality 
reducing effect of lung protective ventilation using low tidal volumes and pressure 
limitation” to prevent alveolar collapse or overdistention in ARDS patients. It is also 
suggested that these strategies may also be beneficial in patients with normal lungs. The 
following summarises several lung protective strategies that were carried out over the years. 
ARDSNet:&
The ARDS Net strategy aims to minimise stretch-induced lung injury, while maintaining 
acceptable oxygenation, by ventilating with small tidal volumes (≤ 6 mL/kg) and plateau 
pressures lower than 30 cmH2O (Spieth et al., 2011b). The ARDSNet trial showed that lower 
tidal volumes (6.2 ± 0.8 mL/kg) are better than higher (11.8 ± 0.8 mL/kg). This low Vt 
strategy uses tables of fixed combinations of FiO2 and PEEP that are periodically adjusted to 
maintain oxygenation goals (Spieth et al., 2011b). ARDS Net is easy to follow, but relies on 
the relationship between PaO2 and FiO2 being generic to all patients at all times as their 
condition evolves. 
However, the physiological rationale and the lack of individuality has been questioned 
(Spieth et al., 2011b). The ARDS Net protocol may also be associated with increased 
atelectasis owing to the low PEEP used and the lack of RMs (Spieth et al., 2011b). Thus, to 
avoid VILI by minimising lung strain and further improving care, the ideal tidal volume 
should be monitored in a patient-specific breath-by-breath or high time resolution approach 
similar to PEEP (Sundaresan and Chase, 2011).  
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OLA:&
The open lung approach (OLA) aims to open and maintain lung recruitment. It also reduces 
dynamic strain (Spieth et al., 2011b). RMs are used to open up the lung and PEEP is titrated 
to gas exchange or respiratory variables to maintain recruitment, avoiding cyclic collapse/re-
opening (Spieth et al., 2011b). One OLA strategy of setting PEEP just above the inflection 
point of a static pressure-volume curve has shown promise by reducing inflammatory 
mediators in bronchoalveolar lavage fluid and blood samples  
The three most significant clinical tests of the OLA are ALVEOLI (Brower et al., 2004), 
LOVS (Meade et al., 2008), and EXPRESS (Mercat et al., 2008). ALVEOLI used two 
predetermined PEEP-FiO2 tables to ensure SpO2 was within acceptable limits of 88 to 95% 
(Brower et al., 2004). The lower PEEP group represented clinical consensus in 1995 whereas 
the higher PEEP group reflected the beneficial results of Amato et al (Amato et al., 1998). 
ALVEOLI used a target Vt of 6 mL/kg predicted body weight with PIP limited to 30 cmH2O 
or less. LOVS also utilised PEEP-FiO2 tables with Vt of 6 mL/kg, but conducted a 40 second 
breath-hold at 40 cmH2O with FiO2 of 1.0 and thus allowed PIP up to 40 cmH2O. 
EXPRESS took a different approach by adjusting FiO2 to maintain oxygenation goals and for 
the control minimal distension group. PEEP and PIP were kept as low as possible without 
dropping out of acceptable oxygenation. Within the increased recruitment group, PEEP was 
kept as high as possible preventing PIP rising above 30 cmH2O regardless of the effect on 
oxygenation. None of these three large multi-centre trials conclusively reported any benefit of 
the OLA or higher PEEP ventilation. However, EXPRESS did report a significant 
improvement in ventilator free-days (median [IQR]: 7 [0-19] vs. 3 [0-17], p=0.04). Although 
the primary outcome of mortality failed to reach significance, benefits including higher 
compliance values, improved oxygenation (Brower et al., 2004; Mercat et al., 2008), and 
reduced rates of, and death from, refractory hypoxemia (Meade et al., 2008).  
An early small trial by Amato et al. (Amato et al., 1998) reported a benefit from ventilation 
above the LIP on a PV curve compared to standard ventilation. Mortality was reduced from 
71% to 38% and rates of barotrauma were greatly reduced (n=53, p<0.001). Villar et al. 
(Villar et al., 2006) conducted a similar trial later setting PEEP 2 cmH2O higher than the LIP 
and reported significant improvements in ICU and hospital mortality, ventilator free days, 
and organ failures (n=95). However, Oba et al. (Oba et al., 2009) argued that the static 
pressure-volume curve may not be the best way to select optimal PEEP for an OLA. 
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Spieth et al. (Spieth et al., 2011b) conducted a recent animal trial involving pigs with 
surfactant washout induced ARDS randomised into either the standard ARDS Net protocol 
(PEEP = 12 cmH2O) or an open lung approach (OLA) with PEEP set to minimal respiratory 
elastance. PEEP and mean airway pressure were higher in OLA. OLA was associated with 
improved oxygenation after 6 hours and redistributed pulmonary perfusion, but with more 
alveolar overdistension, while ARDS Net was associated with more intra-alveolar 
haemorrhage. Inflammatory mediators and markers of lung parenchymal stress did not differ 
significantly. Better redistribution of pulmonary blood flow in the OLA approach may 
contribute to better ventilation-perfusion matching and the reported improved oxygenation. 
Therefore, a patient-specific OLA strategy providing PEEP corresponding to minimal 
elastance is beneficial in pigs but should be tested in a randomized controlled trial. 
Overall, minor clinical benefits of OLA strategies have been shown in different studies. 
However, the improvement in primary patient outcomes have not yet been fully established 
by large multi-centre trials (Amato et al., 1998; Villar et al., 2006; Brower et al., 2004; 
Meade et al., 2008; Mercat et al., 2008). The more recent OLA results by Spieth et al point 
towards a patient-specific elastance as a means of obtaining the best benefits of an OLA 
approach. 
2.3.4 Variable ventilation strategies 
Healthy physiological systems exhibit a natural variability that leads to greater flexibility and 
more robust function compared to diseased systems. In contrast, a low variability breathing 
pattern may be observed in MV patients who failed to wean from MV. Thus, it has been 
proposed to reintroduce variability to replicate this behaviour (Suki et al., 1998). 
Variable controlled ventilation has been associated with improved oxygenation, a reduction 
in mean peak airway pressure, as well as improved pulmonary function in several animal 
studies (Funk et al., 2004; Mutch et al., 2000; Gama de Abreu et al.; Spieth et al., 2009b; 
Spieth et al., 2011a). The best results occur when tidal volume variability matches the 
variability in healthy subjects (Spieth et al., 2009a). The mechanisms responsible may 
include recruitment, surfactant release and improved volume/flow matching as a consequence 
of the redistribution of pulmonary blood flow (Gama de Abreu et al., 2008; Spieth et al., 
2009b). 
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Variable tidal volumes improve pulmonary function by replicating natural variability. 
However, the benefits have yet to be conclusively reported in human trials and the causation 
of improved oxygenation resulting in better patient outcomes are yet to be shown. The 
benefits are likely to be more substantial for patients ventilated for long durations.  
2.3.5 High Frequency Oscillation (HFO) and Airway Pressure Release 
Ventilation (APRV) strategies 
In both these approaches, a relatively high mean airway pressure, referred to as ‘continuous 
distending pressure’ in HFO or ‘Phigh’ in APRV, is used to maintain a healthy end-expiratory 
lung volume and adequate oxygenation levels. Both methods promote alveolar recruitment 
and maintenance due to the continuously elevated pressure within the lung, minimising 
atelectasis as the minimum pressure is relatively high. Recruitment not only depends on the 
pressure in the lung, but also the duration that pressure is held, where elevated pressures for a 
relatively long time can assist with opening more stubborn alveoli. 
HFO ventilation uses rapid application of small tidal volume breaths with a large mean 
airway pressure to ensure adequate oxygenation (Ferguson et al., 2013). The majority of HFO 
studies treated neonatal patients and reported small reductions in chronic lung disease 
(Ferguson et al., 2013). Recent studies to compare HFO with conventional MV have reported 
promising physiological and inflammatory results (Ferguson et al., 2013). One downside of 
HFO is that the patient usually requires sedation whereas during APRV, the patient does not 
necessarily need to be sedated and ideally should be spontaneously breathing to assist CO2 
respiration. 
APRV is similar to HFO, but includes brief periods where the pressure is dropped to release 
air from the lungs and eliminate CO2. These pressure releases must be kept brief to prevent 
the pressure dropping to a point where the alveoli may start to collapse. The pressure releases 
are crucial to eliminate respired CO2 out of the lung. Thus, patients that have hypercapnia 
should be ventilated with more frequent or longer duration releases, whereas patients that 
have hypoxemia require fewer and shorter releases requiring patient-specific adjustment 
(Rasanen et al., 1991). APRV facilitates spontaneous breathing and has been associated with 
progressive recruitment (Sydow et al., 1994), improved oxygenation (Habashi, 2005), 
reduced peak airway pressures (Sydow et al., 1994; Habashi, 2005), and improved 
volume/flow matching (Putensen et al., 1999). 
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Although HFO and APRV are protective strategies operating on similar principles their 
applications are quite different. HFO requires sedation and has not been conclusively proven 
in adult human trials. APRV on the other hand, has been shown to be clinically beneficial in 
spontaneously breathing patients.  
2.3.6 Transpulmonary Pressure and oesophageal pressure PEEP titration 
Talmor et al. (Talmor et al., 2008: ) used an esophageal balloon catheter estimating pleural 
pressure to adjust PEEP with a predetermined FiO2-PLexp table, to maintain positive but small 
transpulmonary pressures, and compared against a control group ventilated based on the 
ARDS Net standard of care (The ARDS Network, 2000). The P/F ratio was higher in the 
intervention group at 72 hours (p=0.002) and compliance was significantly better (P=0.01). 
This result demonstrates the value of pleural pressure, but its invasiveness is not abated. 
2.3.7 Summary 
In summary, it is clear that no general, one size fits all protocol is fully successful. Hence, it 
is equally clear that respiratory failure patients requiring mechanical ventilation are highly 
variable and there is a need to manage mechanical ventilation strategy based on patient-
specific needs. It is thus very important to have the means to assess the dynamic changes in 
patient-specific respiratory disease state regularly in clinical real-time without additional 
invasive measurements or interruptions to care.  
Recently, model-based therapy has emerged as a potential solution to manage specificity in 
patient disease and response to treatment (Schranz et al., 2013; Rees, 2011; Ionescu et al., 
2014). In particular, mathematical models describing the breath-by-breath patient-specific 
respiratory system mechanics can provide unique information to patients’ condition in real 
time, in particular, elastance. These information were translated to medical decision support 
metric to guide bedside mechanical ventilation therapy (Rees, 2011; Thomsen et al., 2013). 
Coupled with regular recruitment and other protective lung strategies, model-based treatment 
offers the opportunity for clinicians to provide patient-specific therapy in a consistent 
fashion. 
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2.4 The real needs highlighted 
2.4.1 Managing intra-patient variability → real-time, breath-to-breath 
The lung of an ARDS or respiratory failure patient can change dramatically over the first 24 
hours of ventilation. The lung condition improves with suitable MV, which can significantly 
alter the patient’s need for subsequent ventilation. Thus, instead of selecting PEEP once, such 
as Amato et al. (Amato et al., 1998) and Villar et al. (Villar et al., 2006) using PV curves at 
the start of MV, ventilation settings should be constantly titrated, either breath-to-breath or 
very regularly, in real-time or to evolve with the patient and reflect their current condition. 
2.4.2 Managing inter- and intra- patient variability using a measurable 
metric for patient-specific titration → minimising respiratory elastance 
Due to the inter- and intra- patient heterogeneity discussed in Section 2.2.6, ventilating 
cohorts of respiratory failure patients with generalised approaches will not cater for 
individual patient-specific ventilation needs. What is needed is the ability to accurately or 
effectively assess lung condition non-invasively, in real-time with no interruption to 
ventilation.  
By using a simple model, lung elastance can be calculated with the airway pressure and flow 
data. Tracking elastance over time provides a clinically useful surrogate to patient condition, 
and patient-specific response to pressure and volume, that can be used with incremental 
PEEP changes to determine an optimal PEEP for continued support. 
2.4.3 Recruit the lung and assess patient-specific response to pressure → 
use of regular RM  
Over time, patient-specific lung condition changes and previously recruited alveoli may start 
to collapse. A RM will attempt to recruit any alveoli that were collapsed. The changing PEEP 
of a staircase RM allows inspection of lung condition, via elastance, over a wide range of 
PEEP that can then be used to select the optimal PEEP given the current ventilation settings 
and patient state. Regular smaller incremental PEEP RMs will assist maintenance of an open-
lung by reopening any recently collapsed alveoli and provides a convenient mode of PEEP 
titration for daily or more frequent adjustments to PEEP to reflect changing lung condition.  
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2.5 The need of Model-Based mechanical ventilation 
2.5.1 Models and background 
Recently, several new model-based metrics for assessing patient-specific lung elastance 
(Chiew et al., 2011; Chiew et al., 2012; Chiew et al., 2015c; Rees, 2011; Pomprapa et al., 
2014), recruitment (Sundaresan et al., 2009; Sundaresan and Chase, 2011) (Rees, 2011; 
Pomprapa et al., 2014), and recruitment or lung volume response to MV (Sundaresan et al., 
2011b) (Rees, 2011; Pomprapa et al., 2014) have been developed. Importantly, they all offer 
insight into patient-specific condition that is not available via typical static surrogate 
estimates (Lucangelo et al., 2007; Brochard et al., 2012), and, equally, they can be estimated 
breath-to-breath, and monitored as a surrogate of patient condition, as well as potentially 
being used to guide therapy (Chiew et al., 2011; Sundaresan et al., 2011a; Rees, 2011; 
Pomprapa et al., 2014). In particular, the single-compartment model (Bates, 2009), arguably 
the simplest respiratory system model (Lucangelo et al., 2007; Ben-Tal, 2012), is 
physiologically relevant, has been clinically validated (Sundaresan et al., 2009; Sundaresan et 
al., 2011a) and offers the potential to guide MV therapy decisions. However, to date, it has 
not yet been used to prospectively guide therapy directly (Chiew et al., 2011; Sundaresan et 
al., 2011a), although pilot trials have been run (Davidson et al., 2014; Chiew et al., 2015c).  
Experimental animal trials by Carvalho et al. (2007), Suarez-Sipmann et al. (2007), and 
Lambermont et al. (2008) have reported that ARDS induced pigs experienced a minimal 
respiratory elastance at a specific PEEP associated with higher oxygenation, maximum 
recruitment, and higher functional residual capacity all without signs of lung overdistension. 
Carvalho et al. tracked the breath-to-breath respiratory elastance, of ALI induced piglets 
during a decremental PEEP trial, and reported that elastance correlated well with the quantity 
of normally aerated lung volume measured by CT (Carvalho et al., 2007). Thus, supporting 
the hypothesise by Suter et al. (Suter et al., 1975) that PEEP at maximum compliance or 
minimum elastance provides the best compromise between recruitment and overdistension. 
It has been proposed that setting PEEP to where the lung has minimal respiratory elastance, 
or maximum compliance, where elastance = 1/compliance, would be clinically beneficial by 
balancing the risks of PEEP too low or too high (Suter et al., 1975; Carvalho et al., 2007; 
Lambermont et al., 2008; Chiew et al., 2011; Pintado et al., 2013). Pilot trials have shown the 
potential benefit of minimal-elastance PEEP selection (Chiew et al., 2011; Davidson et al., 
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2014; Chiew et al., 2015c). Despite the significance of these findings, the application of 
minimal elastance PEEP selection is obstructed by the complete lack of an easy to use 
method available at the bedside (Chiew et al., 2015c). 
2.5.2 Minimum vs inflection elastance 
It has been argued that PEEP should be selected just lower or higher than minimal elastance, 
referred to as inflection-elastance, as a precaution to prevent negative clinical effects caused 
by overdistension, while retaining the benefits of recruitment and titrating PEEP (Chiew et 
al., 2011; Chiew et al., 2015c). Using a valid model, the minimum or inflection-elastance can 
be found for any mechanically ventilated patient and thus could provide a means to 
individualise PEEP settings (Chiew et al., 2015c). However, the clinical benefit of ventilating 
a patient at PEEP selected with either inflection- or minimum-elastance remains to be 
investigated (Chiew et al., 2015c) 
Similar to the PEEP values lying between the two inflection points on a static pressure-
volume curve, there is also debate about the optimal choice of PEEP using elastance. 
Alveolar recruitment is not replaced by overdistension suddenly. Due to the heterogeneity of 
the ARDS patient lung it also occurs incrementally with pressure. The difference between 
minimum and inflection-elastance is thus likely to be small and significantly less than the 
difference from standard practice PEEP. 
2.5.3 PEEP selection via regular RM 
Recruitment manoeuvres were found to be beneficial to improve recruitment and reduce 
pulmonary shunting. In addition, it is common that the patient will undergo a RM prior to 
PEEP titration (Suarez-Sipmann and Bohm, 2009). Hence, clinical protocols that were 
designed to titrate patient-specific PEEP requires a RM before the actual PEEP titration can 
begin. 
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2.6 Chapter Summary: 
In summary, existing MV management is generalised and not patient-specific and thus unable 
to manage patient variability. Hence, there is a need for a strategy that can individualise MV. 
Model-based ventilation has been gaining ground in MV management, specifically, PEEP 
selection through observing minimal elastance PEEP during a recruitment and PEEP titration 
manoeuvre. In the subsequent chapters, a clinical trial designed based on the model-based 
concept is presented. This trial is named Clinical Utilisation of Respiratory Elastance 
(CURE) trial. It is a single centre randomised controlled trial designed as an attempt to 
provide patient-specific MV management and to investigate the effect of its treatment 
compared to standard practice MV management.  
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3.0 Model-Based Mechanical 
Ventilation: Application in a 
Clinical Setting in Real-Time 
3.1 Model-Based Ventilation Theory 
Starting with Suter et al. (Suter et al., 1975; Suter et al., 1978) observing that maximum 
respiratory compliance can be used to estimate optimum cardiopulmonary function and 
compliance peaks at some PEEP setting for a given tidal volume, researchers have proposed 
that ventilating at this maximum compliance or minimum elastance would be clinically 
beneficial. The maximum compliance PEEP represents the critical point, both mathematically 
and clinically, where to either side the ventilation is inferior. As discussed in depth in Chapter 
2.0, at low PEEP the ARDS lung is stiff, under-inflated and is not being used at its capacity. 
Conversely, at high PEEP the ARDS lung is stiff, over-inflated and the tissue is being 
physically overstretched.  
The clinical application of ventilation at maximum compliance, or minimum elastance, is 
wrought with difficulties. Not only does the critical point shift with changes in tidal volume, 
but since the individual patient’s condition defines the compliance/elastance as the patient’s 
condition changes, simply by rolling over, the lung compliance/elastance shifts. It is currently 
impossible to monitor respiratory elastance without invasive measurements or a model-based 
approach.  
As discussed in Chapter 2.0, compliance can be estimated using end-inspiratory pauses or 
more invasive procedures, such as the super syringe method. Regardless of the model used, 
titration over PEEP settings for a given tidal volume is required to inspect the 
compliance/elastance curve and locate the critical point to influence subsequent ventilation. 
Hence, regular monitoring is required.  
3.1.1 Pilot Trials 
A proof of concept animal study by van Drunen et al. (van Drunen et al., 2013) described the 
potential of continuous monitoring of respiratory mechanics in clinical practice. It compared 
several methods of estimating respiratory mechanics. It concluded that the ability to identify 
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and track clinically relevant responses to disease progression and MV in real-time shows 
significant new clinical potential. 
Pintado et al. (Pintado et al., 2013) conducted a pilot study comparing individualised PEEP 
set at highest respiratory system compliance (lowest elastance) against standard practice 
ARDS Network FiO2 guided ventilation. Multiple-organ-dysfunction-free days (median 6.0 
vs 20.5 days), respiratory-failure-free days (median 7.5 vs 14.5 days), and hemodynamic-
failure-free days (median 16 vs 22 days) at 28 days were significantly lower in subjects with 
compliance-guided PEEP. However, the pilot study failed to meet significance comparing 
PaO2/FIO2 during the first 14 days and in 28-day mortality (20.6% vs. 38.9%).  
In particular, in Pintado et al. (2013), PEEP was set daily for the compliance-guided group 
according to the method described by Suter et al. (Suter et al., 1978). Static compliance was 
calculated as tidal volume divided by the pressure difference over a 2 s end-inspiratory pause. 
The PEEP with the highest static compliance was, minimum static elastance, considered best 
and selected for subsequent ventilation. 
3.1.2 Single-Compartment Model and Physiology 
Without any additional intrusion to the patient or interruption to their tidal ventilation, a 
simple model that uses the easily available output pressure and flow data could estimate 
respiratory elastance for every breath (Chiew et al., 2011). This information can track the 
patient’s condition over changing ventilation settings and help quantify recruitment and 
locate the maximum compliance (minimal elastance) PEEP. As mechanics change with 
condition, it can also track condition by this surrogate.  
The&Single4Compartment&Model&
The single-compartment model is arguably the simplest respiratory model represented by 
Figure 3.1 and defined mathematically by Equation 1 (Bates, 2009; Chiew et al., 2011): !"# $ = &'() ∙ + $ + -() & ∙ . $ + !/   (1) 
Where, 
 Paw - Airway pressure 
t - Time 
Rrs - Airway resistance 
Q - Air flow 
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Ers - Respiratory System Elastance 
V - Lung volume 
P0 - Offset pressure (PEEP). 
 
Figure 3.1. Schematic diagram of single-compartment model. 
 
The single-compartment model is applied over inspiration as described in Figure 3.2. The red 
line is the original data and blue line is the model fitted pressure. The data is fit using an 
integral based identification method (Hann et al., 2005). 
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Figure 3.2. Single-compartment model fitting over an inspiration breathing waveform. 
 
One of the major benefits of a simple model is the ease of relating the model parameters to 
physiology (Docherty et al., 2011). In the case of the single-compartment model, the airway 
resistance, R, represents the fluid minor losses of the air flowing through the airways 
(tracheal, bronchus and bronchial) and the respiratory elastance, Ers, represents the stiffness 
of the lung tissue and other elastic components (chestwall and alveoli). This information can 
be used as a surrogate of lung condition, as the overall method is identifiable. 
Preliminary research by Chiew et al. (Chiew et al., 2011; Chiew et al., 2012; Chiew et al., 
2015c) has described how tracking respiratory elastance over time can reflect changes in 
patient lung condition. In particular, tracking respiratory elastance over incrementally 
changing PEEP settings, such as a staircase recruitment manoeuvre (RM), can illustrate how 
respiratory elastance can change with PEEP, as shown in Figure 3.3. The reduction in 
elastance between the increasing PEEP and decreasing PEEP paths can be explained as an 
improvement in the patient’s condition or lung recruitment. 
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Figure 3.3. Elastance (stiffness) against PEEP plot illustrating recruitment in a continuous monitoring software (Szlavecz et 
al., 2014). 
 
Szlavecz et al. (Szlavecz et al., 2014) contributed to the feasibility of model-based MV by 
creating a software platform (CURE Soft). This software monitors mechanical ventilation in 
real-time by tracking breath-to-breath respiratory elastance. It also provides a tool in plotting 
elastance against PEEP to visualise recruitment and calculate and suggest the minimal 
elastance PEEP setting for subsequent care.  
Known causes of respiratory system elastance change, such as administration of muscle 
relaxants and changes in PEEP were used to validate the software. The researchers 
demonstrated that the system is able to provide detailed, previously unavailable information 
on patient-specific respiratory mechanics and response to therapy in real-time. This added 
insight available to clinicians provides the potential for more informed decision-making, and 
thus improved patient care and outcomes. 
Clinical Utilisation of Respiratory Elastance Software (CURE Soft) was developed with the 
plan of implementing in a clinical randomised controlled trial (RCT) to test the efficacy of 
model-based MV. CURE Soft is compatible with any device running Java and can easily be 
customised for the purpose be it research or clinical use. Section 5.4 presents more detailed 
information regarding CURE Soft amendments for implementation by clinicians in CURE 
RCT. 
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3.2 The Early Plan and Primary Goal for Hardware 
During the two previous CURE pilot trials (Szlavecz et al., 2014; Chiew et al., 2015c), laptop 
computers were used to acquire data at the bedside for monitoring. Laptops require an 
additional medical trolley, and cables connecting to a power supply and the ventilator inside a 
confined bed-space. Each ICU bed-space already contains a bed, at least two trolleys, a 
ventilator, two ceiling mounted monitors, and all the associated cables and tubing, and any 
other medical device the patient requires. However, the primary goal of the CURE Soft 
hardware installation is: to reliably collect data while minimising the required floor-space 
and hence the trial’s invasion into the day-to-day operation of the ICU.  
 
3.3 Computer Requirements to operate CURE Soft 
CURE Soft started as several MATLAB codes that performed both data acquisition and 
computation (Redmond et al., 2014a; Davidson et al., 2014). In early 2014, CURE was 
updated into CURE Soft (Szlavecz et al., 2014), an executable Java program that could run 
on any Java supported device: a phone, tablet, or computer. However, serial communication 
necessary with the Christchurch Hospital’s Puritan Bennett PB840 ventilators is much easier 
with a computer and the simultaneous data acquisition and computation is too complex for 
phones and tablets (refer to Section 3.6.3). The schematic process of the application of CURE 
soft is shown in Figure 3.4. 
 
Figure 3.4. Clinician interaction with the ventilator, patient and CURE Soft. 
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CURE Soft was written for use with Windows 7. Unfortunately, universality is not possible 
due to the different methods of serial communication used by different operating systems. 
Although Ubuntu was briefly explored as a possibility, Windows 7 was chosen for simplicity 
as a requirement, as well as because of its ubiquitous usage. Windows 7 is also FDA 
approved as a platform adding weight to future possibilities. Any Windows 7 computer with 
adequate performance to run CURE Soft would suffice, but there are additional physical and 
abstract requirements and wishes for the CURE hardware. The graphical user interface of the 
CURE Soft is shown in Figure 3.5. The user guide can be found in (Szlavecz et al., 2014). 
 
Figure 3.5. An illustrative section of clinical data used for software testing (Szlavecz et al., 2014). 
 
3.4 Hardware Specifications 
There are two components necessary for the CURE RCT hardware: a computer and a 
monitor. Products that combine the two exist, but the requirements of each component need 
to be considered. The fundamental specifications for the hardware were simple: a computer 
with sufficient performance and a touchscreen monitor, yielding: 
1.! Random access memory: At least 4 GB RAM - 4 GB would be low and considering the 
low price of RAM, 8 GB was preferable. 
2.! Processor: At least Intel i5 processor or equivalent - Intel i3 Celeron for example is 
inadequate for the real-time continuous data acquisition and computing necessary to run 
CURESoft.  
3.! Operating system: Windows 7 - CURE Soft was developed for Windows platform. 
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4.! Universal serial bus: At least two USB ports and preferably at least one USB 3.0 port - 
CURE Soft requires one port for serial communication with the ventilator, another to 
retrieve data (USB 3.0 preferably) and possibly another one port for monitor power and 
touch (depending on chosen monitor). 
5.! Cooling capacity: Excellent cooling capacity - Acknowledging the real-time continuous 
data acquisition and computing involved in CURE Soft, the generally warm environment 
of the ICU (~18-20°), and the need to operate uninterrupted for potentially weeks at a 
time, it is crucial that the computer and monitor can operate in these conditions. (Refer to 
Section 3.6.3 for exploration of cooling in a Microsoft Surface Pro 3 and an Intel i5 
NUC.) 
6.! Monitor for graphical user interface: Monitor size (> 12 in.) and resolution (> 1024 × 
768): Since the user must be in close proximity to use the touchscreen, adequate size and 
resolution is necessary for both aesthetics as well as detailed and accurate touch use.  
7.! Device lifetime of at least 3 years: CURE RCT is expected to run for 3 years and the 
hardware should not have to be replaced before the end of the trial. 
8.! Mass and size: The hardware should not be bulky or heavy to ease the hardware mounting 
discussed in Section 3.8. 
9.! Aesthetics and professionalism: Acknowledging that CURE RCT will be running for 
three years in the ICU while being visible to patient families and ICU staff while 
representing both the ICU and UC, it is paramount that the hardware must be aesthetically 
professional to ensure that users and patient families can have confidence in our work. 
Other common computer specifications that need to be considered when comparing similar 
computers were also identified and include: 
1.! Solid state hard-drive (SSD) compared to hard-disk drives (HDD): SSDs have advantages 
over traditional HDD including improved durability to shock, operating quieter, being 
more lightweight, requiring less power while staying cooler and overall improvements in 
speed.  
2.! Graphics card: This computer will not be used to run graphics intensive programs so high 
performance graphics cards are not a requirement. 
3.! Wireless chip: The computer does not need to be connected to the internet during use. 
The necessary install processes can occur using a network port.  
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3.5 Computing and Display Hardware Choices 
As previously mentioned, the computer and monitor could be independent devices or 
combined in one device. Four types of devices were considered: 
1.! All-in-one PC 
2.! Windows 7 Tablet PC (e.g. Microsoft Surface Pro 3) 
3.! Laptop PC 
4.! Mini PC with monitor 
These four categories of devices are vastly different with respect to the number of available 
products and their specifications. The following detailed outline shows the description of 
each devices and their corresponding advantages and disadvantages. 
1.! All-in one PC 
1.1.!These devices integrates all computational components into one case.  
1.2.!Advantages: They are relatively simplistic and portable compared to a full desktop. 
1.3.!Disadvantages: All of the all-in-one PCs on the market in March 2015 were either: 1) 
reasonably low specified with only 4 Gb RAM, i3 or i5 processors (e.g. the Hewlitt-
Packard range), or 2) overly specified towards graphics and overly expensive (e.g. 
the iMac range). 
All-in-ones have large screen sizes to accommodate desktop use and as a result, all of 
the options found were very large and heavy, most around 8 kg1, would be clunky in 
the bed space and without a rear mount would be very difficult to mount on or near 
the ventilator.  
Concerns were raised about the cooling capacity of these kind of machines. Most are 
designed to be sleek with very few cooling vents.  
 
2.! Windows 7 Tablet PC 
2.1.!A lightweight, portable device running Windows 7 in a tablet form – keyboardless. 
2.2.!Advantages: The main benefit of using a tablet is their small weight with a perfect 
sized screen with no unnecessary peripherals.  
                                                
1 http://all-in-one-pc-review.toptenreviews.com/ 
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2.3.!Disadvantages: Most tablets lack the performance to run CURE Soft but those that 
can lack sufficient cooling capacity to maintain operation for days or weeks at a time. 
Further detail is included in Section 3.6.3.  
 
3.! Laptop PC 
3.1.!A lightweight, portable device running Windows 7 with the inbuilt keyboard. 
3.2.!The main appeal of laptops is that they are lightweight, complete machines that are 
available in a range of performance specifications and screen sizes. 
3.3.!The keyboard component of laptops contain the processing components of a 
computer (otherwise it would be classified as a tablet) but the keyboard is not a major 
part of the use of CURE Soft. Keyboards are a major concern of the ICU’s 
technicians as they are very difficult to maintain sterile. The keyboard also makes 
mounting the laptop on or near the ventilator difficult. 
Considering these first three devices, there was no machine on the market that fulfilled all of 
the required computing hardware specifications. Our solution was to construct a machine 
with exactly the specifications desired consisting of a mini PC with an attached touchscreen 
monitor.  
4.! Mini PC with monitor 
4.1.!A mini PC is a miniature desktop unit approximately 4x4 inches, not designed for 
portability and does not include any peripherals and must be paired with a monitor. 
4.2.!One benefit of using a ‘mini’ PC with a touchscreen monitor is the freedom to choose 
the specifications best for this application and the freedom to mount the components 
as we wish. The computer can be built to order with exactly what CURE Soft 
requires and paired with a monitor perfect for the clinical application. 
4.3.!The drawbacks of the mini PC and monitor option is the price – despite the computer 
itself costing less than a similarly specified laptop, the additional cost of an operating 
system and an external touchscreen monitors add to the expense.  
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3.6 Selecting a Tablet PC and mini PC for testing 
In this study, after evaluating the pros and cons of each PC categories, two devices were 
selected for the CURE Soft testing. They are a tablet PC and a mini PC. These devices are 
selected based on the advantage of portability with adequate performance  
3.6.1 Tablet PC 
The emerging consumer market of Tablet PCs is fast-changing and new technologies result in 
more powerful tablet PCs that are increasingly rivalling laptops. The Microsoft Surface Pro 3 
is a high performing, compact device. The Surface Pro 3 is available in an option with 8 GB 
of RAM, a 1.7 GHz Intel i7 processor, and 512 GB of memory and in theory would be more 
than suitable for CURE Soft implementation. However, with the extremely compact design of 
the Surface Pro 3, cooling may be an issue when operating in a 24/7 high intensity data 
acquisition and processing mode. A cooling test was performed with a Surface Pro 3 and is 
included in Section 3.6.3.  
 
Figure 3.6. Microsoft Surface Pro 32. 
 
 3.6.2 NUC mini PC. 
In March 2015, there existed a diverse range of mini PCs from makers including Gigabyte3, 
Lenovo4, Asus5, and Intel6. Mini PCs are often marketed as perfect for video conferencing or 
                                                
2 http://www.microsoftstore.com/store/msusa/en_US/pdp/Surface-Pro-3/productID.300190600 
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graphic design applications. Importantly, the power and sophistication of these machines 
easily rivals modern high-end laptops.  
The Intel Next Unit of Computing (NUC) was selected for a test platform and it could be 
sourced from a local supplier (Dove Electronics, a local wholesale IT distributer7), which 
simplified the overall procurement process.  Dove Electronics can source the NUCs 
barebones or assembled with componentry. The computing hardware requirements were 
easily met by selecting a Dove Electronics product with 8 GB of RAM, 256 GB SSD, a 5th 
generation Intel Core i5 processor with a Windows 7 license. The box itself has four USB 3.0 
ports, uses low power and voltage at 65W and 18V, which is ideal for the ICU. Intel makes 
most of the componentry and sells the barebones PC with assurance that the NUCs will not 
have cooling issues in a high intensity application. The inclusion of a SSD will also help 
maintain acceptable temperatures. An Intel NUC was subject to the same cooling test as the 
Microsoft Surface Pro in Section 3.6.3. 
 
Figure 3.7. Intel NUC mini PC8. 
 
3.6.3 Heat testing of Microsoft Surface Pro versus NUC. 
An Intel i5 powered Microsoft Surface Pro 3 was tested by running CURE Soft with 
previously obtained data. The software Cool Temp9, a free program utilising the inbuilt 
                                                                                                                                                  
3 http://www.gigabyte.co.nz/products/list.aspx?s=47&ck=104 
4 http://shopap.lenovo.com/nz/en/desktops/thinkcentre/tinys/ 
5 https://www.asus.com/nz/Commercial_Desktops/Mini_PC_Products/ 
6 http://www.intel.com/content/www/us/en/nuc/overview.html 
7 http://www.dove.co.nz/ 
8 http://www.intel.com/content/www/us/en/nuc/nuc-board-dn2820fykh.html 
9 http://www.alcpu.com/CoreTemp/ 
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processor digital thermal sensor, was used to monitor the temperature of the computer 
processing unit (CPU) during continuous data monitoring and processing. 
After 2 ½ hours the CPU core temperature of the Surface Pro 3 rose to an alarming 81 °C, 
illustrated by Figure 3.8, at which point testing was stopped. Tablets are not designed for 
continuous use, especially data acquisition and real-time calculation, both of which are 
arduous on the machine. The i5 powered Microsoft Surface Pro 3 is one of the greatest 
specified machines available in early 2015, but fails to sufficiently cool itself in this 
application.  
 
Figure 3.8. Maximum core temperature of a Microsoft Surface Pro 3 after operating CURE Soft for 2 hours. 
 
An Intel i5 powered NUC was conducted to the same testing procedure and ran continuously 
for 4 days and never exceeded 66 °C as described by Figure 3.9. 
 
Figure 3.9. Maximum core temperature of an Intel NUC after operating CURE Soft for 4 days. 
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The poor cooling capability of the Microsoft Surface Pro 3 was evident when compared to 
the Intel NUC. Despite the on-paper specifications of the two devices being identical, as of 
early 2015 tablet PCs are not a viable solution for CURE hardware. However, the Intel NUC 
is acceptable. The Intel NUC that was purchased as a prototype for cooling testing was also 
used to aid design of a hardware mount.  
 
3.7 Monitor Selection 
Using a touchscreen eliminates the need for traditional peripheries such as a keyboard and 
mouse. However, the additional technology comes with an added cost. Use of CURE Soft 
requires mostly clicks or touches with minimal typing. Implementing use of a keyboard with 
touchpad disproportionately weights the importance of the keyboard, while adding 
complexity. A touchscreen monitor allows use of the pop-up on-screen keyboard, which can 
be closed when not in use, maintaining the full screen-size during the majority of use. 
Furthermore, a touchscreen enables quick and easy touch use of the software while standing 
close to the monitor, reducing the screen-size requirement. 
3.7.1 Touch mode 
Several different methods of tactile detection are used in touch devices. Point-of-sale (POS) 
machines mostly use resistive touch where any touch, by a finger or pen, can be detected, but 
requires an aggressive touch and has poor optical quality (Walker, 2012). Personal devices 
such as phones, tablets and laptops usually use capacitive touch, which is more sensitive to 
touch, but relies on the finger to alter the projected capacitive field for detection (Walker, 
2012). Gloved fingers may not work with capacitive touchscreens. The Puritan-Bennett 
ventilators use optical touch, where two beams of light are directed across the two directions 
of the monitor and when the light is interrupted the touch is detected.  
Resistive and optical touch can only register one touch at any time, where capacitive touch 
monitors can commonly register multi-touch. Capacitive touch is commonly regarded as 
superior, especially in high-end personal devices and is the most common in the industry 
(Walker, 2012). Thus, capacitive touch screen monitors were considered for this study. 
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3.7.2 Specific concerns in an ICU environment 
Devices used in the ICU needs to meet certain added and specific criteria for health and 
safety reasons. In particular, several requirements were outlined for this study:   
1.! Electrical connections 
•! Since options with two devices were considered, a computer and monitor, it is 
important to plan the methods of connecting the two devices to mains power supply. 
It will be desirable to use low voltage devices i.e. not regular monitors that require a 
standard IEC C13 mains voltage plug.  
•! If a non-USB-powered monitor was selected, it would need an independent power 
supply. Having two AC plugs into the ICU bedspace wall was undesirable (extra 
cables, extra intrusion into the environment etc.) and residential style double-plugs 
are not allowed in the ICU for electrical safety reasons. Any kind of device that 
would combine the power for the two devices would need to be properly insulated 
and checked for electrical safety.  
•! A USB-powered device only requires one AC plug and since the NUC is low voltage 
(18V after the power supply) and USB supply is 5V, there is virtually no risk of 
electrical shock past the standard NUC power supply.  
2.! Water protection, compliance with international protection (IP) marking, IEC standard 
60529. 
•! In the ICU every mains powered device must meet the liquid ingress requirements of 
IPX1 of the IP code (otherwise known as Ingress Protection Marking which denotes 
the level of protection against intrusion by fingers, water, dust etc. The ‘X’ represents 
no specified protection against solid particles but the ‘1’ represents protection against 
dripping water). Water dripping onto the device must not enter the electrical 
enclosure and potentially cause an electrical fault.  
•! Since the NUC has cooling slots on the top and bottom of the box, to assist with 
natural and assisted convection, a cover must be designed that allows the NUC to be 
slotted into place while ensuring compliance with IPX1. 
3.7.3 Monitor options considered 
Many possibilities were considered, including commercial panel monitors, point-of-sale 
(POS) monitors, replacement laptop screens, stand-alone monitors and USB powered external 
monitors. In summary: 
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−! The majority of commercial and POS monitors are resistive touch and expensive,  
−! POS and stand-alone monitors were heavy and bulky, and  
−! Commercial panels and replacement laptop screens would require complicated 
connections into the mating computer. 
−! The benefit of being USB powered is that the monitor only needs to be connected to 
the computer thus reducing the complication of power supply.  
The best option in terms of easy connection, size, weight and price were USB powered 
external monitors. However, all monitors were considered for preliminary selection. Within 
the heavily restricted desired specification range set out by the investigators and clinical end-
users, only two external monitors were found that are high resolution, lightweight, and USB 
powered. 
1.! Lenovo Thinkvision LT1423p Mobile Touch Monitor 
•! Could be purchased online for 550 AUD 
•! Capacitive 13.3-inch touchscreen supporting 1600x900 resolution 
•! USB 3.0 connection for both power and signal. 
 
Figure 3.10. Lenovo Thinkvision LT1423p Mobile Touch Monitor10. 
 
2.! GeChic On-Lap 1502i Touch Monitor 
                                                
10 http://shop.lenovo.com/ae/en/itemdetails/60ACUAT2EU/460/2D2E6910F1B64671956D698D3C85F912 
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•! Could be purchased online for 400 USD 
•! Capacitive 15.6-inch touchscreen supporting full HD 1920x1080 resolution 
•! USB connection for power and touch but requires second HDMI cable for video. 
 
Figure 3.11. Gechic On-Lap 1502i Touch Monitor11. 
 
 3.7.4 Selecting the monitor 
For a comparable price, weight and ease of mounting the GeChic 1502i was selected for the 
marginally larger screen-size, the wide 16:9 aspect ratio and the higher resolution. One 1502i 
was procured as a prototype for testing and mounting design purposes.  
3.8 Mounting the Computing Hardware 
Per the design goal to minimise intrusion into the ICU environment, the computing hardware 
needs to be mounted to allow easy use of the touchscreen, prevent cases of knocks or drops, 
and run the essential cables as simply and elegantly as possible.  
3.8.1 Mounting concept and key factors 
In a typical ICU bedside, there are various medical equipment used. Thus, there is a limited 
space for the inclusion of a new monitoring tool. After evaluating the bedspace area, the 
                                                
11 http://www.icitouchtech.com/#!product/prd13/1734051055/gechic-1502i-15.6%22-portable-touchscreen-
monitor 
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hardware was mounted directly to the Puritan Bennett 840 ventilator. Key factors in the 
mount design process were identified: 
1.! Modification of the ventilators was not allowed – any attachments to the ventilator must 
use pre-existing brackets, holes etc. 
2.! Any kind of commercial arm would need to be modified to attach to the ventilator. 
3.! The number of computer units will be small (6 or 8) to minimise costs but, there are more 
ventilators in the ICU than this so the mounting should not have to be permanent to 
certain or all machines. 
4.! Simplicity is crucial to minimize weight and cost.  
3.8.2 Commercially available mounts 
Most of the available monitor mounts are designed to support large TVs or monitors and 
usually mount to a desk, wall or ceiling. Monitors and TVs are commonly compatible with 
Video Electronics Standards Association (VESA) 75 or 100 consisting of four impeded 
threads in the device’s housing for use with standard mounts. The Intel NUC also utilises 
VESA 100 by supplying a compatible mounting bracket which once attached secures the 
NUC. Ideally, this monitor mount will be able to support the monitor while also incorporating 
the existing NUC mounting plate. Unfortunately, neither the Lenovo or GeChic external 
monitors are compatible with VESA, so a mounting bracket had to be custom designed to 
support the monitor.  
3.8.3 Simple custom mounting systems 
Several mechanical design were considered. In particular, the hardware can be mounted to 
the side of the ventilator, hidden away behind the ventilator, and pivoted out for use, as 
illustrated by sketch in Figure 3.12. The ventilator itself is a tall, wheeled machine consisting 
of the main, functional body topped with a monitor. The ventilator chassis has very few 
available options to support mounting a device. One available mounting location utilised an 
existing mounting point on the right handrail. Unfortunately, the mechanics of a pivoting or 
folding arm add unnecessary weight and complexity to the mount design.  
The major drawback with the general ‘pivot-out from the side’ concept from a structural 
perspective is the moment arm produced by the cantilevered weight and the lack of rigid 
connection points capable of transferring a moment. The pivoting action adds a great deal of 
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complexity to the design, as well as additional failure points. Positioning the monitor at the 
side of the ventilator also makes it very susceptible to knocks and collisions.  
 
Figure 3.12. Conceptual sketch of the pivot-out concept design. 
 
A much simpler mounting method is to place the monitor above the ventilator monitor, which 
practically is easy to use, adds zero extra foot-print and allows the use of a simple vertical 
mount greatly reducing the acting moment. Originally, a simple five legged stand (analogous 
to an office chair) was considered. This design can be wheeled into place behind the 
ventilator and does not attach to the ventilator at all, except for the RS232 data connection, as 
sketched in Figure 3.13. The main drawback of the wheeled concept is the instability during 
aggressive touching or bumping which may knock the entire stand over and damage the 
equipment.  
A slightly more complex, but more robust, deviation on the vertical mount concept is to 
utilise the rear chassis member of the ventilator as the base of the vertical mount. A straight 
vertical pole from the ventilator chassis would place the mount stem slightly behind the ideal 
location which can be rectified with a small cantilever at the top to position the monitor. A 
concept sketch is shown in Figure 3.14. This concept was further developed and prototyped.  
Gechic 
Monitor 
Ventilator  
body 
Ventilator 
screen 
Mounting point 
with pivoting arm 
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Figure 3.13. Conceptual sketch of the wheeled concept omitting the ventilator body for clarity. 
 
 
Figure 3.14. Conceptual sketch of ventilator chassis mounting design omitting the ventilator body for clarity. 
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A basic design consisting of three separable components was proposed. Figure 3.15 shows 
the Mounting design prototype. The prototype can be separated into 3 major components: 
 1. Monitor and computer mount 
 2. Upright stem 
 3. Chassis mount 
 
Figure 3.15. The three components of the mounting stand prototype. 
 
Inspecting the ventilator legitimised this concept above the others with a few fortuitous 
coincidences. The rear chassis has an odd cross-section but does house two finger screws 
originally designed to secure the optional air compressor, which is never used in Christchurch 
Hospital ICU since compressed air and oxygen is supplied via wall outlets. These screws 
allow easy, fixed attachment without added brackets or cost. If the upright tubing is centred 
on the flat portion of the chassis member, then the pole will narrowly but perfectly miss any 
obstacles on the way past. Care will need to be taken to position the pole slightly off centre to 
the user’s right hand side to avoid the cabling hook on the rear of the ventilator unit box. 
1 
         2 
 
   1 
 
2 
3 
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3.8.4 Prototype mounting design 
The design is summarised: 
1.! Chassis mount 
1.1.!A ‘n’ shaped plate that mates over the existing ventilator rear chassis member located 
laterally with the two finger screws (¼” UNC thread) which also locates a larger boss 
welded vertically onto the flat plate with two triangular ribs for support (refer to 
appendix A). 
2.! Upright stem 
2.1.!A 1.3 m length of tubing which transfers the loading of the hardware into the 
ventilator chassis (refer to appendix A).  
3.! VESA mount 
3.1.!Another boss locating on the upright stem and a bent sheet that locates the monitor 
forward of the centre of the upright and tilted slightly down to face the user. 
3.2.!To secure the Gechic 1502i monitor, a sleeve will encase the monitor. The monitor 
would need to be secured in all three directions. Gravity pulls the monitor down and 
forwards, due to the incline, which must be resisted. The front of the monitor must be 
secured at both the top and bottom to prevent any movement and at least one side 
must locate the monitor sideways. 
Fortuitously, the Gechic 1502i has two M4 threads at the bottom of each side to be 
used for mounting and locating purposes. Since the plugs are accessed from the left 
hand side panel any component must leave this area open. An enclosure that closes 
around three sides of the monitor and leaves the left hand side open, was pursued. 
Since the entire left side is open, the monitor is simply slid in and out of position and 
affixed to the sleeve by a screw on the right hand side. More complicated designs 
could enclose the monitor on the fourth side but would require sliding or folding 
open and shut to place the monitor inside.  
3.3.!To meet the IPX1 requirements, a simple component with one 90° fold was designed 
to be mounted with the top two VESA holes and fold across to cover the NUC like an 
awning.  
3.4.!These three components will be permanently fixed as one subassembly. 
The parts were modelled in SolidWorks Education 2015 to assemble with the known 
dimensions of the ventilator. Discussion with the Clinical Engineers of the Christchurch 
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Hospital suggested that stainless steel is the material of choice for its anti-corrosion and 
sanitation properties as well as its strength and appearance. For the chassis mount and rib 
components, sheet of thickness 3 mm was initially used to be strong enough for the 
application, the upright pole and bosses specified from schedule pipe, and 0.5 mm sheet for 
the 1502i sleeve and IPX1 cover.  
3.8.5 Loading paths 
Neglecting self-weight to start, the only load is gravity acting eccentric from the upright stem 
centre by approximately 100mm. The combined weight of NUC and monitor, considerably 
rounding up for the self-weight of the VESA mount component, is approximately 30N. The 
eccentric loading of the upright will introduce bending and axial loading into the VESA 
mount that will be transferred vertically through the upright and into the chassis mount and 
the ventilator chassis, as diagrammed in Figure 3.16.  
  
Figure 3.16. Eccentricity of loading and loading paths. 
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3.8.6 Prototype manufacture 
The component .dxf files were sent to external contractors, ProMetal Industries12 for laser 
cutting as the 3 mm 302 stainless steel sheet would be very difficult to cut precisely in the 
university workshop. Both the VESA mount and the chassis mount components require a 
radius bend. The smaller bend of the VESA mount was achieved in the small press at UC, but 
after some discussion the chassis mount was sent back to ProMetal for bending. Unbeknown 
at the time of first ordering the prototype material, ProMetal Industries performs laser cutting, 
folding/bending, welding and other fabrication services and would be perfect to fabricate the 
final design all in-house. To weld and assembly the components quickly, a private external 
welder Mr. Russell Major completed the welding and the assembly was finished off ready to 
take into the ICU for proof-of-concept testing and design consideration. Figure 3.15 shows 
the mounting prototype. 
3.8.7 Prototype testing 
The prototype was tested in the ICU and set up with a ventilator connected to a training lung 
(Michigan Instruments, Dual Adult Test Lung, Grand Rapids, MI). The prototype fit well 
against the ventilator chassis. The stand was further secured to the ventilator with an elastic 
tie, for security and seismic resistance as shown in Figure 3.17. 
                                                
12 http://prometal.co.nz/ 
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Figure 3.17. Elastic tie restricting the movement of the prototype. 
 
3.9 Final Mount Design 
The prototype feedback from end user, the clinicians and ICU Bioengineer, and the ICU 
Technician team were very positive, and further modifications based on the prototype were 
made. The prototype was incredibly overdesigned. The 3 mm stainless sheet and the schedule 
pipe was excessively strong and heavy for the application. After more detailed calculations 
and the assurance that the ventilator box will help stabilise the upright, different material 
choices were made for the final design specifications. Furthermore, several minor changes 
were made to the design. The final product was sent to commercial fabrication company 
ProMetal for fabrication.  
3.9.1 Detailed calculations. 
Knowing the final dimensions and the masses of the hardware components, detailed 
calculations were completed. The weight force acting at the top of the upright stem was 
estimated at 35 N, and including self-weight 45 N at the base. Checking the critical force 
required for worst-case (n=0.25) buckling estimated, 
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01(2321"4 &= &1860&9 ≫ 45&9. 
The normal stress created by the axial load was calculated to be =>?(@"4 = 0.5&B!C. 
However, since the gravity load acts eccentric to the centre of the upright stem at a distance 
conservatively estimated at D = 0.1&E. The vertical force induces a moment creating a 
bending stress estimated at =FG>H2>I = 6.6&B!C. Combining the normal and bending stresses 
results in a maximum compression stress of =@"J = 7.1&B!C and maximum tensile stress of =@"J = 6.1&B!C. Thus, the final design will be more than adequate to support the mass of 
the touchscreen monitor and the NUC.  
3.9.2 Procurement Costs  
A budget of $15,000 was set to procure the necessary computers for the CURE RCT. 
Procurement costs were accrued for purchasing components and materials for the prototype 
and the final purchase of 8 computing platforms and mounts. The total cost was $14,050.21. 
A breakdown of the associated costs is given in Table 3.1. 
Table 3.1. Confirmed final procurement costs. 
Confirmed!Final!Procurement!Costs!
Item! Item!No.!
Supplier!
No.! Qnty! Supplier!! Shipping! Cost!
Intel!NUC!plus!SSD!and!RAM! D54250WYKH! NUC287! 1! Dove!Electronics! !$!!!!!!!4.00!! !$!!!!!!!!!757.00!!
Win!7!Home!Premium! !! PC063! 1! Dove!Electronics! !$!!!!!!!4.00!! !$!!!!!!!!!145.00!!
GeChic!1502i! 1502i! !! 1! ICI!TouchTech! !$!!!!!!!!!!!!Q!!!! !$!!!!!!!!!676.07!!
Laser!Cut!parts! Quote!13582! !! 1! ProMetal!Industries! !$!!!!!!!!!!!!Q!!!! !$!!!!!!!!!!!60.00!!
SS!tube!order! !! !! 1! S&T!Stainless! !$!!!!!!!!!!!!Q!!!! !$!!!!!!!!!!!77.05!!
Intel!NUC!plus!SSD!and!RAM! NUC515RYH! NUC293! 7! Dove!Electronics! !$!!!!!!!8.00!! !$!!!!!5,460.00!!
Win!7!Home!Premium! !! PC063! 7! Dove!Electronics! !$!!!!!!!4.00!! !$!!!!!!!!!973.00!!
25mm!SS!handrail!tube! !! !! 2! S&T!Stainless! !$!!!!!23.63!! !$!!!!!!!!!!!64.23!!
GeChic!1502i! 1502i! !! 7! ICI!TouchTech! !$!!!!!!!!!!!!Q!!!! !$!!!!!3,872.81!!
ProMetal! Quote!13727! !! 8! ProMetal!Industries! !$!!!!!!!!!!!!Q!!!! !$!!!!!1,760.00!!
Customs!entry!service! INV60577! !! Q! Anglo!Pacific!Int.! !$!!!!!!!!!!!!Q!!!! !$!!!!!!!!!!!90.00!!
75x50!Timber,!5.6m!lengths! !! !! 2! Placemakers!Ric.! !$!!!!!40.00!! !$!!!!!!!!!!!31.42!!
!     
Total! !$!!!14,050.21!!
 
3.9.3 Final Engineering Drawings 
Figure 3.18 shows the final product developed for CURE RCT. The system is attached to the 
ventilator, the top most screen is CURE Soft and the lower one is the ventilator. The final 
engineering drawings for the hardware mounts are included in Appendix A.  
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Figure 3.18. Final design of mounting stand mounted to a ventilator. 
 
3.10 Chapter Summary: 
In summary, to implement CURE Soft in the upcoming randomised controlled trial, an 
appropriate computer hardware was necessary. To minimise footprint and intrusion into the 
busy ICU, a hardware system comprising of a tiny PC, a touchscreen monitor and a simple 
stainless steel stand was devised. A prototype was produced and tested in the ICU and with 
positive feedback several changes were made before a total of eight units were procured. The 
total cost of prototype and eight units was $14,050 within the specified budget of $15,000. In 
the next chapter, retrospective analysis of the ICU data were carried out. These analyses were 
able to provide unique insight to the potential patient cohort that were eligible for the trial, 
and hence, allow better understanding and trial planning. Specifically, 8 hardware units were 
procured based on a utility analysis that was carried out in the next chapter.  
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4.0 Retrospective Analysis of ICU 
Patient Data 
 
Data derived from retrospective cohorts provides important information on the current state 
of care, the cohort, and its response to treatment. This information can also be used to aid 
future planning of clinical resources and clinical practice as well as to design a clinical trial 
(Mantel and Haenszel, 1959). In this study, we investigated ICU patient data from a single 
centre, Christchurch Hospital. Data were collected from 2011 – 2014, a four year cohort of 
5176 patients.  
Three important metrics were studied: 1) length of mechanical ventilation; 2) risk of death; 
and 3) readmission rate. These three metrics can assist planning of the CURE RCT to 
determine the necessary recruitment rate, the required number of computing platforms, and 
the baseline mortality and readmission rates before the CURE intervention. The last of these 
points can be used to evaluate well-powered stopping criteria. 
4.1 Determining the Required Number of Hardware Units 
4.1.1 Introduction 
The CURE RCT is a clinical trial investigating the performance of a model-based method in 
guiding mechanical ventilation PEEP (MBV) compared to the current standard practice 
(SPV) of the participating hospital, Christchurch Hospital. MBV aids clinicians in selecting 
PEEP using computer software, CURE Soft. CURE Soft is installed in a dedicated computing 
platform developed for the application, as presented in Chapter 3.  
The participating hospital adult intensive care unit (ICU) is an 18 bed tertiary affiliated ICU. 
Ideally, one CURE computing platform would be set up for each bed for the duration of the 
trial. However, not all patients admitted to the ICU need invasive MV. Thus, there is no need 
for 18 computing platforms as they may not be fully utilised, and reducing the number of 
units will reduce the operation cost of the planned clinical trial. 
In this section, retrospective use of the mechanical ventilation from Jan 1st 2011 to Dec 31st 
2014 is studied. This study will provide information on how many patients were eligible for 
the CURE RCT and the number of computing platforms required can be safely estimated. It 
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assumes the retrospective cohort is comparable to the cohort captured by the study. 
Furthermore, this utility analysis will highlight any major seasonal effects that may have been 
overlooked during the initial trial design stage.  
4.1.2 Methods 
Based on the sample size analysis in Chiew et al. (Chiew et al., 2015b), a strict and objective 
patient selection criteria is implemented using the Acute Physiology and Chronic Health 
Evaluation diagnostic code (APACHE III). These objective criteria are capable of creating a 
simulated patient cohort based on objective criteria that could be exactly matched by the 
actual patient cohort, negating any subjective choices or effects. Table 4.1 shows the 
comparison between the actual trial inclusion and exclusion criteria versus the simulation of 
objective selection criteria. In addition to these selection criteria, patients with LoMV of 
more than 28 days were also excluded for the analysis to achieve a cohort that is shorter 
tailed, and thus matches the CURE trial design as well. 
Table 4.1. Trial inclusion and exclusion translated into retrospective analysis. 
Trial Inclusion/Exclusion Criteria Simulation selection method 
Inc. Patients requiring invasive MV. Only patients with recorded invasive MV 
are selected from the data pool. 
Exc. LoMV expected to be < 24 hours. Excluded patients with recorded LoMV < 
24 hours and all patients with APACHE 
III codes within groups 100 and 1200 
(non-operative and post-operative 
cardiovascular diagnoses). 
Exc. Patients with measured or suspicion of 
raised intracranial pressure. 
Excluded patients with APACHE III codes 
within the groups 400 or 1500 (non-
operative and operative neurological 
diagnoses) as well as 601 or 1601 (non-
operative and operative head trauma with 
or without multi trauma). 
Exc. Spinal cord injury patients. Excluded patients with APACHE III codes 
604/1604 (non-operative and operative 
multi trauma with spinal injury) and 
605/1605 (non-operative and operative 
isolated cervical spine injury). 
Exc. Asthma or chronic obstructive 
pulmonary disease (COPD). 
Excluded patients with non-operative 
asthma or COPD using APACHE III 
codes 206 (COPD) and 209 (asthma). 
*See Appendix F for a summarised description for the APACHE III Diagnostic code. 
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After imposing the selection criteria, the remaining patient data captures the length of 
mechanical ventilation distribution profile for patients expected to benefit from the 
intervention and who will enter the trial as described in Figure 4.1. Using the patient date and 
time of invasive ventilation, when it started and finished, the expected number of patients 
requiring MV at any given hour can be calculated. Resolution of one hour was used and 
expected to be adequate. An example is shown in Figure 4.2. 
Resolution of one day is too large as a patient will be weaned from MV and the equipment 
will be cleaned and may be introduced to a new participant later that same day. Resolution 
finer than one hour is an unnecessary complexity, especially considering the time delay for 
cleaning that must occur between participants. The start time was rounded down and the end 
time rounded up to account for these unproductive delays. 
In addition, this analysis reflects the process that would occur within the ICU. If a patient 
enters the ICU and is eligible for the trial, but there is no computing platform available at that 
time, they cannot be included in the study. These patients will be missed opportunities to 
collect data and as such should be minimised by ensuring sufficient computing platforms are 
available. However, an excess of platforms will be a wasted cost. The hardware utility will be 
estimated as the proportion of hours where the platforms are in operation.  
4.1.3 Results and discussion 
Using the selection criteria, the number of eligible patients over four years was reduced to 
645, with median LoMV of 4.6 days [Interquartile range (IQR): 1.9-14], with a total of 6200 
days of ventilation. Figure 4.1 describes the distribution of LoMV data for the refined cohort. 
An estimate of the number of patients recruitable for CURE RCT is calculated and the results 
are shown in Figure 4.2 by months (1-48). Extrapolating the sample cohort can aid estimating 
the number of CURE computing platforms required. 
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Figure 4.1. Length of mechanical ventilation distribution after sample selection. 
 
Figure 4.1. The number of hardware units required to follow each of the 645 patients, for their entire length of ventilation. 
 
As Figure 4.2 illustrates, to collect data from every one of the 645 patients eligible for the 
trial, a total of 12 hardware units would be required. However, 12 units are only necessary for 
three hours throughout the four year period. The utility of procuring 12 hardware units would 
be 29%, and on average almost two-thirds (71%) of the hardware units would be unused at 
any time. Thus, the utility is defined as the percentage of time the units are being used to 
collect data. From Figure 4.2, the black shaded area is time where the hardware is being used 
and the white is underutilised time so the utility is calculated as the percentage of black 
shaded area within the total area. 
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In this simulated cohort, it was observed that 119 eligible participants required MV for 4 
weeks. Thus, these types of patients would also occupy a unit of CURE hardware for a long 
time with little added benefit. An improved strategy would stop collecting data from these 
long-term MV participants after 10 or 14 days and free the hardware for a newly recruited 
participant. This strategy would still seek patients likely to benefit, but would also reduce 
costs, while preserving the number of participants. It also allows more participants to be 
recruited in a shorter time period for the same number of hardware units.  
If only 5, 6, or 7 units were procured, they would, on average, be operating for a greater 
proportion of time. Using a maximum data collection limit of 10 or 14 days will be explored 
with 5, 6, or 7 hardware units. If a patient is ventilated for more than 10 or 14 days, the 
hardware will be removed and made available to newly entering participants. However, if 
fewer units are available then some patients entering the ICU may not be able to be included 
in the study, as there would be no currently available hardware units. The number of missed 
patients and the utility of each of the six cases is presented in Table 4.2 and Figures 4.3a-
4.3.f.  
 
Table 4.2. The six cases comparing the number of missed patients and hardware utility. 
No. of 
Machines 
10 days max. 14 days max. 
Missed patients 
(of N=645) 
Utility 
Missed patients 
(of N=645) 
Utility 
5 49 50% 76 56% 
6 18 44% 33 50% 
7 8 38% 15 44% 
 
As illustrated in Figures 4.3.a - 4.3.f, restricting the length of data collection reduced the units 
required in any given hour compared to Figure 4.2. Table 4.2 and Figure 4.3 demonstrate that 
limiting the number of hardware units does in fact require some of the 645 eligible patients to 
be missed from the trial. Limiting the number of hardware units increases the hardware utility 
but sacrifices some patients (< 15%). However, these small missed numbers would not 
significantly affect trial length or the generality of the cohort. Hence, it is acceptable given 
the 50% reduction in computing platforms and associated maintenance.  
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Figure 4.3.a. The number of hardware units used over four 
years for a maximum of 10 days and limited to 5 units. 
 
Figure 4.3.b. The number of hardware units used over four 
years for a maximum of 14 days and limited to 5 units. 
 
Figure 4.3.c. The number of hardware units used over four 
years for a maximum of 10 days and limited to 6 units. 
 
Figure 4.3.d. The number of hardware units used over four 
years for a maximum of 14 days and limited to 6 units. 
 
Figure 4.3.e. The number of hardware units used over four 
years for a maximum of 10 days and limited to 7 units. 
 
Figure 4.3.f. The number of hardware units used over four 
years for a maximum of 14 days and limited to 7 units. 
 
From the results shown in Figures 4.3, there are few times where more than six units are 
required, but a larger proportion of times where only five units is inadequate. The estimated 
utility of 57% is unlikely be improved due to the large fluctuations in admissions and demand 
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for MV in this ICU. In addition, there is little added cost involved in having spare hardware 
units that are not fully utilised.  
The CURE RCT plans to recruit 300 patients over two years compared to the 645 eligible in 
this four year analysis. The number of participants will be significantly lower during the trial, 
reflecting slightly stricter inclusion/exclusion criteria and any patients that drop out. Note that 
the trial will recruit patients under presumed consent at ICU admission with the option to 
withdraw later. Thus, recruitment rates are expected to be high, and there are also potential 
withdrawals that will lower the utility.  
Based on the findings in utility analysis and collective opinion of the trial team, 8 computing 
platforms will be procured allowing for 2 units to be used for research purposes, while being 
available if any problems occur with the 6 in operation at the ICU or at times of high demand.  
The total cost of 8 hardware units is $14,000, as detailed in Section 3.9.2, 56% less than 18 
units based on the number of ICU beds.  
4.1.4.1&Limitations&and&recommendations&
One of the limitations of this analysis is that the patient’s LoMV is aligned according to 
chronological order of the retrospective data. The analysis can be extended using a Monte-
Carlo simulation to randomly select 300 patients from the 645 eligible patient cohort to 
simulate the recruited cohort. This recruited cohort is then used to inspect the number of 
hardware units necessary to capture each patient and thus provide a potentially more robust 
approximation in the utility analysis. However, this kind of simulated cohort analysis would 
also not be perfect as determining the recruited patients from the beginning does not reflect 
the daily choices in the ICU. Hence, this analysis was deemed suitable.  
4.1.5 Summary: Utility Analysis 
A retrospective analysis of the ICU patients admitted from Jan 1st 2011 through to Dec 31st 
2014 found 645 patients would have been eligible for the CURE RCT. An hourly analysis 
found that for the vast majority of the time, 6 hardware units would be sufficient. However, 
to manage any hardware problems, 2 replacement units should be procured for research 
purposes and backup. Therefore, 8 hardware units will be sourced for CURE RCT. 
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4.2 ICU Diagnostic Codes and Estimated Risk of Death 
Metrics 
4.2.1 Introduction 
Patients admitted to the ICU are in critical condition (Marini, 2013) and commonly have 
respiratory failure requiring support (Marini, 2013). These patients have considerable risk of 
death (RoD). In particular, MV patients have typical mortality rates of 30% (Esteban et al., 
2002) but patients with ALI/ARDS have mortality reported over a wide range covering 15-
72% (Bersten et al., 2002; Rubenfeld et al., 2005; The ARDS Network, 2000) (Esteban et al., 
2002; Zambon and Vincent, 2008). However, since 1980, ARDS mortality has been dropping 
from approximately 50% closer to 30% (Sigurdsson et al., 2013; Zambon and Vincent, 2008; 
Phua et al., 2009). 
There are various metrics to quantify risk of death, for example, the APACHE II, APACHE 
III, and SAPS scores all have associated RoD metrics (Knaus et al., 1985; Knaus et al., 1991; 
Gall et al., 1984). These scores are based on simple parameters including age, body 
temperature, mean arterial pressure, heart rate, respiratory rate, fraction of inspired oxygen, 
arterial oxygenation, arterial pH, blood chemistry. They are used to broadly classify diagnosis 
and patient condition. This information provides prognostic value for the clinicians and they 
are well associated to outcome (Knaus et al., 1985; Knaus et al., 1991; Gall et al., 1984). 
In this study, the risk of death metrics of the Christchurch hospital ICU are studied and 
compared with the actual mortality rate. This comparison investigates how well these 
mortality predictors perform currently to the participating hospital. In addition, 
retrospectively investigating mortality rates will provide insight into the expected mortality of 
the cohort of patients eligible for the CURE RCT. This information can be used to assist in 
sample size and power analysis, as well as interim and stopping rule analyses (Schoenfeld 
and Meade, 2004), where mortality can be used as a primary or secondary outcome. 
4.2.2 Methods 
Extracting all patients eligible for the CURE RCT from the 5176 patients admitted to 
Christchurch Hospital ICU over 4 years (2011-2014), left 645 patients. By grouping patients 
by Acute Physiology and Chronic Health Evaluation III (APACHE III) diagnostic code 
groups (100-cadiovascular, 200-respiratory etc.) and subgroups (101-cardiogenic shock, 102-
cardiac arrest, 201-aspiration pneumonia, 202-respiratory neoplasm etc.), the population’s 
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ICU and hospital mortality and risk of death (RoD) predicted by APACHE II, APACHE III 
and Simplified Acute Physiology Score (SAPS) scores can be directly compared. For both 
APACHE III diagnostic code groups and subgroups, the actual mortality rate is compared to 
the predicted RoDs with Pearson’s correlation plot and Bland-Altman plot. 
4.2.3 Results 
From the cohort of 645 patients, 546 survived post ICU discharge corresponding to an ICU 
mortality rate of 15.4%. Compared to published mortality rates for ARDS upwards of 30% 
(Bersten et al., 2002; Rubenfeld et al., 2005; The ARDS Network, 2000; Esteban et al., 2002; 
Zambon and Vincent, 2008; Sigurdsson et al., 2013; Phua et al., 2009), the mortality of 
CURE RCT eligible patients is significantly lower, representing the more diverse population 
selected for this trial. APACHE II, III and SAPS estimate a cohort RoD of 28.0, 25.2 and 
32.4%, respectively.  
The group and subgroup information is illustrated in Tables 4.3 and 4.4, respectively. The 
three rightmost columns represent the absolute error of the estimated RoDs compared to the 
actual mortality. In many cases, the RoDs were significantly greater than the reported 
mortality for the group or subgroup. This difference is expected as the RoD metrics are 
created from an aggregate of data at the specific time they are constructed and may no longer 
be indicative of current care and outcomes. 
Cells shaded green represents greater than 100% overestimation and shaded orange 
represents any underestimation of risk. Green cases are indicative of greater than average 
performance or inadequacy of the RoD measures, whereas orange cases represent an 
underestimation of the risk facing patients. Thus, SAPS, the oldest calibrated score has the 
most green cases. APACHE III generally predicts lower RoD compared to the other methods 
and is subsequently more accurate to the measured ICU mortality. Importantly, APACHE III 
is best in all of the large sampled groups.  
Using APACHE II, 9 of 16 groups observed in this study had predicted mortality rate higher 
than actual mortality rate. 6 of 16 group had lower predicted mortality rate. Using APACHE 
III, 12 of 16 groups had predicted mortality rate higher than actual mortality rate with 3 
lower. Using SAPS, 14 of 16 groups had predicted mortality rate higher and 1 of 16 lower 
than actual mortality rate. 
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-20%
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41%
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-21%
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600 
27 
7%
 
11%
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43%
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Some interesting cases that arise in Table 4.3 include: 
•! Group 200, non-operative respiratory. APACHE II, III and SAPS predict 32, 29 and 29% 
mortality, but the actual recorded mortality is only 21%. All three metrics moderately 
overestimate (N=213). This group is the largest group and most likely to have ARDS and 
be included in the CURE RCT. 
•! Group 700, non-operative metabolic. APACHE II and III predict 3 and 8% RoD, but 
SAPS predicts 39%. Actual ICU mortality is 4% (N=69). APACHE II and III are 
moderately incorrect while SAPS significantly overestimates mortality and should not be 
used for this group. 
•! Group 800, non-operative haematological. APACHE II predicts 0% while ICU mortality 
is reported at 43% (N=7). APACHE II should not be used for this group as it may not 
account for factors affecting this particular subgroup. 
•! Group 1600, post-operative trauma. Actual mortality of 11% (N=37) is higher than 
predicted by both APACHE II and III of 6 and 4%. These patients may need additional 
care.  
 
 
Figure 4.4. Pearson's correlation coefficient and correlation plots for group analysis. 
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Figure 4.5. Bland-Altman plot for group analysis. 
 
Figure 4.4 illustrates that APACHE III is the superior metric, as expected as it is the newest 
and updated metric, while comparing diagnostic code groups with the highest correlation 
coefficient of R=0.85 compared to 0.30 and 0.72 of APACHE II and SAPS respectively. This 
result aligns with literature findings, where APACHE III provides a better estimation of 
patient risk of death compared to APACHE II or SAPS or the newer SAPS II iteration (Reina 
et al., 1997; Wunder et al., 2004). Since APACHE II, III and SAPS were developed in 
particular sets of ICUs and published in 1985, 1991 and 1984 respectively (Knaus et al., 
1985; Knaus et al., 1991; Gall et al., 1984), calibration must be performed for the individual 
ICU (Katsaragakis et al., 2000) after which the method’s performance is more comparable 
(Markgraf et al., 2000; Kim et al., 2005).  
Furthermore, the Bland-Altman plot of Figure 4.5 describes a zero bias of the APACHE III 
metric with only one instance of poor performance outside the bounds of ± 2 standard 
deviations from the mean. Although APACHE III has the largest bounds, likely skewed by 
the one outlier, the combination of greatest correlation coefficient with zero bias and 
acceptance variation reinforces that APACHE III is the superior metric for determining ICU 
RoD for a grouped cohort similar to that expected for the CURE RCT. The approach and 
result is thus of use when designing such a trial. 
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There are several interesting cases described by subgroup results shown in Table 4.4. 
Presented here are those with N > 9 recorded cases in this analysis. 
•! Group 203, respiratory arrest. All three metrics significantly overestimate RoD by 27 and 
46% compared to the actual mortality of 10% (N=10). Similarly, group 503, sepsis with 
shock other than urinary, a common cause of ARDS. Actual mortality is high at 28% 
(N=40), but predicted much higher at 52, 49, and 48%. These two cases may be indicative 
of exceptional care provided to these patients. 
•! Group 208, mechanical airway obstruction. All three metrics underestimate RoD by 5 and 
14% compared to the actual mortality of 33% (N=12). Patients with this diagnosis may 
require additional care.  
•! Group 501, sepsis other than urinary. Actual observed mortality is high at 33% (N=12), 
but predicted at 35, 19, and 18%. Both APACHE III and SAPS significantly 
underestimates the risk to these patients, while APACHE II performs well. This could 
perhaps be an area for the ICU to focus on. 
•! Group 504, sepsis of urinary tract origin with shock. Predicted high RoD of 47, 27 and 
48%, but out of the N=10 patients included, all survived. This may be indicative of 
exceptional care provided to these patients. 
Similar to the overall result presented in Section 4.2.3.1 for each subgroup, APACHE III 
appears to be the superior estimated RoD metric. Figure 4.6 describes an APACHE III 
correlation coefficient of R=0.56 compared to 0.43 and 0.34 for APACHE II and SAPS. 
Figure 4.7 illustrates the slight positive bias of APACHE III compared to the larger, 
potentially expected negative bias of APACHE II and SAPS. Both Figures 4.6 and 4.7 
include small sample size subgroups and subgroups with estimated or actual mortality of 
zero. 
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Figure 4.6. Pearson's correlation coefficient and correlation plots for subgroup analysis. 
 
Figure 4.7. Bland-Altman plot for subgroup analysis. 
 
4.2.3.3%Limitations%
The major limitation of this analysis is assuming that every patient with an identical 
APACHE III diagnostic code is similar in disease severity. This assumption is unavoidable, 
but improved by inspecting the subgroups. However, for a large group such as 703, drug 
overdose, there is a very significant variation between patients in their condition and thus 
their real risk of death. In particular, this group contains many patients who have estimated 
RoDs near the combined mortality rate of 5%, but there are also outliers within the 
population of N=301. The RoD estimated for one particular patient is 13, 22 and 66% by 
APACHE II, III and SAPS respectively and another patient 0, 2 and 31%. There is thus a 
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huge disparity among patients and the method of pooling similar patients with a simple mean 
of individual RoDs may not be valid in these cases.  
Figures 4.6 and 4.7 include all of the subgroups, some of which only include 1 or 2 patients, 
at equal weightings to those with 85 patients. A more detailed analysis could weight the 
patient groups and subgroups by their sample size to focus on the groups and subgroups with 
the most patients. Generalised RoD metrics can only provide an overall estimation of RoD 
and may not be specific for a single centre. However, it is found that, overall, it was able to 
capture the mortality rate of this participating centre relatively well with R = 0.85 for 
APACHE III. 
4.2.4 Summary: RoD Analysis 
It appears from this retrospective analysis of 645 ICU patients from Jan 1st 2011 to March 
31st 2015, that APACHE III is the best method to assess the patient’s risk of death based on 
their APACHE III diagnostic codes. APACHE II and SAPS are comparable over all groups 
and subgroups but each do perform best for specific diagnoses. However, APACHE III is not 
able to completely capture risk of death or cohort mortality rate of the ICU patients groups 
due to the variability in hospital practice, care and outcome, but can provide a good first 
estimate for design.  
 
4.3 Retrospective Analysis of ICU Readmissions 
4.3.1 Introduction 
It was observed in the previous analyses that several of the 5176 ICU patients were 
readmitted into the ICU at a later date. Naturally, the length of time between admissions, as 
well as the first and second diagnoses differed for each patient. It was hypothesised that 
readmissions could be categorised and future readmissions predicted. If patients susceptible 
to similar readmission could be identified and the reason for reoccurring admission resolved, 
the demand for ICU beds and the associated cost of treatment could be reduced.  
4.3.2 Methods 
Patients were identified using their National Health Index (NHI) number [but could not be 
identified outside of research analyses] and compared to every other admission into the ICU 
over the 4 years from Jan 1st 2011 to Dec 31st 2014. Occurrences of the same patient being 
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admitted were extracted and collated. The length of time between initial discharge and 
subsequent readmission was calculated and used to define three categories: 
1.! Short-term readmissions (< 7 days): These cases are likely to be due to re-development of 
the initial condition or cases of complications where surgical intervention may have been 
required.  
2.! Mid-term readmission (> 7 but < 28 days): Readmissions in this category are likely to be 
of mixed causality. 
3.! Long-term readmissions (> 28 days): These cases are less likely to be direct results of the 
initial insult, but may represent chronic disease progression, severely ill patients in-and-
out of hospital wards, or distinct illnesses. 
4.3.3 Results and Discussion 
4.3.3.1%Complete%ICU%cohort%of%5176%
From the 5176 patients included in this retrospective analysis, a total of 510 (~10%) 
readmissions were identified. From these cases, the majority were cases of a single 
readmission with 96 cases being a third or higher admission. Thus, 414 different patients 
were readmitted at some time. Table 4.5 includes the number of readmission cases for each of 
the three categories outlined.  
To investigate each readmission separately, the diagnostic code for the first admission is 
compared to the second. Patients are pooled based on their APACHE III diagnostic code 
groups and the number of occurrences. The result is presented in Tables 4.6-4.8 for short-, 
mid-, and long-term readmissions, respectively. 
Table 4.5. Number of readmissions in each of the three categories (N=5176). 
Time before readmission Number of readmissions  
t < 7 days 198 (39% of 510; 3.8% of 5176) 
7 < t < 28 days 81 (16% of 510; 1.6% of 5176) 
t > 28 days 231 (45% of 510; 4.5% of 5176) 
 
Illustrative example from Tables 4.6 indicated by *: 
Row 400, Column 200: 8 patients are first admitted with diagnostic code of 400 and were 
subsequently readmitted in less than 7 days with 200 diagnostic code. 
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Table 4.6. Short-term
 (t <
 7 days) readm
issions. (N
  =
 198) 
APACHEIII'
Diagnostic'
Code'
Second'Adm
ission'
0'
100'
200'
300'
400'
500'
600'
700'
800'
900'
1000'
1100'
1200'
1300'
1400'
1500'
1600'
1700'
1800'
1900'
2000'
2100'
2200'
First'Admission'
0'
4'
''
1'
''
''
''
''
''
''
''
''
''
1'
''
''
''
''
''
''
''
''
''
''
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''
4'
''
1'
1'
''
1'
''
''
''
''
''
4'
1'
1'
''
''
''
''
''
''
''
''
200'
1'
1'
24'
1'
1'
1'
''
''
1'
''
''
''
1'
''
1'
''
''
''
''
''
''
''
''
300'
''
''
2'
1'
''
1'
''
''
''
''
''
''
''
''
1'
''
''
''
''
''
''
''
''
400'
''
''
8*'
''
7'
1'
''
''
''
''
''
''
1'
''
''
1'
''
''
''
''
''
''
''
500'
''
''
1'
''
2'
4'
''
''
''
''
''
''
''
''
''
''
''
''
''
''
''
''
''
600'
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''
2'
''
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''
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''
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''
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''
''
''
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''
''
''
''
''
''
''
''
''
''
''
''
''
''
''
''
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''
11'
7'
1'
2'
2'
1'
1'
''
2'
''
''
7'
''
2'
''
''
''
''
1'
''
''
''
1300'
''
1'
5'
''
1'
''
''
''
''
''
''
''
''
1'
''
''
''
''
''
2'
''
''
''
1400'
''
1'
5'
4'
''
2'
''
2'
''
''
''
''
1'
''
13'
''
''
1'
''
''
''
''
''
1500'
''
''
2'
''
3'
''
''
''
''
''
''
''
''
''
''
1'
''
''
''
''
''
''
''
1600'
''
''
1'
''
''
''
''
''
''
''
''
''
1'
''
''
''
4'
''
''
''
''
''
''
1700'
''
''
1'
''
''
''
1'
''
''
''
''
''
'
''
''
''
''
1'
''
''
''
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''
''
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''
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''
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''
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''
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''
''
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''
''
''
''
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''
''
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''
''
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''
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''
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''
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''
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''
''
''
''
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''
''
''
''
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Table 4.7. M
id-term
 (7 <
 t <
 28 days) readm
issions. (N
 =
 81) 
APACHEIII'
Diagnostic'
Code'
Second'Adm
ission'
0'
100'
200'
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400'
500'
600'
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800'
900'
1000'
1100'
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1300'
1400'
1500'
1600'
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''
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''
''
''
''
''
''
''
''
''
1'
''
''
''
''
''
''
''
''
''
100'
''
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1'
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''
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''
''
''
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5'
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''
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1'
''
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''
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Table 4.8. Long-term
 (t >
 28 days) readm
issions. (N
 =
 231) 
APACHEIII'
Diagnostic'
Code'
Second'Adm
ission'
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900'
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1200'
1300'
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''
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200'
''
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1'
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''
''
''
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1'
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As expected, there is a large spread of readmission occurrences in both axes reflecting the 
wide range of ailments in the ICU and reinforcing that readmissions at Christchurch Hospital 
are not caused by negligence in one or a few particular areas.  
The following are the six most significant trends, based on the number of cases recorded with 
an emphasis on respiratory significance, and are outlined by colour in Tables 4.6-4.8.  
1.! To be readmitted into the same diagnostic code group (shaded green): This trend tends to 
be a significant proportion of the total sample (40%, 37% and 46% for short-, mid-, and 
long-term readmissions respectively). 
2.! To start in 200 (non-operative respiratory) and move elsewhere (shaded blue): Only 
occurs to small numbers, but significant to MV research (4, 2 and 10%). 
3.! To start in 1200 (post-operative cardiovascular) and move elsewhere (shaded 
yellow):Most significant for short-term readmissions (15, 10 and 9%). 
4.! To be readmitted into 200 (non-operative respiratory) (shaded orange): Occurs in 
moderate to small numbers but is significant to MV research (20, 9 and 9%). 
5.! To be readmitted into 1200 (post-operative cardiovascular) (shaded red): Occurs in small 
numbers (7, 9 and 9%) but is a major use of ICU and hospital resources. 
6.! To be admitted post-operative and readmitted non-operative with similar diagnosis, i.e. 
cardiovascular 1200 to cardiovascular 100 or respiratory 1300 to respiratory 200 (shaded 
purple): Most common for short-term readmissions (12, 5, and 3%) and is most likely to 
reflect complications post-surgery in the short-term or chronic illness in the long-term. 
 
Tables 4.6-4.8 outline four quadrants defined by non-operative or post-operative in each axis. 
1.! Non-operative to non-operative (APACHE III diagnostics ≤ 1100): Contains the largest 
proportion of cases (41, 41 and 52%) that occur most often for long-term readmissions. 
2.! Initially admitted post-operative (APACHE III diagnostics ≥ 1200) and readmitted non-
operative: Common to not very common (30, 16, and 13%). Most common for likely 
related short-term readmissions and may be caused by chronic illness or unrelated long-
term readmissions. 
3.! Initially admitted non-operative and readmitted post-operative: Not very common but 
greater proportion for mid- and long-term readmissions (10, 17, and 17%), likely caused 
by complications or planned interventions of chronic illness. 
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4.! Post-operative to post-operative: Common to not very common. The greatest proportion 
occurs for mid-term readmissions (19, 26, and 18%) which may be caused by insults that 
require several surgeries. 
From the 5176 patients admitted to the ICU from Jan 1st 2011 to Dec 31st 2014, there were a 
total of 510 cases of a readmission. Only considering these 4 years of the Christchurch 
Hospital ICU, it can be estimated that 10% of patients being admitted would have either 
previously been admitted into the ICU or can be expected to be readmitted after discharge. In 
reality, many more patients are likely to have already been admitted and discharged from this 
or another ICU in previous years due to the limited time-span included in this analysis. Data 
from many more years and other ICUs is needed to reinforce the arguments made in this 
analysis. 
Tables 4.6-4.8 describe the occurrences of short-, mid-, and long-term readmissions of less 
than 7 days, between 7 and 28 days, and greater than 28 days respectively.  Tables 4.6-4.8 
illustrate the basic trends of changing patient condition, pre- and post- operative admissions, 
and worsening chronic illness. In many cases, patients are readmitted within their previous 
diagnostic code suggesting the prevalence of chronic illness and return of the same or similar 
insult. In particular, non-operative respiratory and metabolic and post-operative 
cardiovascular and gastrointestinal diagnoses in all three groups, as well as non-operative 
neurological and sepsis diagnoses were short-term cases.  
4.3.3.2%Refined%CURE%RCT%Eligible%cohort%of%645%
A similar analysis to Section 4.3.3.1 was conducted on the cohort of patients that have 
previously been used to estimate the cohort that may be enrolled for the CURE RCT. Due to 
the much smaller sample size of 645 only 20 (~3%) cases of readmission were observed 
affecting 19 different patients. In similar proportions to the larger cohort, the number of cases 
on short-, mid- and long-term, readmissions were 7, 3 and 10, respectively. The APACHE III 
diagnostic code groups for the readmissions of the smaller CURE RCT cohort are compared 
for short-, mid- and long-term cases as shown in Table 4.9-4.11. 
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Table 4.9. Short-term (< 7 days) readmissions for the estimated CURE RCT cohort. 
N"="7"
Second"
Admission"
0" 200" 1900"
Fi
rs
t"A
dm
iss
io
n" 0" 2" "" ""
200" "" 2" ""
300" "" 1" ""
700" "" 1" ""
1900" "" "" 1"
 
Table 4.10. Mid-term (> 7 but < 28 days) readmissions for the estimated CURE RCT cohort. 
N"="3"
Second"
Admission"
0" 200" 1400"
Fi
rs
t"
Ad
m
iss
io
n"
0" 1" "" ""
200" "" 1" ""
500" "" "" 1"
 
Table 4.11. Long-term (> 28 days) readmissions for the estimated CURE RCT cohort. 
N"="10"
Second"Admission"
0" 200" 500" 700" 1300" 1400" 1600"
Fi
rs
t"A
dm
iss
io
n" 0" 1" "" "" "" "" "" ""
200" "" 3" "" "" "" "" ""
500" "" "" 1" "" "" "" ""
700" "" 1" "" 1" "" "" 1"
1300" "" "" "" "" 1" "" ""
1400" "" "" "" "" "" 1" ""
 
Almost all of the cases described in Tables 4.9-4.11 are shaded green representing 
readmission with similar diagnosis. The three other cases otherwise are shaded orange 
representing a readmission into group 200, non-operative respiratory.  
The readmission results for the smaller CURE RCT cohort illustrate that of the 645 patients 
considered to be eligible for the trial, 19 would have already been admitted and discharged 
from the ICU for common, similar conditions. Over the two year period expected of the 
CURE RCT, 9 (3% of 300) cases of readmission can be expected of patients who are eligible 
for CURE at both admissions. It is even more likely that recruited trial participants may have 
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previously been admitted and discharged from the ICU at a rate of approximately 10% or 30 
during the study. There is thus little chance of a patient being enrolled twice. This 
information can used to determine the inclusion and exclusion criteria of a clinical trial 
accounting for readmission.  
4.3.3.3%Limitations%
The major limitations of this early work are the lack of very long term data, the basic nature 
of the available data, and the grouping of patients into APACHE III groups. Being able to 
trace individual patients who have been readmitted to identify the reason for their 
readmission and whether it was clinically linked to the initial insult would add complexity to 
the analysis but reinforce the causal speculation included in this discussion. A more complete 
analysis would inspect the subgroups of patients with identical diagnoses, but would require 
much more data.  
Readmissions are defined by a change in ICU identification number for the same NHI 
number. Thus, the patient must have recovered fully or improved enough to be discharged 
home or to another ward before being readmitted. The ICU has both acute (e.g. drug 
overdose, trauma etc.) and planned admissions (e.g. cardiac surgeries). It is thus likely that 
readmissions into post-operative codes may correspond to planned surgeries, rather than 
complications caused by the initial insult where the patient would not be discharged.  
4.3.4 Summary: Readmission Analysis 
Recording a hospital’s ICU admissions is routine practice but inspection of cases of 
readmission is rarely performed. By retrospectively tracking readmission cases, it may be 
possible to forecast which patients are susceptible for short-, mid-, or long-term readmissions. 
The clinicians could use this information to forecast readmissions and provide sustained care 
or management of chronic disease to prevent patient deterioration and costly ICU 
readmissions. It can be expected that at least 10% of patients being admitted into the ICU 
have or will be admitted again and likely with a similar diagnosis. 
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4.4 Chapter Summary: 
Three metrics were retrospectively analysed with data from Christchurch Hospital ICU from 
1st Jan 2011 to 31st Dec 2014. 5176 patients were included and a cohort of 645 patients who 
would have been likely to be eligible for the CURE RCT were extracted. The length of 
mechanical ventilation was investigated to determine that 6 CURE hardware units would 
suffice but 8 would be procured with 2 additional units for research and backup purposes.  
The estimated risk of death of the cohort was investigated against the actual mortality of 
15.4% and determined that APACHE III was superior to APACHE II and SAPS. These 
metrics were generally able to capture RoD for this participating ICU. However, small 
deviations arise as standard of practice care varies from one centre to another.  
Cases of readmission were investigated first, on the N=5176 cohort and second, on the 
N=645 CURE RCT cohort. ICU readmissions are estimated at greater than 10% however, the 
addition of more data will likely raise the estimate. Within the smaller CURE RCT cohort, a 
readmission rate of only 3% was estimated within the 4 year period. Over the course of the 
CURE RCT, it was estimated that only 9 occurrences of trial eligibility may be prevented by 
prior enrolment into the trial. This number is small and negligible but is noted and taken into 
account for the planned RCT.  
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5.0 Trial Commencement 
Commencement of any randomised controlled trial (RCT) can be complicated with ethics 
approval, clinical protocol design, financial planning, hardware procurement, and data 
storage (Farrell, 1998). To date, the ethics approval and the majority of the clinical protocol 
design had already been completed during the ethics application process. However, it is often 
that during pre-trial, a minor changes in clinical protocol for example, can result in updating 
various documentations related to the changes.  
5.1 Pre Trial Commencement 
One of the main tasks before a trial commences, is the completion of the clinical training 
documents. To accompany the clinical protocol and CURE Soft should be a CURE RCT 
manual. The CURE RCT manual includes all the instructions for every aspect of the trial. 
CURE%RCT%Manual%
CURE Soft was intended for use by intensivists, registrars and attending nurses. The 
clinicians are qualified for their jobs, but the added burden of having to participate in a trial 
and learn how to use a new software could discourage some. To ease potential anxiety, it was 
decided to focus on software use in the documentation. A selected few people will be trained 
in the finer details of hardware and software setup but every clinician involved in the trial 
should understand how to complete a recruitment manoeuvre (denoted as max RM) and 
PEEP titration (denoted as PUMP manoeuvre) manoeuvre for example.  
A training manual for the clinicians is attached at the end of the thesis. Please refer to 
Appendix B for the Training Manual. It is subject to continual changes as the research team 
gather feedback on the software, protocol and training documents. 
 
5.2 CURE RCT Work-Flow 
The expected work-flow of the CURE RCT trial is depicted in Figure 5.1. This work flow is 
generated from the perspective of an ICU patient, and is part of CURE trial RCT training. 
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Figure 5.1. The expected work-flow diagram of the CURE RCT trial from the perspective of one patient. 
Patient admitted to ICU and 
intubated
Screening form filled out by 
nurse
Screening information is entered 
in to Excel for randomisation 
(possibly located in technicians’ 
space or by the mechanical lung) 
Randomised into Control and 
Intervention group
Eligible
Intervention Group
Control Group
Technician setup the computer for 
CURE Soft 
Nurse/registrars setup CURE Soft 
and start recording the data
Family/Relative/Whanau Consent 
Patient discontinued from 
ventilator
Consent from patient unless 
deceased.
Standard Practice Ventilation 
(SPV)
Model Based ventilation (MBV)
Maximum Recruitment Manoeuvre 
and performed by Senior Medical 
Officer or trained Registrars
PUMP performed by 
registrars/nurses every 6 hours 
and added event into CURE Soft
Have either the SMOs or the 
trained registrars talk to the 
family about the trial and 
consent. Ideally we would 
want it <48 hours.
Ask if we can keep the data 
currently available (done by 
SMOs/UC/Registrars)
Store data but cannot use it
Archive data and paper work
If ventilator is ever disconnected 
from patient. Add event to CURE 
Soft then stop recording data 
CURE Soft
Ventilator reconnected by 
nurses/registrars and CURE Soft 
is started again.
No
Patient withdrawn from trial
NoYes
Yes/deceased
No
Have either the SMOs or 
the trained registrars talk 
to the patient giving 
consent to keep the data 
for research purposes.
Not Eligible
Archive Paper work to a file
Yes
Yes
If true on Weaning Assessment
Family/Relative/Whanau 
Available 
Collect patient data using the
dedicated HDD and collect
every fortnight (this includes
backing up data)
Technician setup the computer for 
CURE Soft 
Nurse/ registrars setup CURE Soft 
and start recording the data
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When a patient is admitted to the ICU and subsequently intubated for invasive ventilation, the 
patient will be screened for eligibility. A nurse or attending clinicians will need to fill out a 
hard copy form using a patient identification label to confirm patient name, date of birth and 
NHI number. The information will then be transferred into an electronic database for data 
storage. The details of the screening sheet are shown in Appendix C. 
Once the screening information has been entered into the electronic database, a 
randomisation algorithm assigns eligible patients into different treatment groups. In this 
CURE RCT study, the intervention group (MBV) and control group (SPV). A block 
randomisation sequence was utilised with blocks of 4, 6, and 8. The block randomisation 
eliminates bias (Schulz and Grimes, 2002) and is commonly recommended for RCTs over 
traditional randomisation techniques (Kernan et al., 1999). 
Once enrolled into either treatment group, the data collection equipment will be set up and 
started. A CURE Soft stand will be attached to the rear of the participant’s ventilator and set 
up to start collecting data. Setup should be performed by an ICU technician.  
If the participant is randomised into the SPV group, the computer will collect data for the 
duration of their ICU stay up to 14 days. This group is the control group and has no 
additional invasion or interruption to regular care. 
In contrast, if the participant is randomised into the MBV group, a MaxRM should be 
performed by a doctor or registrar as soon as the participant’s respiratory mechanics have 
stabilised after muscle relaxant administration. From this point, the computer will continue to 
collect data and every time the patient is turned onto their back in a supine position, a PUMP 
should be performed by anyone trained to do so, most likely the attending nurse.  
At any point from now, the informed family/relative/whanau consent process begins. The 
trial will be explained to the family using an official family information sheet. The patient’s 
family will have time to think, ask questions, and discuss how they think the patient would 
respond after which time the family/friend consent form will be completed. If consent is not 
given, the patient’s participation will immediately stop and if requested all data will be 
erased.  
If family/friend consent is given, the trial and use of data will continue until any point at 
which consent is removed by family/friends or the patient themselves upon recovery. The 
family/friend and patient information sheets and consent forms are all included in Appendix 
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D. Completed consent forms, either accepting or rejecting consent, should be filed back into 
the CURE trial paperwork repository. 
 
5.3 Data Collection and Repository 
In CURE RCT, eight CURE Soft units were prepared for mechanical ventilation data 
collection. Each of the eight hardware units have 256 GB of storage space and in most cases, 
less than 250 MB will be obtained from one patient per day of ventilation. Since the CURE 
RCT will include 300 patients at an average length of ventilation of 2-4 days, approximately 
300 GB of raw data will be recorded. Thus, the inbuilt hard-drives are more than adequate to 
last the entire trial if necessary.  
Regardless of the capacity of the hardware, the data will regularly be collected, encrypted and 
backed-up on external hard-drives and in Cloud type storage to ensure the data is safe and to 
allow preliminary and interim analyses (Pocock, 1983; Grant et al., 2005). A portable 
external drive, Seagate Expansion with 1 TB of storage and a commercial Dropbox account 
with 1 TB of storage have been set up to be the permanent storage of CURE RCT raw data. 
It is crucial that the primary investigators and statisticians can identify exactly who the data 
was recorded from and when exactly it was recorded. CURE Soft includes in the Settings tab 
the ability to adjust the file path to which the data will be saved. Within each folder are 
subfolders named by the computer’s date and within those are raw data and processed data 
labelled by the computer’s time. During staff/user training the concept of using the user’s 
trial identification number, i.e. MBV-XXX or SPV-XXX, to save all of the patient data in 
one folder labelled with their unique identifier will be reinforced. The use of trial identifier as 
the first folder name will also facilitate an intuitive layout of the data archive. If a participant 
recovers and denies consent to use the data collected the entire folder can be easily deleted.  
 
5.4 CURE Software Amendments 
Within the course of this research project, many discussions regarding the software with ICU 
staff resulted in many minor and major changes to CURE Soft for improved ease-of-use for 
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the large expected audience. In addition, the target audience for the software had to change 
from primarily researchers to include ICU nurses, registrars, and intensivists. 
In this study, discussion with two members of the ICU, Mr Miles Peters, a Nurse Educator, 
and Garry Anderson, a Senior ICU Nurse were carried out. They are the ICU team front-line 
that will be involved in carrying out further trial trainings to nurses. They are experienced and 
knowledgeable on the clinical and nursing workload. Hence, their feedback on CURE soft 
applicability and feasibility will be very useful for end user product design requirements. 
Discussion with Miles Peters and Garry Anderson yielded the following points: 
1.! The software needs to be intuitive and as simple as possible for everyday use. ICU 
nursing workload was found to be tedious work and have major impact on patients 
outcome (Spence Laschinger and Leiter, 2006; Sasichay-Akkadechanunt et al., 2003; 
Kane et al., 2007). Hence, application of CURE Soft and trial should aimed at not 
inducing additional burden to their clinical practice. 
2.! Additional one-click buttons to record clinical events. There should be some extra buttons 
to easily add events to the event log such as suctioning, disconnection (accidental or 
otherwise) and other. These buttons provides ease of recording of critical events 
involving/ affecting mechanical ventilation therapy, and reduce the nursing time spend on 
typing/ writing the events manually.  
3.! Conducting a PUMP manoeuvre is within the capabilities of nurses as they are 
responsible for a significant number of critical tasks. The current MV management 
practice conducted by nurses are mostly on setting FiO2 based on desaturation events. 
Having the nursing to work on PUMP, which is a procedure to adjust PEEP will 
significantly ease the overall RCT workload needed to be conducted by the registrars.  
Continual discussion with ICU clinician Professor Geoffrey Shaw yielded more detailed 
software changes. These changes also focused on ease of use and include: 
1.! Renaming specific identifiers so that the CURE Soft is more intuitive. 
2.! Using larger font sizes in CURE Soft for easier read and usage.. 
3.! Include additional tabs for events selection.  
4.! Fixing PEEP scale to a realistic testing range. 
5.! Provide real-time step by step indicators/ instruction for the CURE Soft users during 
Recruitment manoeuvres or PUMPs. 
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Some of these changes are illustrated in the following figures. Figure 5.2 describes the 
change made to ease selection and enforce standardisation of Patient ID in the Settings Tab, 
which influences the saved data folder. Figure 5.3 depicts the changes made to split the old 
‘Start RM’ button into three to simplify the process of conducting a PUMP and the addition 
of a pop-up number pad to easily type numbers such as PEEP, SpO2 and FiO2 rather than 
using the full keyboard.  
                        
Figure 5.2. Illustrative screenshots describing the changes made to the Settings Tab. 
 
 
Figure 5.3. Illustrative screenshot describing the changes made to the ‘Start RM’ button and the pop-up number pad. 
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Figure 5.4 describes the PEEP tracker addition to CURE Soft, which simplifies the process of 
a maxRM or PUMP manoeuvre by instructing the user the PEEP setting to select next. The 
use of three columns and colour directs the user to where they may have made an error in 
protocol. It can also highlight, for safety, when PIP may be exceeding 55 cmH2O.  
 
 
 
Figure 5.4. Illustrative screenshot describing the addition of a PEEP tracker. 
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These changes were relayed to the principle software developer Dr. Akos Szlavecz who 
implemented them into the current CURE Soft version (Szlavecz et al., 2014). Although these 
changes to CURE Soft interface may delay commencement of the RCT, the current version is 
significantly easier to use by leading the user through the steps and leaving many fewer tasks 
open to forget or bypass.  
 
5.5 Chapter Summary: 
Numerous aspects of documentation have been created or refined over the course of this 
project. These documentations and planning are necessary in order to improve the teaching of 
ICU staff, to manage the trial efficiently. They provide illustrations of the RCT work-flow of 
multiple staff members together, ensure the necessary documentation is completed correctly 
and to ensure the data collected is safely added to the data repository.  
The software and some documentation are continuing to change and improved at the 
recommendations of other ICU staff. In particular, the training material is likely to evolve as 
more feedback and questions are received from staff progressing through training. Hence, 
managing this documentation is vital for a successful clinical trial. 
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6.0 Challenges and Future Work 
6.1 Challenges Faced  
Many challenges are faced as engineers trying to collaborate in medicine. For this research 
project the main two challenges were  
1.! Getting approval to incorporate the designed ICU hardware that will be used by ICU 
staff for a clinical trial in the indirect treatment of patients, and 
2.! Gaining consensus between the ICU intensivists of the fundamental theory supporting 
CURE in order to proceed in the study. 
6.1.1 Hardware into the ICU 
As previously mentioned in Chapter 3.0, the ICU has strict requirements of its equipment, 
and rightly so. Having to satisfy electrical safety standards is one thing, but the greater 
challenge was designing components to a professional standard that is intuitive and suitable 
for a RCT with non-engineering end-users. The final products of this project may not meet 
commercial standard, but the effort spent to make simple, robust, and easy to use hardware 
was justified and the designs should be commercialisable.  
6.1.2 Intensivist Consensus 
A major challenge for the clinicians, Professor Geoffrey Shaw was discussing with his peers 
the benefits of CURE, the details of the CURE RCT clinical protocol, and the implementation 
of CURE RCT. Mechanical ventilation management is challenging and with little consensus 
and each intensivist had their own opinion of the best ventilation strategy and compromise 
between peers is always difficult. Respiratory RCTs are notoriously difficult to conduct and 
in particular, the effect size is small compared to the number of competing factors. Thus, the 
CURE RCT is a bold step towards individualised patient care.  
 
6.2 Future Work 
As a result of this research project, the task of commencing the study is firmly in the hands of 
the clinical investigators. The necessary components have been assembled, but there remain a 
few more abstract hurdles to overcome. However, research is continuing with a number of 
  95 
Vincent Major  ME Research Thesis November 2015 
undergraduate and postgraduate students at the University of Canterbury. The main research 
areas are those sprouting from the commencement of CURE RCT. 
6.2.1 Preliminary Analyses 
Once the study commences, a steady stream of data will be collected and available for 
preliminary analyses. As the number of patients included increases the significance of 
differences in each trial outcome will improve and the efficacy of model-based ventilation 
will start to be assessable.  
6.2.2 Virtual Patients 
The CURE RCT recruits eligible patients into the trial from the start of mechanical 
ventilation until the end of mechanical ventilation. Thus, CURE RCT will be able to provide 
an unprecedented level of real-time respiratory mechanics data that can be used to track the 
trajectory of patients based on their ventilation therapy. Pooling data from many different 
patients can build an aggregated database that can be used to further inspect how different 
ventilation settings can affect patient condition and their end outcomes. The end goal of this 
kind of analysis is to identify some generalizable aspects of optimal ventilation that may not 
have been elucidated among the optimal ventilation debate. Further research on this area can 
be performed once the trial has commenced.  
6.2.3 Improved Signal Processing  
During the CURE pilot trials, several different branches of signal processing research have 
branched from the core project. It was observed that monitoring real time airway pressure and 
flow enables the quantification of the quality of mechanical ventilation therapy, and patient 
ventilation interaction. These studies found that patients exhibit ventilation asynchronies but 
the research was not completed prior to this project. Automated asynchrony detection (Poole 
et al., 2014; Chiew et al., 2015a) and waveform reconstruction (Redmond et al., 2014c; 
Redmond et al., 2014b; Major et al., 2016) during spontaneous breathing are ongoing 
research areas that will broaden the scope of CURE Soft and broaden the spectrum of eligible 
patients, ideally to any invasively ventilated patient. Further optimisation of these methods 
will be conducted with the plan to implement in successive versions of CURE Soft.  
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6.3 Chapter Summary: 
The most difficult challenge faced in commencing the trial is the ongoing amendments made 
to the clinical protocol, work-flow, training strategy and CURE Soft. The amendments are 
created by the extensive discussion among the ICU intensivists regarding the best way to 
organise or run the study. The amendments are improving the documentation and software 
but are significantly delaying commencement. Research into mechanical ventilation is 
continuing at UC and the scope of the research is expanding as CURE RCT starts and new 
data is collected with much wider breadth and depth than available before.  
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7.0 Conclusions 
 
The current standard of care in the intensive care unit regarding invasive mechanical 
ventilation is to follow generalised guidelines set out by the ARDS Network. These 
guidelines fail to consider the significant inter- and intra-patient variability associated with 
the respiratory system in the critically ill. During recent years, a push towards individualised 
patient care is revolutionising medicine but, mechanical ventilation is lagging behind. 
Improved monitoring of real-time, patient-specific respiratory mechanics can direct clinical 
professionals to select optimal ventilation settings for every patient at any time with zero 
additional clinical invasion.  
A state-of-the-art software, CURE Soft, has been presented in previous work but an 
accompanying hardware system has been described in this thesis. In this study, prototype 
development and testing was conducted extensively and eight units were procured for 
implementation in the upcoming CURE randomised controlled trial. Each hardware unit 
accompanies a portable PC with touchscreen monitor. The unit is mounted on a stainless steel 
stand behind the ICU’s existing ventilators to facilitate ergonomic use of the system and 
minimise the footprint and perceived burden of participating in the trial.  
Respiratory studies are notoriously difficult to conduct with various management aspect 
needs to be considered. Many steps have been taken to streamline the clinical protocol and 
simplify the procedures necessary for the study through extensive discussions with clinicians 
and other ICU staff. Numerous challenges have been faced which have delayed 
commencement of the trial. However, this research has ensured every necessary non-clinical 
aspect has been organised so that the trial can commence once the clinical aspects have been 
confirmed. To aid the clinical discussion a thorough literature review has been conducted and 
presented here as a Review of Mechanical Ventilation. Every piece of critical background 
information can now be presented easily from one document containing many applicable 
references.  
Retrospective analyses, using previous ICU admission data, were conducted and were able to 
give significant insight to the estimated patient cohort that may be enrolled into the RCT. In 
particular, results from these analyses contributed to planning of the RCT, such as hardware 
utility study, modification of CURE Soft and clinical protocol development. Future research 
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will likely be much broader than that possible from the limited retrospective data. Research 
improving signal processing and the capabilities of CURE Soft will be necessary as 
inevitable issues arise during the study and the large amount of data will allow researchers to 
create a virtual patient database where their outcome can be influenced by the respiratory 
therapy supplied. 
With the physical resources created and refined during this research project, the primary 
investigators of CURE are fully equipped to commence the trial. The setbacks faced during 
this project have allowed for more rigorous discussion with a wider audience of stakeholders 
and supplied the necessary time to refine a complete set of documentation to proceed with the 
trial confident in our planning. Our tools and resources are easily scalable once the trial 
commences and the daily responsibility shifts from the primary investigators onto other 
trained ICU staff and if shown effective, scalable to higher powered, multi-centre studies to 
help transform and personalise ventilation therapy worldwide.  
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CU
RESoftTraining/M
anual
For(doctors,(nurses(and(researchers
Patient/Eligibility/and/G
rouping
All(invasively(ventilated(patients(w
ho(com
e(into(ICU(w
ill(be(screened(with(inclusion(and(exclusion(
criteria(as(to(w
hether(they(are(eligible(to(be(included(in(the(trial.
First,(a(paperBbased(checklist(w
ill(com
pare(the(patient(against(the(inclusion/exclusion(criteria.(
Second,(patient(inform
ation(is(entered(into(the(random
isation(softw
are(and(each
eligible(patient(is(
random
ised(into(either(SPV$(standard$practice$ventilation)or(M
BV$(m
odel7based$ventilation).(Both(
groups(are(participants(in(the(CURESofttrial.(
It(is(very(im
portant(that(data(from
(every(participant(gets(collected.
Setting/U
p/the/H
ardw
are/and/Ventilator
•
Each(unit(consists(of(a(com
puter(and(touchscreen(m
onitor(m
ounted(on(a(m
etal(stand(that(is(
secured(on(the(back(of(the(ventilator.(The(unit(is(secured(w
ith(tw
o(finger(screw
s(at(the(base(of(
the(ventilator(and(an(elastic(tie(around(the(ventilator(fram
e.
•
W
hen(not(in(use,(the(stands(w
ill(be(stored(in(the(technician(area(w
ith(the(other(equipm
ent.
•
Tw
o(connections(need(to(be(m
ade(to(the(ventilator.
1.
The(pow
er(cable(needs(to(be(connected(to(the(threeBpin(plug(on(the(right(hand(side(of(the(
ventilator.
2.
The(9Bpin(plug(m
ust(be(connected(to(socket'3
on(the(rear(of(the(ventilator(m
onitor.(To(ensure(
data(can(flow,(under(the(Com
m
unication(Setup(tab(on(the(ventilator,(the(options(m
ust(be(set(
to(W
aveform
s
w
ith(a(Baud(Rate(of(38400.(
•
O
nce(the(com
puter(pow
er(is(connected(the(com
puter(can(be(turned(on(by(pressing(the(single(
button(on(the(rear(black(coloured
panel.(The(button(should(illum
inate(blue.
Logging/on/to/the/Com
puter
Each(com
puter(has(tw
o(logBins
1.
Adm
in(–
used(only(for(softw
are(developm
ent,(and
2.
CURE01,(02(etc.(–
this(is(the(prim
ary(logBin(for(the(CURE(trial(and(w
ill(be(the(only(logBin(you(
use.
N
o(passw
ord(is(required(to(logBin(to(CURE01(or(02(etc.
A
ppendix B
: Training M
anual
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Com
puter/layout
!
Sw
ipe(right(to(open(the(
onscreen(keyboard
Touch(near(the(top(of(the(screen(to(reveal(the(taskbar
Com
puter/layout
Keyboard(open(–
to(close,(touch(the(red(X
Taskbar(and(start(m
enu(as(norm
al
D
oubleBclick(to(open(CU
RESoft
O
pening/CU
RESoft
M
axim
ise(w
ith(the(usual(button
First,(check(the(Settings(tab
Settings/Tab
Ensure(that(the(Serial(port(option(is(selected(w
ith(CO
M
3(and(change(the
D
ata(Folder(to(the(participant’s(trial(identification(num
ber(i.e.(M
BVB001
or(SPVB001.(You(m
usttouch(Apply(to(change(the(settings.
From
(here,(select(Start(Collecting(D
ata(and(sw
itch(
back(to(the(H
istory(tab.(
5/10/153
H
istory/Tab
The(Start(
Collecting(
D
ata(button(
w
ill(turn(red.
D
ata(w
ill(start(
to(be(
collected(and(
plotted(in(this(
tab.
PEEP/Calibration
It(is(good(
practice(to(
straight(aw
ay(
calibrate(PEEP(
by(touching(
Calibration(
and(entering(
the(ventilator(
set(PEEP(and(
selecting(O
k.
Enter(the(PEEP(selected(on(the(ventilator
Individual/Breath/Cycle/View
/Tab
If(desired,
individual
breaths(can(
beinspected(in
this(tab(by(
touching(Start
Listening,(and(
stopped(by(
touching(Stop(
Listening.
M
axim
um
/Recruitm
ent/M
anoeuvre
A(m
axim
um
(recruitm
ent(m
anoeuvre((M
axRM
)(procedure(is(only(com
pleted(once(per(patient(at(the(
start(of(ventilation(unless(a(doctor(decides(to(repeat.
Prior(to(M
axRM
:
•
Increase(the(patient(airw
ay(cuff(pressure(to(50(cm
H
2 O
•
Adm
inister(appropriate(m
uscle(relaxant(and(sedation(
•
Set(peak(airw
ay(pressure(alarm
(on(ventilator(to(55(cm
H
2 O
For(participants(in(the(intervention(M
BV(group(only
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M
axim
um
/Recruitm
ent/M
anoeuvre
O
nce(CU
RE(
elastance
has(
stabilised,(
a(
recruitm
ent(
m
anoeuvre(
m
ust(be(run.
Touch(Start(
Recruitm
ent(
M
anoeuvre,(
enter(the(
ventilator(
selected(PEEP(
and(touch(O
k.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
Enter(the(
patient(
position(
(usually(backB
side(dow
n),(
the(protocol(
to(follow,(
m
axRM
or(
PU
M
P,(the(
SPO
2and(FiO
2
and(touch(
Add.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
Starting(the(
RM
(w
ill(m
ove(
the(interface(
to(this,(the(
Recruitm
ent(
tab.
The(w
indow
(
in(the(bottom
(
right(corner(is(
the(history(
figure.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
The(yellow
(
banner(
inform
s(you(
that(PEEP(is(
changing(and(
you(m
ust(
w
ait.
For(participants(in(the(intervention(M
BV(group(only
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M
axim
um
/Recruitm
ent/M
anoeuvre
The(green(
banner(
inform
s(you(
that(PEEP(has(
stabilised(and(
PEEP(can(be(
adjusted.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
For(each(PEEP(
increm
ent,(
the(softw
are(
w
ill(plot(one(
point,(the(
stiffness(at(
the(m
atching(
PEEP.
As(PEEP(is(
changed(the(
points(are(
connected.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
O
nce(the(m
ax(
PEEP(has(
been(reached(
and(PEEP(is(
decreased,(
the(points(
and(lines(w
ill(
appear(
differently.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
At(the(sam
e(
PEEP(you(
started(at(a(
PU
M
P(w
ill(be(
com
plete(
w
hereas(a(
m
axRM
needs(
to(increase(
and(decrease(
again.
For(participants(in(the(intervention(M
BV(group(only
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M
axim
um
/Recruitm
ent/M
anoeuvre
The(softw
are(
detects(this(
point(and(
rem
inds(you(
to(continue(
for(a(m
axRM
.
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
G
oing(up(
again!
For(participants(in(the(intervention(M
BV(group(only
M
axim
um
/Recruitm
ent/M
anoeuvre
Back(dow
n(
and(the(
m
axRM
is(
com
plete!
O
nce(done,(
touch(Stop(
Recruitm
ent(
M
anoeuvre.
Return(the(
cuff(pressure(
back(to(~30(
cm
H
2O
(and(
reset(
ventilator(
alarm
s.
For(participants(in(the(intervention(M
BV(group(only
PU
M
P/Protocol
A(PU
M
P(is(a(
sm
all(m
axRM
to(be(
perform
ed(
each(tim
e(the(
patient(is(
turned(onto(
their(back.
Firstly,(reduce&
PEEP&by&2&
cm
H
2O
&and(
Touch(Start(
Recruitm
ent(
M
anoeuvre(
and(calibrate(
PEEP.
For(participants(in(the(intervention(M
BV(group(only
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PU
M
P/Protocol
As(before,(fill(
out(the(text(
boxes,(this(
tim
e(selecting(
PU
M
P
and(
touching(Add
For(a(PU
M
P,(
the(patient(
w
ill(be(backB
side(dow
n.
For(participants(in(the(intervention(M
BV(group(only
PU
M
P/Protocol
Increase(
PEEP
D
ecrease
PEEP
PU
M
Ps(are(
sim
ply(an(
increase(in(
PEEP(by(4(
cm
H
2O
(three(
tim
es(and(
then(
decreasing(
back(to(the(
start.
O
nce(done,(
stop(the(
PU
M
P.
For(participants(in(the(intervention(M
BV(group(only
PEEP/Suggestion
At(the(end(of(
a(M
axRM
or(
PU
M
P,(a(PEEP(
value(w
ill(be(
suggested(
and(the(user(
m
ust(either(
accept(or(
decline.(
If(you(accept,(
you(m
ust(
m
anually(
change(the(
ventilator(
PEEP.
For(participants(in(the(intervention(M
BV(group(only
PEEP/Suggestion
H
ow
ever,(if(
the(user(
decides(to(
reject(the(
suggested(
PEEP,(please(
let(us(know
(
w
hy(you(
rejected(the(
suggestion(by(
typing(into(
the(textbox.
For(participants(in(the(intervention(M
BV(group(only
5/10/158
Back/to/the/H
istory/Tab
A(m
axRM
looks(sim
ilar(
to(this(in(the(
H
istory(tab(
and(can(take(
20(m
inutes(to(
perform
.
For(participants(in(the(intervention(M
BV(group(only
Events/Tab
Sim
ilar(to(the(
first(step(in(a(
RM
,(users(can(
state(events(
in(the(Events(
tab.
Exam
ples(are:(
turning(the(
patient,(
desaturation(
events,(
coughing(etc.(
Libre
O
pen/O
ffice
Also(on(the(
com
puters(is(
a(copy(of(
O
pen(O
ffice.
Please(leave(
detailed(notes(
here(if(you(
w
ish.(
Save(the(file(
to(
D
ocum
ents.(
Please(state(
the(patient(
num
ber,(the(
date,(tim
e,(
SpO
2,(and(
FiO
2.
Are/There/Any/Q
uestions?
Thank(you(very(m
uch.
Vincent(M
ajor,(KT(Kim
027(286(0069,(027(300(5899
Inclusion)criteria:"
Patient:(
1.! ( Diagnosed(with(ARDS(by(intensive(care(clinicians(
as"per"Berlin"Definition*(
2.! ( Arterial(line(in(situ(
(
(
*“Berlin"Definition"of"Acute"Respiratory"
Distress"Syndrome”""
The"ARDS"Definition"Task"Force,"A."2012"
(
(
(
(
(
(
(
(
Exclusion)criteria:"
Patient:(
(
(
(
(
(
(
(
(
(
(
(
(
( (
Abbreviations:(
ICP:(Intracranial(Pressure(
COPD:(Chronic(Obstructive(Pulmonary(Disease(
(
1.! ( Likely(to(be(discontinued(from(MV(within(24(hours"
2.! ( <"16"years"old"
3.! ( Moderate"or"severe"traumatic"brain"injury,(and/or(a(
measured(ICP"≥"20cmH2O(
4.! ( Any(medical(condition(associated(with(a(clinical(
suspicion(of(raised"ICP(
5.! ( High"spinal"cord"injury(with(loss(of(motor(function(
6.! ( Significant(weakness(from(any(neurological"disease(
7.! ( Barotrauma((pneumothorax,(pneumomediastinum,(
subcutaneous(emphysema(or(any(intercostal(catheter(
for(the(treatment(of(air(leak)(
8.! ( Asthma"as"primary"presenting"condition(or(a(history"
of"significant"COPD(
9.! ( Moribund(and/or(not(expected(to(survive(for(>72"
hours(
10.! ( Have"received"MV"for">"48"hours((including(time(
spent(ventilated(in(a(referring(unit)(
11.! ( Lack"of"clinical"equipoise(by(intensive(care(unit((ICU)(
medical(staff(managing(the(patient(
12.! ( Readmitted"to"ICU"within"28"days(of(the(first(day(
entered(into(the(study(
13.! ( Readmitted(to(ICU(at(any(time(if(they(have(
participated(in(the(study(during(the(same"hospital"
admission(
PATIENT"IS"ON"INVASIVE"MECHANICAL"VENTILATION"(MV)(
(
Appendix C: Screening Sheet
Patient"Info:"
Ethnicity( :(________________________(
ICU(Admission(Date( :(________________________(
Clinical(Diagnostic:(________________________(
Is(the(patients(under(Apache(III(diagnostic(code(200(or(1300:(( ( Yes( ( No((
(
PaO2:(________________________(FiO2:(________________________(SPO2:(________________________(
Inclusion"Criteria"(Tick"if"applicable)"
( 1.! Patients(requiring(invasive(mechanical(ventilation((MV)((intubation(or(tracheotomy)(
( 2.! Patients(diagnosed(with(acute(respiratory(distress(syndrome((ARDS)(of(any(severity((PF([Oxygen(
partial(pressure(to(fraction(of(inspired(oxygen](ratio(<300mmHg)(by(intensive(care(clinicians.(
( 3.! Arterial(line(in(situ.(
"
Exclusion"Criteria"(Tick"if"applicable)"
( 1.! Patient(who(are(likely(to(be(discontinued(from(MV(within(24(hours.(
( 2.! Patient(with(age(<(16.(
( 3.! Patients(who(have(moderate(or(severe( traumatic(brain( injury,(and/or(a(measured( intracranial(
pressure(≥(20(cmH2O(
( 4.! Patients(who(have(a(high(spinal(cord( injury(with( loss(of(motor( function(and/(or(have(
significant(weakness(from(any(neurological(disease.((
( 5.! Patients(who(have(a(Barotrauma((pneumothorax,(pneumomediastinum,(subcutaneous(
emphysema(or(any(intercostal(catheter(for(the(treatment(of(air(leak).((
( 6.! Patients(who(have(asthma(as(the(primary(presenting(condition(or(a(history(of(significant(
chronic(obstructive(pulmonary(disease.((
( 7.! Patients(who(are(moribund(and/or(not(expected(to(survive(for(>(72(hours.((
( 8.! (Patients(who(have(already(received(MV(for(>(48(hours((including(time(spent(ventilated(
in(a(referring(unit).((
( 9.! Lack(of(clinical(equipoise(by(intensive(care(unit((ICU)(medical(staff(managing(the(patient.((
(
Is(the(Patient(eligible(for(CURE(RCT:(( ( ( Yes( No(
*If(Yes,(which(RCT(group(is(the(patient(assigned(to:(Control(/(Intervention(
(
Fill(this(portion(only(after(patients/(family/(relative/(Whanau(has(been(contacted(and(informed(about(CURE(
Is(the(Family/Relative/Whanau(consenting(to(the(trials:((Yes(( No( Date:(________________________(
If(Yes,(complete(consent(forms.(
( If(No,(please(remove(the(patient(from(trial(and(update(Excel(forms.(
(
Is(the(Patient(consenting(to(the(trials:(( ( ( Yes( No(((((( Date:(________________________(
If(Yes,(complete(consent(forms.(
( If(No,(please(remove(the(patient(from(trial(and(update(Excel(forms.(
(
(
(
(
Updated(by:(________________________(( ( ( Date:(________________________(
Paste(the(Patient(info(here
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1)
Information*Sheet*for*Relative,*Friend,*Family/Whanau*
*
Clinical'Utilisation'of'Respiratory'Elastance:'the'‘CURE’'Study'
:Optimising'PEEP'in'people'on'mechanical'ventilation''
*
Co9ordinating*Investigator*
*
Assoc*Professor*Geoffrey*M*Shaw*
Intensivist*
Department*of*Intensive*Care*Medicine*
Private*Bag*4710.*Christchurch*Mail*Centre*8140*
Christchurch*Hospital*
Phone:*(03)*364*1077*
'
Co*Investigators*
*
Dist.*Prof.*J.*Geoffrey*Chase* Dr.*Yeong*Shiong*Chiew* *
Professor*at*University*of*Canterbury*
*
Post*Doctoral*Researcher*Fellow** *
Department*of*Mechanical*Engineering* Department*of*Mechanical*Engineering* *
University*of*Canterbury* University*of*Canterbury* *
Phone:*(03)*364*2987*ext*7224* Phone:*(03)*364*2987* *
*
'
Participation'
Your*relative*or*friend*is*being*mechanically*ventilated*because*their*lungs*are*not*working*properly.*
They*are* invited* to* take*part* in*a* study*called*a*Clinical*Utilisation*of*Respiratory*Elastance* (CURE)*
randomised*control*trial*(RCT).*This*study*is*trying*to*find*out*whether*ICU*doctors*and*nurses*using*a*
computerised*method*of*adjusting*the*ventilator*settings*can*improve*the*care*of*people*in*ICU.***
**
Before**you**consider**whether**your**relative**or**friend**would**want**to**take**part**in**this**study,**it*
is* important* * that* *you* * read* *and* *understand* * this* * information* * sheet.* * It*describes* the*purpose,*
procedures,*and*benefits*of*the*study*and*your*right*to*withdraw*at*any*time.*
*
Introduction'
Intensive*care*doctors*and*nurses*use*ventilators*to*support*a*person’s*breathing* in* intensive*care.*
Pneumonia,**trauma,**inflammation,**or**too**much**fluid**in**the**lung**stops**it**from**working**properly.*
When**this**happens**the**lung**gets**“stiff”;**this**makes**breathing**difficult.*The*lungs*become*stiffer*
because*the*injury*or*infection*causes*many*of*the*air*sacs,*(alveoli)*to*collapse.*This*is*known*as*Acute*
Respiratory*Distress*Syndrome*(ARDS).***
**
Some**people**with**stiff** lungs**will* *need**their**breathing**helped**by**a**ventilator.*However,*the*
ventilator,*keeping*them*alive,*may*make*their*lungs*worse.*High*breathing*volumes*and/or*pressures*
can*damage*stiff*lungs.*Unfortunately,*the*lung*can’t*be*rested*and*immobilised*like*a*broken*bone,*so*
it*is*very*important*we*ensure*the*ventilator*does*not*cause*more*lung*injury.**
*
*
Appendix D: Information Sheets and Consent
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2)
The* stiffness* of* the* lung* may* be* reduced* by* carefully* inflating* the* collapsed* regions* using* a*
“recruitment*manoeuvre”*(RM).*During*a*RM*the*lung*is*gently*inflated*over*a*number*of*breaths*by*
not*allowing* the* lung* to* completely*breathe*out.* ICU*doctors*and*nurses*do* this*by* increasing* the*
Positive*End*Expiratory*Pressure*(PEEP)*setting*on*the*ventilator.*
**
Our'research'aims'to'find'out' if'people'on'mechanical'ventilation'in' intensive'care'are'helped'by'
keeping'their'lung'stiffness'as'low'as'possible'through'use'of'RMs'and'optimal'levels'of'PEEP.*In*this*
way,*we*hope*to*minimise*the*damage*done*to*the*lung*by*the*ventilator.*
*
Selection'
Your* relative* or* friend* has* been* asked* to* consider* participation* in* this* study* because* they* are*
ventilated*and*have*been*diagnosed*with*ARDS.*
*
The'Study'
Your*relative*or*friend*is*currently*being*ventilated*using*settings*chosen*by*the*ICU*doctors.*Currently,*
doctors* have* no* standard* way* of* selecting* PEEP,* so* they* use* their* best* guess.* Too* much* PEEP*
overstretches*the*lung,*while*too*little*PEEP*causes*collapse.*Too*much,*or*too*little,*PEEP*makes*the*
lung*stiffer.*Every*person’s*lung*is*different,*and*his*or*her*lung*condition*may*also*change*during*their*
stay*in*ICU.*Therefore,*choosing*the*level*of*PEEP*can*be*quite*tricky,*and*might*not*always*be*right.*
**
The*lung’s*stiffness,*or*elastance,*is*measured*directly*at*the*bedside*using*a*laptop*computer.**To*help*
doctors*decide*the*best*settings,*the*PEEP*will*be*changed*upwards*and*then*downwards.*For*each*of*
the*changes,*their*responses*will*be*recorded.*
**
Your*relative*or*friend*may*be*allocated*to*either*A)*a*standard*ventilation*treatment*or*B)*a*ventilation*
treatment*using*a*computerised*method,*which*selects*PEEP*according*to*how*stiff*their*lungs*are.*A*
randomised*trial*means*every*person,*who*is*eligible*to*take*part*in*this*study,*has*an*equal*chance*of*
receiving* either* treatment.* This*means* the* results* of* this* research* are* not* influenced* by* the* ICU*
doctors*or*nurses.**
**
If*your*friend*or*relative*is*in*group*A)*they*will*receive*usual*ventilation*care*by*ICU*doctors*and*nurses.*
A*computer*will*record*the*information*from*the*ventilator,*but*this*will*not*influence*their*care.*
**
If*your*friend*or*relative*is*in*group*B)*a'computer'will'record'the'information'from'the'ventilator'and'
recommend'the'best'PEEP'setting'on'the'ventilator.*The*doctors*will*use*the*PEEP*calculated*by*the*
computer* setting* if* they* think* it*will*help*your* relative’s*or* friend’s* care.*Their* lung* “stiffness”*will*
change*over*time,*so*we*will*also*check*the*lung*stiffness*at*regular*intervals*and*each*time*they*are*
turned*in*bed.*The*PEEP*settings*will*be*adjusted*as*necessary.*
*
Risks'
There*is*a*small*risk*that*the*PEEP*setting*suggested*by*the*computer*might*not*be*the*most*suitable*
for*your*relative*or*friend.*This*risk*is*minimised*by*asking*the*doctor*if*they*agree*with*the*PEEP*level*
suggested*by*the*computer.*If*the*ICU*doctor*is*not*satisfied*with*the*computer’s*suggestion,*they*will*
choose*another*PEEP,*which*they*consider*more*appropriate.*The*computer*cannot*adjust*the*PEEP*
itself;*an*ICU*staff*member*must*manually*change*this*setting.*
'
'
'
'
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Possible'Benefits'
Your*relative*or*friend*may*or*may*not*experience*any*benefits*by*taking*part*in*this*study.*However,*
there*will*be*more*frequent*attention*paid*to*their*ventilation*and*changes*to*the*ventilator*will*be*
made*more*frequently,*which*may*result*in*a*faster*recovery.***
**
If*our*method*is*found*to*help*people*receiving*ventilation*in*ICU,*this*treatment*could*become*more*
widely*adopted*and*significantly*change*the*experiences*of*people*in*ICUs*all*over*the*world.*
 
 
Compensation'
In*the*unlikely*event*of*a*physical*injury*as*a*result*of*your*friends/relatives*participation*in*this*study,*
they*will*be*eligible*to*apply*for*accident*compensation*(ACC)*within*its* limitations.*If*you*have*any*
questions*about*ACC*please*feel*free*to*ask*the*researcher*for*more*information*before*you*agree*to*
take*part*in*this*trial.**
**
ACC*cover*is*not*automatic*and*their*case*will*need*to*be*assessed*by*ACC*according*to*the*provisions*
of*the*2001*Injury*Prevention*Rehabilitation*and*Compensation*Act.*If*the*claim*is*accepted*by*ACC,*
they*still*might*not*get*any*compensation.*This*depends*on*a*number*of*factors*such*as*whether*they*
are*an*earner*or*non9earner.*ACC*usually*provides*only*partial*reimbursement*of*costs*and*expenses*
and*there*may*be*no*lump*sum*compensation*payable.*There*is*no*cover*for*mental*injury*unless*it*is*
a*result*of*physical*injury.*If*your*relative*or*friend*has*ACC*cover,*generally*this*will*affect*their*right*
to*sue*the*investigators.**
**
If*you*have*any*questions*about*ACC,*contact*your*nearest*ACC*office*or*the*investigator.*
'
Stopping'participation'in'this'study'
If*your*friend/relative*takes*part*in*this*study,*you*are*always*free*to*offer*your*opinions*about*their*
ongoing*participation*at*any*time,*without*having*to*give*a*reason.*This*will*not*affect*their*continuing*
health*care.*
**
Your*friend’s/relative’s*doctors*may*stop*this*study,*or*their*participation*in*this*study,*at*any*time,*for*
any*reason,*without*seeking*your*opinions.* If* this*happens,* it*might*be*because*their*condition*has*
changed,*or*because*of*technical*problems*relating*to*the*equipment.*
*
Investigator'Payment'
The*investigators*are*not*paid*for*this*study.*
*
Confidentiality'
If*you*agree*to*your*relative*or*friend*taking*part*in*this*study,*the*information*obtained*will*be*shared*
amongst* investigators*within*the*Department*of* Intensive*Care,*and*the*Centre* for*Bioengineering,*
University*of*Canterbury.*However,*no*sensitive*information*will*be*collected,*discussed*or*shared*even$
amongst$the$research$team.*Only*information*that*is*directly*relevant*to*this*study*will*be*used.*
**
On*any*documents*relating*to*the*study,*only*a*study*code,*or*local*ICU*admission*number,*will*identify*
them.*Their*National*Health*Information*(NHI)*number*or*any*personal*details*that*could*identify*them*
will* not* be*used.* They*will* not* be*personally* identified* in* any* reports* on* this* study.* Their*medical*
information*will*be*processed*on*a*computer*and*held*for*up*to*20*years.*Study*information*will*be*
kept*secure.*De9identified*information*may*be*shared*amongst*other*researchers*in*this*field.*Results*
of* this* study* will* be* presented* at* conferences* and* submitted* for* publication* in* medical* and*
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bioengineering*journals.*By*signing*the*accompanying*form,*you*consider*your*friend*or*relative*would*
agree* to* participate* in* this* research,* the* record* review,* information* storage,* and* data* transfer*
described*above.*
*
Research'Funding'
This*research*is*supported*by*the*Health*Research*Council*of*New*Zealand*(HRC).*
*
Contact'Details'
For*more* information*about* this* study,*please* feel* free* to* contact* the*people*below.*You*are*also*
welcome*to*discuss*this*study*with*any*of*the*Intensive*Care*doctors.*You*may*telephone*the*ICU*staff*
at*any*time*(day*or*night)*if*you*have*any*important*concerns.*
*
! Health!and!Disability!Services!Consumer!Advocate:!
If* you,* your* relative,* or* friend* have* any* queries* or* concerns* regarding* their* rights* as* a*
participant*in*this*study,*they*may*wish*to*contact*a*Health*and*Disability*Services*Consumer*
Advocate:**
!!
Telephone*(03)*377*7501*or*0800*377*766*outside*Christchurch.*
*
Maori!Health!Support:!!
Eru*Waiti**
Maori*Health*Services**
Canterbury*District*Health*Board**
Telephone:*(03)*364*0640*Ext*88797;*Mobile:*027*382*6587**
Email:*Eru.Waiti@cdhb.health.nz**
**
Intensive!Care:!!
Assoc*Prof*Geoffrey*M*Shaw*(Co9ordinating*Investigator)**
Department*of*Intensive*Care**
Christchurch*Hospital**
Private*Bag*4710**
Christchurch*8011**
Email:*Geoff.Shaw@cdhb.health.nz**
**
Intensive*Care*Unit*Reception:**
Direct*Dial:*(03)*364*1077*
*
This*study*has*received*ethical*approval*from*the*Southern*Health*and*Disability*Ethics*Committee.*
*
Thank*you*for*considering*your*relative*or*friend’s*participation*in*this*study.*
*
*
Geoff*Shaw,*
*
Co9ordinating*Investigator*
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STATEMENT'BY'RELATIVE/FRIEND/FAMILY/WHANAU''
Clinical'Utilisation'of'Respiratory'Elastance'(CURE)'Trial''
6Optimising'PEEP'in'mechanically'ventilated'patients'
'
Lay'title:' Optimising'PEEP'during'mechanical'ventilation'
' '
CoJordinating'investigator:' Assoc'Prof.'Geoffrey'M'Shaw'
' '
Participant’s'name:' '
'
'
English! I'wish'to'have'an'interpreter' Yes' No'
Deaf' I'wish'to'have'a'NZ'sign'language'interpreter' Yes' No'
Māori! E'hiahia'ana'ahau'ki'tetahi'kaiwhaka'Māori/kaiwhaka'pakeha'korero' Ae' Kao'
Cook'Island'
Māori!
Ka'inangaro'au'i'tetai'tangata'uri'reo' Ae' Kare'
Fijian' Au'gadreva'me'dua'e'vakadewa'vosa'vei'au' Io' Sega'
Niuean! Fia'manako'au'ke'fakaaoga'e'taha'tagata'fakahokohoko'kupu' E' Nakai'
Sāmoan! Ou'te'mana’o'ia'i'ai'se'fa’amatala'upu' Ioe' Leai'
Tokelaun' Ko'au'e'fofou'ki'he'tino'ke'fakaliliu'te'gagana'Peletania'ki'na'gagana'o'na'
motu'o'te'Pahefika'
Ioe' Leai'
Tongan! Oku'ou'fiema’u'ha'fakatonulea' Io' Ikai'
I'have'read'and'I'understand'the'information'sheet'dated'4th'September'2014'for'people'taking'part'in'the'
randomised'control'trial'designed'to'optimise'PEEP'in'mechanically'ventilated'patients'in'ICU.'I'have'had'the'
opportunity'to'discuss'this'study.''I'am'satisfied'with'the'answers'I'have'been'given.'
I'have'had'the'opportunity'to'use'family/whanau'support'or'a'friend'to'help'me'ask'questions'and'understand'
the'study.'
I'believe'that'________________________________________'(participant’s'name)'would'have'chosen'and'
consented' to' participate' in' this' study' if' he/she' had' been' able' to' understand' the' information' that' I' have'
received'and'understood.'
I'understand'that'taking'part' in'this'study' is'voluntary'and'that'my'relative/friend'may'withdraw'from'the'
study'at'any'time'if'I'or'he/she'wishes.''This'will'not'affect'his/her'continuing'health'care.'
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I'understand'that'his/her'participation'in'this'study'is'confidential'and'that'no'material'which'could'identify'
him/her'will'be'used'in'any'reports'on'this'study.'
I'understand'that'the'study'will'be'stopped'if'it'should'appear'to'be'harmful.'
I'understand'the'compensation'provisions'for'this'study.'
I'know'whom'to'contact'if'anything'occurs'that'might'make'my'relative/friend'consider'withdrawing'from'the'
study.'
I'know'whom'to'contact'if'I'have'any'questions'about'the'study.'
This'study'has'been'given'ethical'approval'by'the'Southern'Health'and'Disability'Ethics'Committee.''This'means'
that'the'Committee'may'check'at'any'time'that'the'study'is'following'appropriate'ethical'procedures.'
'
'
Date:' ' ' /' ' /'201__'
' '
Signature:' '
' '
Printed'name:' '
' '
Relationship'to'participant:' '
' '
Address'for'results:' '
'
'
'
' '
Full'names'of'researchers:' Assoc'Prof'Geoffrey'M'Shaw'
Dist'Prof'J'Geoffrey'Chase'
Dr'Yeong'Shiong'Chiew'
' '
Contact'phone'number'for'researchers:' (03)'364'1077'
' '
Project'explained'by:' '
' '
ICU'position'or'project'role:' '
' '
Signature:' '
' '
Date:' ' ' /' ' /'201__'
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'
STATEMENT'BY'CO6ORDINATING'INVESTIGATOR'
I,' Assoc'Prof.'Geoffrey'M'Shaw'declare' that' this' study' is' in' the'potential' health' interest' of' the' group'of'
patients' of' which' _________________________________' (name! of! participant)' is' a' member' and' that'
participation' in'this'study' is'not'adverse'to'________________________________'(name!of!participant)’s'
interests.'
'
I' confirm' that' if' the' participant' becomes' competent' to'make' an' informed' choice' and' give' an' informed'
consent,' full' information' will' be' given' to' him/her' as' soon' as' possible,' and' his/her' participation' will' be'
explained.' ' If' the'participant'makes'an' informed'choice' to'continue' in' the' study,'written'consent'will'be'
requested'and'if'the'participant'does'not'wish'to'continue'in'the'study,'he/she'will'be'withdrawn.'
'
Signed:' ' Date:' '
' (CoJordinating'Investigator)' ' '
'
(If'applicable'at'a'later'stage)'
I'__________________________'(participant)'have'read'the'information'sheet'for'participants'in'the'study'
“Clinical! Utilisation! of! Respiratory! Elastance! (CURE)! Study:! Optimising! PEEP! in! mechanically! ventilated!
patients”.'I'have'had'the'opportunity'to'ask'questions'so'that'I'can'be'fully'informed'about'this'study'agree'
to'continue'taking'part'in'it.'
'
'
II'wish'to'receive'a'copy'of'my'results.' ' '''Yes' ' '''No'
'
II'wish'to'receive'copies'of'scientific'publications'from'this'study.' ' '''Yes' ' '''No'
'
II'agree'to'my'GP'being'informed'of'my'participation'in'this'study.' ' '''Yes' ' '''No'
'
'
'
Signed:' ' Date:' '
' (Participant)' ' '
'
'
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Information*Sheet*for*Participants*
*
Clinical'Utilisation'of'Respiratory'Elastance:'the'‘CURE’'Study'
8Optimising'PEEP'in'mechanically'ventilated'patients.'
*
Co3ordinating*Investigator*
*
Assoc*Professor*Geoffrey*M*Shaw*
Intensivist*
Department*of*Intensive*Care*Medicine*
Christchurch*Hospital*
Phone:*(03)*364*1077*
*
'
Co*Investigators*
*
Dist.*Prof*J.*Geoffrey*Chase* Dr.*Yeong*Shiong*Chiew* *
Professor*at*University*of*Canterbury* Post*Doctoral*Fellow* *
Department*of*Mechanical*Engineering* Department*of*Mechanical*Engineering* *
University*of*Canterbury* University*of*Canterbury* *
Phone:*(03)*364*2987*ext*7224* Phone:*(03)*364*2987* *
*
'
Participation'
You*were*recently*looked*after*in*the*Intensive*Care*Unit*(ICU)*because*at*that*time*your*lungs*were*
not*working*properly,*so*a*ventilator*was*used*to*help*you*breathe.*We*are*currently*conducting*a*
research*study*looking*at*safer*ways*to*ventilate*patients*who*have*sick*lungs.**
*
The*study*is*called*a*Clinical*Utilisation*of*Respiratory*Elastance*(CURE)*randomised*control*trial*(RCT).*
A*RCT*involves*a*random*allocation*of*yourself* into*one*of*two*groups.*You*have*either*A)*received*
standard* treatment* or* B)* received* standard* treatment* with* the* aid* to* potentially* improve* your*
recovery.* In*either*treatment,*breathing*data*was*recorded*using*a*bedside*computer*with*doctors*
choosing*the*safest*mechanical*ventilator*setting.*You*will*not*know*which*random*allocation*you*have*
been*assigned*whether*it*be*A)*or*B).***
*
It*was*not*possible*to*ask*you*to*participate*in*this*study*because*you*were*too*unwell*and*had*been*
given*sedation.*However,*we*discussed*this*study*with*your* family,*and*/*or*close* friends,*and*/*or*
whanau,*who*believed*you*would*have*agreed*to*participate*if*you*had*been*able*to*provide*consent*
at*that*time.*The*information*below*was*considered*by*your*family,*close*friends,*or*whanau,*when*
they*agreed*to*the*participation* in* the*study.*We*would* like*you*to*consider* the*same* information*
agreeing*to*continue*participation*in*the*study.*You*do*not*have*to*take*part*in*this*study,*and*if*you*
do*not*wish*to*take*part,*your*future*healthcare*will*not*be*affected.*
*
It* is* important* that* you* read* and* understand* this* information* sheet.* It* describes* the* purpose,*
procedures,*and*benefits*of*the*study*and*your*right*to*withdraw.*
*
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Introduction'
Intensive*care*doctors*and*nurses*use*ventilators*to*support*a*person’s*breathing* in* intensive*care.*
Pneumonia,*trauma,*inflammation,*or*too*much*fluid*in*the*lung*stops*it*from*working*properly.*When*
this*happens*the*lung*gets*“stiff”;*this*makes*breathing*difficult.*The*lungs*become*stiffer*because*the*
injury*or*infection*causes*many*of*the*air*sacs,*(alveoli)*to*collapse.*This*is*known*as*Acute*Respiratory*
Distress*Syndrome*(ARDS).*
**
Some*people*with*stiff*lungs*will*need*their*breathing*helped*by*a*ventilator.*However,*the*ventilator,*
keeping*them*alive,*may*make*their*lungs*worse.*High*breathing*volumes*and/or*pressures*can*damage*
stiff* lungs.*Unfortunately,*the*lung*can’t*be*rested*and*immobilised*like*a*broken*bone,*so*it* is*very*
important*we*ensure*the*ventilator*does*not*cause*more*lung*injury.*
*
The* stiffness* of* the* lung* may* be* reduced* by* carefully* inflating* the* collapsed* regions* using* a*
“recruitment*manoeuvre”*(RM).*During*a*RM*the*lung*is*gently*inflated*over*a*number*of*breaths*by*
not*allowing* the* lung* to* completely*breathe*out.* ICU*doctors*and*nurses*do* this*by* increasing* the*
Positive*End*Expiratory*Pressure*(PEEP)*setting*on*the*ventilator.*
**
Our'research'aims'to'find'out' if'people'on'mechanical'ventilation'in' intensive'care'are'helped'by'
keeping'their'lung'stiffness'as'low'as'possible'through'use'of'RMs'and'optimal'levels'of'PEEP.*In*this*
way,*we*hope*to*minimise*the*damage*done*to*the*lung*by*the*ventilator.*
*
Selection'
Your*relative*or*friend*has*been*asked*to*consider*your*participation*in*this*study*because*you*were*
ventilated*and*had*a*diagnosis*of*ARDS.*
*
The'Study'
You*were*ventilated*using*settings*chosen*by*the*ICU*doctors.*Currently,*doctors*have*no*standard*way*
of*selecting*PEEP,*so*they*use*their*best*guess.*Too*much*PEEP*over*stretches*the*lung,*while*too*little*
PEEP* causes* collapse.* Too*much,* or* too* little,* PEEP*makes* the* lung* stiffer.* Every* person’s* lung* is*
different,*and*his*or*her*lung*condition*may*also*change*during*their*stay*in*ICU.*Therefore,*choosing*
the*level*of*PEEP*can*be*quite*tricky,*and*might*not*always*be*right.***
**
The*lung’s*stiffness,*or*elastance,*is*measured*directly*at*the*bedside*using*a*laptop*computer.*To*help*
doctors*decide*the*best*settings,*the*PEEP*will*be*changed*upwards*and*then*downwards.*For*each*of*
the*changes,*their*responses*will*be*recorded.*
**
You*were*allocated*to*either*A)*a*standard*ventilation*treatment*or*B)*a*ventilation*treatment*using*a*
computerised*method,*which*selects*PEEP*according*to*how*stiff*their*lungs*are.*A*randomised*trial*
means*every*person,*who*is*eligible*to*take*part*in*this*study,*has*an*equal*chance*of*receiving*either*
treatment.*This*means*the*results*of*this*research*are*not*influenced*by*the*ICU*doctors*or*nurses.*
**
If*you*were* in*group*A)*you*received*usual*ventilation*care*by* ICU*doctors*and*nurses.*A*computer*
recorded*the*information*from*the*ventilator,*but*this*did*not*influence*your*care.**
**
If*you*were*in*group*B)*a'computer'recorded'the'information'from'the'ventilator'and'recommend'
the'best'PEEP'setting'on'the'ventilator.*The*doctors*used*the*PEEP*calculated*by*the*computer*setting*
if*they*thought*it*would*help*your*care.*Your*lung*“stiffness”*would*have*changed*over*time,*so*we*will*
also*checked*your*lung*stiffness*at*regular*intervals*and*each*time*you*were*turned*in*bed.*The*PEEP*
settings*were*adjusted*as*necessary.*
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*
Risks'
There*was*a*risk*that*the*PEEP*setting*suggested*by*the*computer*model*might*not*have*been*the*best*
for*your*lungs.*This*risk*was*minimised*by*asking*the*doctor*if*they*agree*with*the*PEEP*level*suggested*
by* the* computer.* * If* the* ICU* doctor*was* not* satisfied*with* the* computer’s* suggestion,* they* chose*
another*PEEP,*which*they*considered*more*appropriate.*The*computer*could*not*adjust*the*PEEP*by*
itself;*an*ICU*staff*member*made*these*changes*manually.*
'
Possible'Benefits'
You*may*or*may*not*have*experience*any*benefits*from*taking*part*in*this*study.*However,*frequent*
attention*was*paid*to*the*way*you*were*ventilated,*and*the*settings*were*adjusted*more*than*usual,*
which*might*have*allowed*you*to*get*faster*better.***
**
If*our*method*is*found*to*help*ICU*patients*in*Christchurch,*this*method*could*be*become*more*widely*
adopted,*and*significantly*change*the*experiences*of*patients*receiving*ventilation*in*ICUs*all*over*the*
world.*
 
Compensation'
In*the*unlikely*event*of*a*physical*injury*as*a*result*of*your*participation*in*this*study,*you*will*be*eligible*
to*apply*for*accident*compensation*(ACC)*within*its*limitations.*If*you*have*any*questions*about*ACC,*
please*feel*free*to*ask*the*researcher*for*more*information*before*you*agree*to*take*part*in*this*trial.**
**
ACC*cover*is*not*automatic*and*your*case*will*need*to*be*assessed*by*ACC*according*to*the*provisions*
of*the*2001*Injury*Prevention*Rehabilitation*and*Compensation*Act.*If*your*claim*is*accepted*by*ACC,*
you*still*might*not*get*any*compensation.*This*depends*on*a*number*of*factors*such*as*whether*you*
are*an*earner*or*non3earner.*ACC*usually*provides*only*partial*reimbursement*of*costs*and*expenses*
and*there*may*be*no*lump*sum*compensation*payable.*There*is*no*cover*for*mental*injury*unless*it*is*
a* result* of* physical* injury.* If* you* have* ACC* cover,* generally* this* will* affect* your* right* to* sue* the*
investigators.**
**
If*you*have*any*questions*about*ACC,*contact*your*nearest*ACC*office*or*the*investigator.*
'
Stopping'participation'in'this'study'
You*are*free*to*withdraw*from*this*study,*without*having*to*give*a*reason,*and*this*will*not*affect*your*
continuing*health*care.*
**
The*ICU*doctors*might*have*stopped*your*participation*in*this*study,*at*any*time*and*for*any*reason.*If*
this* did* happen,* it*might* have*been*because* your* condition*had* changed,* or* because*of* technical*
problems*relating*to*the*equipment.*In*any*case,*we*will*tell*you*why.*
*
Research'Funding'
This*research*is*supported*by*the*Health*Research*Council*of*New*Zealand*(HRC).*
*
Confidentiality'
If*you*agree*to*take*part*in*this*study,*the*information*obtained*will*be*shared*amongst*investigators*
within*the*Department*of*Intensive*Care,*and*the*Centre*for*Bioengineering,*University*of*Canterbury.*
However,*no*sensitive*information*will*be*collected,*discussed*or*shared*even*amongst*the*research*
team.*Only*information*that*is*directly*relevant*to*this*study*will*be*used.*
*
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On*any*documents*relating*to*the*study,*only*a*study*code,*or*local*ICU*admission*number,*will*identify*
them.*Your*National*Health*Information*(NHI)*number*or*any*personal*details*that*could*identify*you*
will* not* be* used.* You* will* not* be* personally* identified* in* any* reports* on* this* study.* Your*medical*
information*will*be*processed*on*a*computer*and*held*for*up*to*20*years.*Study*information*will*be*
kept*secure.*De3identified*information*may*be*shared*amongst*other*researchers*in*this*field.*Results*
of* this* study* will* be* presented* at* conferences* and* submitted* for* publication* in* medical* and*
bioengineering*journals.*By*signing*the*accompanying*form,*you*agree*to*participate*in*this*research,*
the*record*review,*information*storage,*and*data*transfer*described*above.*
*
Contact'Details'
For*more* information*about* this* study,*please* feel* free* to* contact* the*people*below.*You*are*also*
welcome*to*discuss*this*study*with*any*of*the*Intensive*Care*doctors.*You*may*telephone*the*ICU*staff*
at*any*time*(day*or*night)*if*you*have*any*important*concerns.*
*
' Health'and'Disability'Services'Consumer'Advocate:'
If* you,* your* relative,* or* friend* have* any* queries* or* concerns* regarding* their* rights* as* a*
participant*in*this*study,*they*may*wish*to*contact*a*Health*and*Disability*Services*Consumer*
Advocate:**
''
Telephone*(03)*377*7501*or*0800*377*766*outside*Christchurch.*
*
Maori'Health'Support:''
Eru*Waiti**
Maori*Health*Services**
Canterbury*District*Health*Board**
Telephone:*(03)*364*0640*Ext*88797;*Mobile:*027*382*6587**
Email:*Eru.Waiti@cdhb.health.nz**
**
Intensive'Care:''
Assoc*Prof*Geoffrey*M*Shaw*(Co3ordinating*Investigator)**
Department*of*Intensive*Care**
Christchurch*Hospital**
Private*Bag*4710**
Christchurch*8011**
Email:*Geoff.Shaw@cdhb.health.nz**
**
Intensive*Care*Unit*Reception:**
Direct*Dial:*(03)*364*1077*
*
This*study*has*received*ethical*approval*from*the*Southern*Health*and*Disability*Ethics*Committee.*
*
Thank*you*for*considering*participation*in*this*study.*
*
Geoff*Shaw,*
*
Co3ordinating*Investigator*
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